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BAck PAin
Worldwide, back pain is a frequently occurring and disabling disease. The point preva-
lence of back pain is reported to be 11.9% in the general population1 and back pain is a 
leading cause of years lived with disability.2 Although many patients do not seek help for 
their back pain,3-5 a considerable number of consultations in general practice are related 
to musculoskeletal complaints, including a large amount of back complaints.6 7 Also in 
the Netherlands, back complaints reported to the general practitioner (GP) are the most 
common of all musculoskeletal complaints. The incidence of back pain without radiating 
pain in the leg is reported to account for 27 per 1000 patients - and these numbers have 
increased over time.8 Moreover, the costs related to back pain are a substantial burden 
on society. For example, patients with back pain use almost twice as much health care 
as patients without back pain.6
OldeR Adults with BAck PAin
In older adults benign or mild back pain is generally less frequent compared to younger 
age groups, but older adults experience more episodes with severe or disabling back pain.9 
With the aging population a greater number of people are likely to suffer from severe back 
pain in the future. Moreover, because the prevalence of seeking health care for back pain 
increases with age6 these healthcare costs are also likely to increase in the future.10 Another 
point is that, indirect costs resulting from lost work productivity also represent a large 
percentage of the overall costs associated with back pain,11 because of retirement these 
indirect costs might be lower in the older population; this is probably why older adults 
with back pain are often excluded from randomized trials performed among back pain 
patients.12 However, from the perspective of an aging population and increasing numbers 
of older patients with back pain, this is unfortunate. Furthermore, it seems that this trend 
will not improve over time, even though the proportion of older patients is rising. 
Information on patients’ characteristics and their associations with back complaints 
is important for back pain management and may help identify factors that can have 
a beneficial influence on the course of back pain or treatment response. However, the 
characteristics of back pain in older patients probably differ from those in younger 
persons; for example, more severe back pain occurs more frequently in the higher age 
groups.9 Furthermore, older patients more often have co-morbidities;13 this can influ-
ence the back pain episode, resulting in a different course and prognosis of back pain 
complaints. Finally, older adults with musculoskeletal pain more often report difficulties 
in activities of daily living,14 which can have a considerable impact on the independence 
of these patients. 
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suBgROuPs
Defining subgroups in the heterogeneous 
population of back pain patients might 
help us to better inform and treat these 
patients. In this thesis, subgroups are 
identified in different ways and at various 
time points during follow-up in a popula-
tion of older adults included in the BACE 
cohort study (figure 1).15 Patients with 
neuropathic pain are identified using the 
‘Dolour Neuropathique four questions’ 
(DN4) posed at baseline.16 Non-recovery 
of patients is assessed at three months af-
ter baseline using self-reported recovery. 
Specific underlying pathology is assessed 
after one year to ensure that all underlying 
specific pathology has become apparent. 
Within this study population, trajectories 
are identified based on different courses 
of pain over time. 
neuropathic pain
Neuropathic pain is defined as pain arising as a direct consequence of a lesion or disease 
affecting the somatosensory system, either at the peripheral or central level.17 In back 
pain, although the mechanism of neuropathic pain is not fully understood, different 
mechanisms probably play a role in the development of neuropathic pain. It is suggested 
that back pain can be a ‘mixed’ type of pain, consisting of nociceptive and neuropathic 
components. Neuropathic pain may be caused by lesions of nociceptive sprouts in the 
degenerated intervertebral discs, by mechanical compression of the nerve root, or by 
action of inflammatory mediators from degenerated intervertebral discs.18 Patients 
with neuropathic pain report a lower quality of life and have more functional disability 
compared to patients with nociceptive pain.19 It is important to identify patients with 
neuropathic pain because conventional analgesic treatment may be less effective in 
this population,20-22 and a different type of treatment may be more beneficial for them. 
Therefore, it is important to establish how many older patients with back pain experi-
ence neuropathic pain and to examine the characteristics of these patients. 
BACE study N
e
u
ro
p
at
h
ic
 p
ai
n
Se
lf
-r
e
p
o
rt
e
d
 n
o
n
-r
e
co
ve
ry
Sp
e
ci
fi
c 
u
n
d
e
rl
yi
n
g
 p
at
h
o
lo
g
y
B
ac
k 
p
ai
n
 t
ra
je
ct
o
ri
e
s
Baseline
3 months
1 year
3 years
figure 1. Different subgroups at different time 
points within the BACE study
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non-recovery
The majority of older patients in primary care have persistent symptoms of back pain.23 
This differs from back pain patients in general for whom the course of back pain is de-
scribed as being favourable. Knowledge as to which patients will develop chronic back 
pain or experience more episodes of recurrent back pain will help healthcare profes-
sionals to better inform their patients. Therefore, we need to identify these predictive 
characteristics. Furthermore, if we can identify patients with a less favourable outcome, 
we may also develop better and more focused interventions for these patients in order 
to prevent this poor outcome. 
specific underlying pathology
A specific subgroup concerns patients with an underlying serious pathology that is the 
cause of their back pain. Although most patients with back pain have this condition 
without serious underlying pathology,24-26 about 1-5% of back pain in primary care is 
caused by serious pathology.27 28 This includes vertebral fractures, malignancies, infec-
tion, cauda equina syndrome and ankylosing spondylitis. Vertebral fractures are the 
most common underlying serious pathology in patients with back pain25 and these 
fractures frequently occur among older patients.24 
To identify these underlying causes of back pain, most clinical guidelines recommend 
to use so-called red flags.29 30 These alarming symptoms, derived from history taking 
and/or physical examination, are suggested to have an association with serious pathol-
ogy as a cause of back pain. Because the prevalence of serious pathology as a cause of 
back pain increases with age, red flags may be more important in patients aged over 55 
years.31 However, analysis of these red flags and their diagnostic value is scarce, espe-
cially among older adults with back pain.
Back pain trajectories
Defining different trajectories in the course of back pain may help to identify patients 
at risk for a non-favourable course of back pain. Although trajectories have been fitted 
for some populations with back pain,32-36 they are not yet widely used to describe back 
pain patterns. Older adults may well show different course(s) of back pain compared to 
younger patients, especially since older age is associated with non-recovery.36 37 
heAlthcARe utilizAtiOn
Older patients with chronic back pain have the highest healthcare costs; however, this 
association is mainly due to their increased number of co-morbidities.38 Patients with a 
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fracture as underlying cause of back pain, and patients with neuropathic pain, also have 
higher healthcare costs.38 39 
Analgesic therapy
A large percentage of all back pain patients receive analgesics after a first visit to their 
GP.40 Of these, paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) can 
be obtained either by prescription from a physician or over-the-counter. Analgesics 
are mostly prescribed to support patients to stay active, because staying active is an 
important element in a positive course of back pain. Older patients with back pain are 
more likely to be prescribed analgesics compared with younger adults with back pain.41 
With regard to the analgesic options, international guidelines for back pain usually rec-
ommend paracetamol as first choice, followed by NSAIDs.42 This is mainly because the 
adverse side-effects of paracetamol are more favourable than those of NSAIDs. Never-
theless, because each class of medication is associated with (serious) adverse reactions 
it is important to consider the different types of analgesics. This applies particularly to 
older adults, who are more prone to adverse events due to co-morbidities and the use 
of co-medication. 
One of the aims of this thesis is to describe the kind of analgesics (both prescribed and 
over-the-counter) among older adults with back pain.
efficacy of nsAids
NSAIDs are a frequently used analgesic. Based on their working profile they can be 
divided into i) non-selective NSAIDs, which inhibit both cyclooxygenase 1 (COX-1) 
and 2 (COX-2), and ii) selective NSAIDs, which inhibit only the COX-2 enzyme. These 
COX enzymes play a key role in the synthesis of prostaglandins, which contribute to 
inflammation, pain and fever. Because NSAIDs inhibit the COX enzyme this inhibits the 
production of prostaglandins which, in turn, reduces inflammation, pain and fever. Both 
non-selective and selective NSAIDs are used in the treatment of pain. However, inhi-
bition of these enzymes can also cause adverse events, since COX-1 produces prosta-
glandins that also support platelets, protect the stomach lining and may help maintain 
kidney function. Nonselective NSAIDs are also called ‘traditional’ NSAIDs and, compared 
to selective NSAIDs, carry a higher risk of gastro-intestinal adverse reactions,43 such as 
gastritis or stomach bleeding, due to inhibition of both the COX enzymes. Although 
selective NSAIDs have fewer gastro-intestinal adverse reactions they are associated with 
cardiovascular risk.44 Therefore, in view of this risk of serious adverse events, it is very 
important to establish whether these analgesics are really effective for back pain.
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Aim And Outline Of this thesis
The aim of this thesis is to describe: 1) the characteristics of older adults with back pain; 
2) the various ways of identifying different types of patient subgroups, and their course 
and prognosis of back pain; and 3) healthcare use due to back pain in a population of 
older adults. 
Most of the results described in this thesis are based on the BACE study population. 
The characteristics of these older adults with back pain are described in chapter 2. All 
these patients aged over 55 years were included after visiting their GP due to back pain. 
Results on prevalence and associations of neuropathic pain in this cohort of older 
adults is presented and discussed in chapter 3. The number of patients and variables 
associated with non-recovery of their back pain after three months was assessed and 
reported in chapter 4. chapter 5 reports the assessment of underlying pathology as 
a cause for back pain in this population of older adults. Furthermore it discusses the 
diagnostic value of red flags to identify vertebral fractures in these patients. Based on 
the back pain course during 3 years, different trajectories were defined in this popula-
tion. Also characteristics of patients in these different trajectories were identified and 
described in chapter 6.
Pain medication is often prescribed for patients with back pain. The use of these anal-
gesics, both prescribed and over-the-counter are described in chapter 7. To determine 
the efficacy of NSAIDs for patients with chronic back pain, a Cochrane systematic review 
was performed and the results are reported in chapter 8. 
14 Chapter 1 
RefeRences
 1. Hoy D, Bain C, Williams G, March L, Brooks P, Blyth F, et al. A systematic review of the global preva-
lence of low back pain. Arthritis Rheum 2012;64(6):2028-37.
 2. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability 
(YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the 
Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163-96.
 3. Ferreira ML, Machado G, Latimer J, Maher C, Ferreira PH, Smeets RJ. Factors defining care-seeking 
in low back pain--a meta-analysis of population based surveys. Eur J Pain 2010;14(7):747 e1-7.
 4. IJzelenberg W, Burdorf A. Patterns of care for low back pain in a working population. Spine (Phila 
Pa 1976) 2004;29(12):1362-8.
 5. Walker BF, Muller R, Grant WD. Low back pain in Australian adults. health provider utilization and 
care seeking. Journal of manipulative and physiological therapeutics 2004;27(5):327-35.
 6. Joud A, Petersson IF, Englund M. Low back pain: epidemiology of consultations. Arthritis Care Res 
(Hoboken) 2012;64(7):1084-8.
 7. Yokota RTC, Berger N, Nusselder WJ, Robine JM, Tafforeau J, Deboosere P, et al. Contribution of 
chronic diseases to the disability burden in a population 15 years and older, Belgium, 1997-2008. 
Bmc Public Health 2015;15.
 8. Linden MWvd, Westert GP, Bakker Dd, Schellevis F. Tweede Nationale Studie naar ziekten en 
verrichtingen in de huisartspraktijk: klachten en aandoeningen in de bevolking en in de huisart-
spraktijk: NIVEL, 2004.
 9. Dionne CE, Dunn KM, Croft PR. Does back pain prevalence really decrease with increasing age? A 
systematic review. Age Ageing 2006;35(3):229-34.
 10. Smith M, Davis MA, Stano M, Whedon JM. Aging baby boomers and the rising cost of chronic back 
pain: secular trend analysis of longitudinal Medical Expenditures Panel Survey data for years 2000 
to 2007. Journal of manipulative and physiological therapeutics 2013;36(1):2-11.
 11. Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the 
United States and internationally. Spine J 2008;8(1):8-20.
 12. Paeck T, Ferreira ML, Sun C, Lin CW, Tiedemann A, Maher CG. Are older adults missing from low 
back pain clinical trials? A systematic review and meta-analysis. Arthritis Care Res (Hoboken) 
2014;66(8):1220-6.
 13. Westert GP, Satariano WA, Schellevis FG, van den Bos GA. Patterns of comorbidity and the use of 
health services in the Dutch population. Eur J Public Health 2001;11(4):365-72.
 14. Thomas E, Mottram S, Peat G, Wilkie R, Croft P. The effect of age on the onset of pain interfer-
ence in a general population of older adults: prospective findings from the North Staffordshire 
Osteoarthritis Project (NorStOP). Pain 2007;129(1-2):21-7.
 15. Scheele J, Luijsterburg PA, Ferreira ML, Maher CG, Pereira L, Peul WC, et al. Back complaints in 
the elders (BACE); design of cohort studies in primary care: an international consortium. BMC 
Musculoskelet Disord 2011;12:193.
 16. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syn-
dromes associated with nervous or somatic lesions and development of a new neuropathic pain 
diagnostic questionnaire (DN4). Pain 2005;114(1-2):29-36.
 17. Haanpaa M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, et al. NeuPSIG guidelines on 
neuropathic pain assessment. Pain 2011;152(1):14-27.
 18. Baron R, Binder A. [How neuropathic is sciatica? The mixed pain concept] Wie neuropathisch ist 
die Lumboischialgie? Das Mixed-pain-Konzept. Orthopade 2004;33(5):568-75.
General Introduction 15
 19. Smart KM, Blake C, Staines A, Doody C. Self-reported pain severity, quality of life, disability, anxi-
ety and depression in patients classified with ‘nociceptive’, ‘peripheral neuropathic’ and ‘central 
sensitisation’ pain. The discriminant validity of mechanisms-based classifications of low back 
(+/-leg) pain. Man Ther 2012;17(2):119-25.
 20. Ahmad M, Goucke CR. Management strategies for the treatment of neuropathic pain in the 
elderly. Drugs Aging 2002;19(12):929-45.
 21. Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic 
management of neuropathic pain: evidence-based recommendations. Pain 2007;132(3):237-51.
 22. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treat-
ment: an evidence based proposal. Pain 2005;118(3):289-305.
 23. Rundell SD, Sherman KJ, Heagerty PJ, Mock CN, Jarvik JG. The clinical course of pain and function 
in older adults with a new primary care visit for back pain. J Am Geriatr Soc 2015;63(3):524-30.
 24. Deyo RA, Weinstein JN. Primary care - Low back pain. New Engl J Med 2001;344(5):363-70.
 25. Henschke N, Maher CG, Refshauge KM, Herbert RD, Cumming RG, Bleasel J, et al. Prevalence of 
and screening for serious spinal pathology in patients presenting to primary care settings with 
acute low back pain. Arthritis Rheum 2009;60(10):3072-80.
 26. Jarvik JG, Deyo RA. Diagnostic evaluation of low back pain with emphasis on imaging. Ann Intern 
Med 2002;137(7):586-97.
 27. Chou R, Qaseem A, Snow V, Casey D, Cross JT, Jr., Shekelle P, et al. Diagnosis and treatment of low 
back pain: a joint clinical practice guideline from the American College of Physicians and the 
American Pain Society. Ann Intern Med 2007;147(7):478-91.
 28. Henschke N, Maher CG, Refshauge KM. A systematic review identifies five 'red flags' to screen for 
vertebral fracture in patients with low back pain. J Clin Epidemiol 2008;61(2):110-18.
 29. Koes BW, van Tulder MW, Lin CW, Macedo LG, McAuley J, Maher C. An updated overview of 
clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J 
2010;19(12):2075-94.
 30. van Tulder M, Becker A, Bekkering T, Breen A, del Real MT, Hutchinson A, et al. Chapter 3. European 
guidelines for the management of acute nonspecific low back pain in primary care. Eur Spine J 
2006;15 Suppl 2:S169-91.
 31. Royal College of General Practitioners. Clinical Guidelines for the management of Acute Low Back 
Pain (UK), 2001.
 32. Axen I, Bodin L, Bergstrom G, Halasz L, Lange F, Lovgren PW, et al. Clustering patients on the basis 
of their individual course of low back pain over a six month period. Bmc Musculoskel Dis 2011;12.
 33. Dunn KM, Jordan K, Croft PR. Characterizing the course of low back pain: A latent class analysis. 
Am J Epidemiol 2006;163(8):754-61.
 34. Kongsted A, Leboeuf-Yde C. The Nordic back pain subpopulation program: course patterns 
established through weekly follow-ups in patients treated for low back pain. Chiropr Osteopat 
2010;18:2.
 35. Macedo LG, Maher CG, Latimer J, McAuley JH, Hodges PW, Rogers WT. Nature and determinants 
of the course of chronic low back pain over a 12-month period: a cluster analysis. Phys Ther 
2014;94(2):210-21.
 36. Tamcan O, Mannion AF, Eisenring C, Horisberger B, Elfering A, Muller U. The course of chronic and 
recurrent low back pain in the general population. Pain 2010;150(3):451-7.
 37. Chen C, Hogg-Johnson S, Smith P. The recovery patterns of back pain among workers with com-
pensated occupational back injuries. Occup Environ Med 2007;64(8):534-40.
16 Chapter 1 
 38. Lazkani A, Delespierre T, Bauduceau B, Pasquier F, Bertin P, Berrut G, et al. Healthcare costs associ-
ated with elderly chronic pain patients in primary care. Eur J Clin Pharmacol 2015.
 39. Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira D. The specific disease burden of 
neuropathic pain: results of a French nationwide survey. Pain 2011;152(12):2836-43.
 40. Schers H, Braspenning J, Drijver R, Wensing M, Grol R. Low back pain in general practice: reported 
management and reasons for not adhering to the guidelines in The Netherlands. Br J Gen Pract 
2000;50(457):640-4.
 41. Macfarlane GJ, Beasley M, Jones EA, Prescott GJ, Docking R, Keeley P, et al. The prevalence and 
management of low back pain across adulthood: results from a population-based cross-sectional 
study (the MUSICIAN study). Pain 2012;153(1):27-32.
 42. Koes BW, van Tulder M, Lin CW, Macedo LG, McAuley J, Maher C. An updated overview of 
clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J 
2010;19(12):2075-94.
 43. Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower 
gastrointestinal mucosal damage. Arthritis Res Ther 2013;15 Suppl 3:S3.
 44. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular 
safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086.


Chapter 2 
Characteristics of older back pain 
patients in general practice: 
BACE cohort study
J Scheele, WT Enthoven, SM Bierma-Zeinstra, 
WC Peul, MW van Tulder, AM Bohnen, MY Berger, 
BW Koes, PA Luijsterburg. 
Eur J Pain. 2014 Feb;18(2):279-87
20 Chapter 2 
ABstRAct
Background 
Although back pain is common among older people, limited information is available 
about the characteristics of these patients in primary care. Earlier research suggests that 
the severity of back symptoms increases with older age.
methods 
Patients aged >55 years visiting a general practitioner with a new episode of back pain 
were included in the BACE study. Information on patients’ characteristics, characteristics 
of the complaint and physical examination were derived from the baseline measure-
ment. Cross-sectional differences between patients aged >55–74 and ≥75 years were 
analysed using an unpaired t-test, Mann–Whitney U-test or a chi-square test. 
Results 
A total of 675 back pain patients were included in the BACE study, with a median age of 
65 (interquartile range 60–71) years. Patients aged >55–74 years had a mean disability 
score (measured with the Roland Disability Questionnaire) of 9.4 (standard deviation 
(SD) 5.8) compared with 12.1 (SD 5.5) in patients aged ≥75 years (p ≤ 0.01). The older 
group reported more additional musculoskeletal disorders and more often had low 
bone quality (based on ultrasound measurement of the heel) than patients aged >55–74 
years. Average back pain severity over the previous week showed no difference (p = 
0.11) between the age groups, but severity of back pain at the moment of filling in the 
questionnaire was higher (p = 0.03) in the older age group.
conclusions 
In this study, older back pain patients reported more disabilities and co-morbidity. How-
ever, the clinical relevance of these differences for the course of the back pain episode in 
older patients remains a subject for further research.
Characteristics of older back pain patients in general practice 21
intROductiOn
Although back pain is a common health problem in older adult patients, back pain 
research focuses mainly on the working-age population. Patients aged >60 or 65 years 
are often excluded from studies.1-3 It is suggested that older patients have a lower preva-
lence of back pain compared with the working population.4 5 Some studies suggest that 
the prevalence of mild back pain decreases with increasing age, but that the prevalence 
of severe back pain increases with increasing age.4 However, back pain in the older 
population remains the most common musculoskeletal disorder.5 In the Netherlands, 
most back pain patients who seek medical care visit the general practitioner (GP); back 
pain without radiation is the sixth most prevalent complaint for which patients visit 
their GP, with a prevalence of 39.7 per 1000 registered patients per year.6 Because back 
pain is a prevalent musculoskeletal complaint, also in older adults, it is important to 
gain insight into the characteristics of these patients. Although there are reports on the 
characteristics of back pain patients visiting their GP, information on older adults is lack-
ing.7 8 Compared with younger adults, the characteristics of back pain in older patients 
might differ because 1) older people have more co-morbidities;9 2) older people with 
musculoskeletal pain more often report difficulty in activities of daily living;10 11 and 3) 
older people might have more severe back complaints.4 12 Use of different age catego-
ries within the same study population enables the comparison of older and younger 
back pain patients on several patient and complaint characteristics. Information about 
patients’ characteristics and their complaints in a relevant setting is important for back 
pain management and may help identify factors that can influence the course or treat-
ment response of these back pain patients. Therefore, the aim of the present study was 
to describe the patients’ characteristics and characteristics of the complaint, of back 
pain patients aged >55 years in general practice. The aim of the present study was also 
to investigate whether these characteristics differ between the age categories >55–74 
and ≥75 years.
methOds
Patient selection
The BACE study is a prospective observational cohort. Details of the study protocol 
are described elsewhere.13 Patients aged >55 years were invited to participate in the 
BACE study if they consulted their GP with a new episode of back pain. An episode is 
considered ‘new’ if the patient had not visited a GP during the preceding 6 months for 
the same back complaint. All back complaints (defined as pain located in the region 
from the top of the shoulder blades to the first sacral vertebra) were included. Patients 
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were excluded if they were unable to fill in the questionnaire due to a language prob-
lem or cognitive disorders, or were unable to participate in the physical examination 
(wheelchair-bound patients). Patients were invited by their GP during the consultation 
or were retrospectively identified and approached within 2 weeks after the consultation 
in writing. In order to invite patients after consultation, medical patient records of the 
GPs were searched. A research assistant searched records using ICPC codes L02, L03, L84, 
L85 and L86. Hereafter, the GPs selected eligible patients using the inclusion and exclu-
sion criteria. Only if the patient had visited the GP due to back complaints no more than 
2 weeks before the search, the patient received a letter from the GP with an invitation to 
enter the study. The inclusion and exclusion criteria and rest of the study procedure re-
mained the same. The only difference is the longer time period between GP consultation 
and inclusion to the study in this ‘population which is identified in medical records’. The 
study protocol was approved by the Medical Ethics Committee of the Erasmus Medical 
Center, Rotterdam, the Netherlands.
data collection
Baseline measurements included a questionnaire and a physical examination. The 
questionnaire and history taking during physical examination included questions on 
1) patient characteristics: age, gender, education level, body mass index (BMI), marital 
status, employment status, smoking, measured as pack years (number of packs per day 
× years of smoking) and hazardous drinking, measured with the alcohol use disorders 
identification test (AUDIT-C);14 15 2) characteristics of the back complaint: duration of the 
current complaint, severity of back pain averaged during the previous week, and sever-
ity of back pain at the moment of filling in the questionnaire measured on an 11-point 
numerical rating scale (NRS 0–10),16 disability measured with the Roland disability 
questionnaire (RDQ scale 0–24),17 location of the back pain, cause of the back pain, his-
tory of back pain, back surgery in the past, radiating pain in the legs below the knee, 
severity of leg pain if present measured on an NRS (scale 0–10)16 and morning stiffness 
of the back; 3) medical consumption: use of pain medication for back pain and care from 
a physical therapist; 4) psychological factors: quality of life measured with the Short 
Form-36, physical and mental component summary scale (SF-36 range 0–100),18 depres-
sive symptoms measured with the Center for Epidemiologic Studies Depression Scale 
(range 0–60),19 kinesiophobia (fear-avoidance beliefs questionnaire, physical activity 
subscale range 0–28),20 pain catastrophizing (pain catastrophizing scale, range 0–52),21 
and attitude and beliefs about back pain (back beliefs questionnaire, range 9–45);22 and 
5) co-morbidity, measured with the self-administered co-morbidity questionnaire.23 The 
physical examination included 1) general examination of the body, such as pain during 
palpation of the paravertebral muscles, pain during palpation of the spinous processes 
and sacroiliac joint, and Heberden’s or Bouchard’s nodules; 2) range of motion of the 
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back and hip: anteflexion (finger–floor distance) and difference between left- and right-
sided lateroflexion, left- and right-sided rotation of the upper body, left- and right-sided 
hip joint exorotation and endorotation; and 3) additional diagnostic tests: knee tendon 
reflex, difference in quadriceps strength, test of Lasegue,24 difference in sensation be-
tween left and right feet, timed up and go test.25 Laboratory test: C-reactive protein (CRP) 
level was determined during the physical examination. Increased CRP level was defined 
as CRP level >10 mg/L. Bone quality test: Bone quality was measured with the Lunar 
Achilles InSight (quantitative ultrasound measurement of the heel).26 The bone quality 
is presented as a T-score, which is a comparison between the individual’s bone quality 
index and a reference population mean, and expressed in standard deviation (SD) units 
difference. Low bone quality is defined as a T-score of > –2.5, which means that patients 
bone quality score was more than 2.5 SD lower than the population mean.27
data analysis
First, the characteristics of the study population were reported using descriptive statis-
tics and we compared the two inclusion methods used. Patients included directly dur-
ing consultation were compared with those retrospectively identified and approached 
within 2 weeks after the consultation in writing on the following characteristics: age, 
gender, duration of current complaint, severity of back pain, level of disability, and 
duration between consultation and baseline measurements. Levene’s test was used to 
assess the equality of variance for each variable. The chi-square test was used to com-
pare categorical variables and an unpaired t-test to compare numerical variables. The 
Mann–Whitney U-test was used instead of the unpaired t-test for variables for which 
the p-value of the Levene’s test was <0.01. Second, patients in the age category >55–74 
years were compared with those aged ≥75 years on information from the baseline 
questionnaire and physical examination. In order to examine the differences between 
the age categories (>55–74 years vs. ≥75 years), the chi-square test was used to compare 
the categorical variables, and an unpaired t-test or Mann–Whitney U-test was used to 
compare the numeric variables. All analyses were performed using the SPSS version 17.0 
(SPSS Inc., Chicago, IL, USA).
Results
Population characteristics and selection
Of the 1402 back pain patients invited by 103 GPs to participate in this cohort study, 675 
patients (48%) were included and 727 patients were excluded. Reasons for exclusion 
were as follows: not willing to participate (n = 291), not meeting the inclusion criteria (n 
= 118) or the patient did not respond (n = 318). Of the 675 included back pain patients, 
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105 were included during the consultation and 570 after they received a written invita-
tion within 2 weeks after their consultation. Of these patients, 669 patients (99%) filled in 
the baseline questionnaire and 670 patients (99%) completed the physical examination. 
Patient selection is described in figure 1. The study population consisted of 274 men and 
401 women, median age was 65 (interquartile range (IQR) 60–71) years and 479 (71%) 
were married. At baseline, median duration of back pain was 35 (IQR 20–100) days, and 
156 (23%) patients had back pain lasting >3 months. Pain radiation in the legs below 
the knee was reported by 205 (30%) patients. Comparison of patients included during 
consultation and after the consultation revealed some differences. Patients included 
after a written invitation had slightly less severe back pain (mean 4.9; median 7; IQR 5–8) 
compared with those invited directly during the consultation (mean 6.5; median 5; IQR 
3–7); also, they had a lower level of disability as measured with the RDQ (mean 9.5 and 
11.3, respectively). However, these differences between the groups might be attributed 
to the difference in the (mean) number of days between consultation and completing 
the baseline measurement (the physical examination); i.e., 26 days for those with a writ-
ten invitation and 8 days for those invited directly during consultation (table 1).
All patients with back complaints,
aged >55 years, consulting  their 
general practitioner
 
Patients invited to participate (n= 1402)
- A: Direct during consultation (n=141)
- B: In writing after consultation (n= 1261)
 
Reason for exclusion (not invited to participate):
- Patients did not meet inclusion criteria
- Reason unknown
 
 
Reason for exclusion (n= 727):
- Patients not willing to participate (n= 291)
- Patients did not meet inclusion criteria (n= 118)
• No new back pain episode  (n= 77)
• Language problem (n= 12)
• Cognitive disorder (n= 5)
• No back pain consult (n= 24)
- Did not respond (n= 318)
Inclusion (n= 675)
- Via A: direct during consult (n= 105)
- Via B: In writing after consult (n= 570)
figure 1. Flow chart of the study
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Age groups: patient and complaint characteristics
Table 2 presents the patients and complaint characteristics per age category. The per-
centage of patients retrospectively identified and approached within 2 weeks after the 
consultation was the same in both age categories (84%). Significantly more patients aged 
≥75 years had a lower education level compared with the younger group (58% and 38%, 
respectively). The older group had a lower percentage of smokers (5% and 21%, respec-
tively) and of hazardous drinking (32% and 53%, respectively) than patients in the age 
category >55–74 years. However, these differences might be explained by the healthy 
survival effect, whereby those with a healthy lifestyle live longer than those with an un-
healthy lifestyle. In 67% of the patients, the back pain was located in the lumbar spine. 
The (mean) severity of back pain in the previous week showed no significant differences 
between the two groups: 5.1 (SD 2.7) for patients aged >55–74 years and 5.6 (SD 2.5) for 
patients aged ≥75 years. In contrast, (mean) back pain severity at the moment of filling 
in the baseline questionnaire was significantly different between the groups (p < 0.05); 
(mean) 4.5 (SD 2.5) for patients aged >55–74 years and 5.1 (SD 2.5) for patients aged ≥75 
years. There was a significant difference in disability between the two groups: 9.4 (SD 5.8) 
for the younger patients and 12.1 (SD 5.5) for patients aged ≥75 years, indicating that older 
patients experienced more disability due to back pain. Regarding medical consumption, 
483 (72%) of all patients took pain medication for their back pain, with no significant dif-
table 1. Comparison of the inclusion methods
direct during 
consultation 
(n=105) n (%)
in writing after 
consultation 
(n= 570) n (%)
total 
(n=675)
n (%)
Number of days between consultation and baseline 
measurements: median (IQR)
8 (6-13) 26 (20-33) 23 (16-31)**
Patient characteristics
Age in years: mean ± SD 66.8 ± 7.3 66.3 ±7.7 66.4 ±7.6
Male 50 (48) 224 (39) 274 (41)
Low education level 43 (41) 236 (41) 279 (41)
Married 70 (67) 409 (72) 479 (71)
Paid job 24 (23) 153 (27) 177 (26)
characteristics of the complaint
Duration of back pain > 3 months 32 (31) 124 (21.8) 156 (23)
 Severity of back pain (NRS average previous week): 
mean ± SD
6.5 ± 2.1 4.9 ± 2.7 5.2 ± 2.7**
Radiating pain in the legs below the knee 27 (26) 178 (31) 205 (30)
Disability (RDQ): mean ± SD 11.3 ± 5.7 9.5 ± 5.8 9.8 ± 5.8**
** p< 0.01
IQR: interquartile range (presented as 25-75 IQR), SD: standard deviation, NRS: numeric rating scale, RDQ: 
Roland Disability Questionnaire
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table 2. Characteristics of the back pain patients (n=675).
>55-74 years 
(n=566)
n (%)
≥ 75 years 
(n=109)
n (%)
total
(n=675)
n (%)
Number of days between consultation and baseline 
measurements: median (IQR)
23 (17-31) 23 (15-29) 23 (16-31)
Patient characteristics
Male 237 (42) 37 (34) 274 (41)
Education level:
Low 216 (38) 63 (58) 279 (41)**
Middle 246 (44) 29 (27) 275 (41)
High 98 (17) 16 (15) 114 (17)
Body mass index: mean ± SD 27.6 ± 4.7 27.1 ± 4.5 27.5 ± 4.7
Marital status: married 426 (75) 53 (49) 479 (71)**
Paid job 177 (31) 0 177 (26)**
Smoking 117 (21) 5 (5) 122 (18)**
Hazardous drinking (AUDIT-C) 298 (53) 35 (32) 333 (49)**
characteristics of the complaint
Duration of back pain:
< 1 week 55 (10) 7 (6) 62 (9)
1 week-6 weeks 229 (40) 44 (40) 273 (40)
6 weeks-3 months 94 (17) 10 (9) 104 (15)
> 3 months 129 (23) 27 (25) 156 (23)
Average back pain previous week (NRS): mean ± SD 5.1 ± 2.7 5.6 ± 2.5 5.2 ±2.7
Disability (RDQ): mean ± SD 9.4 ± 5.8 12.1 ± 5.5 9.8 ± 5.8**
Pain location:
Only thoracic 34 (6) 9 (8) 43 (6)
Only lumbar 382 (67) 68 (62) 450 (67)
Thoracic and lumbar 91 (16) 20 (18) 111 (16)
Perceived cause: accident or trauma 20 (4) 8 (7) 28 (4)
History of back pain 493 (87) 86 (79) 579 (86)
Back surgery in the past 46 (8) 10 (9) 56 (8)
Radiating pain in the leg below the knee 170 (30) 35 (32) 205 (30)
Severity of leg pain (NRS): mean ± SDa 4.0 ± 2.8 4.0 ± 2.8 4.0 ± 2.8
Morning stiffness of the back 10 (2) 4 (4) 14 (2)
medical consumption
Use of pain medication for back pain 403 (71) 80 (73) 483 (72)
Care from a physical therapist 251 (44) 48 (44) 299 (44)
Psychological factors
Quality of life (SF-36) physical summary scale: mean ± SD 43.8 ± 8.7 40.0 ± 9.5 43.2 ± 8.9**
Depressive symptomatology (CES-D): mean ± SD 9.7 ± 7.8 11.8 ± 7.6 10.0 ± 7.8*
Kinesiophobia (FABQ) physical activity subscale: mean ± SD 13.2 ± 5.7 14.6 ± 6.1 13.4 ± 5.8*
Pain catastrophizing (PCS): mean ± SD 13.9 ± 10.6 15.5± 10.5 14.1 ± 10.6
Attitude and beliefs about back pain (BBQ): mean ± SD 26.8 ± 7.1 24.5 ± 7.5 26.4 ± 7.2**
* p< 0.05, ** p< 0.01 a Means and SD computed only with the patients which reported leg pain (n=375)
IQR: interquartile range (presented as 25-75 IQR), SD: standard deviation, AUDIT-C: Alcohol Use Disorders 
Identification Test, NRS: numeric rating scale (range 0-10), RDQ: Roland disability questionnaire (range 
0-24), SF-36: Short Form-36, physical summary scale (range 0-100), CES-D: Center for Epidemiologic Studies 
Depression Scale (range 0-60), FABQ: Fear avoidance beliefs questionnaire, physical activity subscale (range 
0-28), PCS: Pain Catastrophizing Scale (range 0-52), BBQ: Back beliefs questionnaire (range 9-45)
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ference between the two groups. Patients aged ≥75 years reported lower quality of life, 
more depressive symptoms, more fear and avoidance beliefs, and more negative thoughts 
about back pain compared with patients aged >55–74 years.
Physical examination
Table 3 presents the results of the physical examination tests. Pain during palpation 
was more often present with palpation of the paravertebral muscles (34%) than with 
palpation of the spinous processes and sacroiliac joint (19%). Differences between left 
and right knee tendon reflex was found in 21% of the back pain patients, and a positive 
test of Lasegue in 15%. A significant difference was found between the two groups in 
lateroflexion: 44% of the patients aged ≥75 years had differences between lateroflexion 
to the left and right compared to 34% in the younger group. The older group took longer 
to complete the timed up and go test (median 13.0; IQR 10.2–17.1 s) compared with the 
younger group (median 9.9; IQR 8.5–11.9 s).
table 3. Results of the physical baseline examination.
>55-74 years 
(n=566)
n (%)
≥ 75 years 
(n=109)
n (%)
total
(n=675)
n (%)
general examination
 Pain during palpation of the paravertebral muscles 193 (34) 34 (31) 227 (34)
 Pain during palpation of the spinous processes and 
sacroiliac joint
105 (19) 22 (20) 127 (19)
Heberden’s or Bouchard’s nodules 131 (23) 30 (28) 161 (24)
Range of motion
 Anteflexion (finger-floor distance in cm): mean ± SD 10.6 ± 12.0 12.2 ± 11.4 10.9 ± 11.9
Lateroflexiona 194 (34) 48 (44) 242 (36)*
Rotation upper bodya 133 (24) 23 (21) 156 (23)
Hip external rotationa 68 (12) 14 (13) 82 (12)
Hip internal rotationa 86 (15) 16 (15) 102 (15)
Additional diagnostic tests
Knee tendon reflexa 117 (21) 25 (23) 142 (21)
Quadriceps strengtha 67 (11) 11 (10) 78 (12)
Positive Laseque 87 (15) 13 (12) 100 (15)
Sensation of the foota 101 (18) 18 (17) 119 (18)
 Timed up and go test, in sec: median (IQR) 9.9 (8.5-11.9) 13.0 (10.2-17.1) 10.2 (8.6-12.6)**
Low bone quality 45 (8) 32 (29) 77 (11)**
CRP level > 10 mg/l 20 (4) 6 (6) 26 (4)
* p< 0.05, ** p< 0.01
SD: standard deviation, IQR: interquartile range (presented as 25-75 IQR), CRP: C-reactive protein 
a Difference between left and right side of the body
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laboratory test and bone quality test
Only 4% of the patients had an increased CRP level. There was no statistically significant 
difference between the age groups. The older group more often had low bone quality, 
indicating a higher risk for fractures: 29% of patients aged ≥75 years compared with 8% 
of patients aged >55–74 years.
co-morbidity
Table 4 presents the patients’ self-reported comorbidity. The musculoskeletal disorders 
occurring most frequently were neck/shoulder complaints (52% of all patients), knee 
complaints (46%) and hip complaints (41%). There were no significant differences 
between the two age groups for the prevalence of these complaints. Several other dis-
orders were more often present in patients aged ≥75 years than in the younger group: 
high blood pressure (50% vs. 35%), heart diseases (29% vs. 13%), osteoporosis (21% vs. 
13%), kidney disease (9% vs. 3%), and anaemia or other blood disease (6% vs. 1%). There 
table 4. Reported co-morbidity (n=675).
>55-74 years 
(n=566) n (%)
≥ 75 years 
(n=109) n (%)
total
(n=675) n (%)
Heart disease 72 (13) 32 (29) 104 (15)**
High blood pressure 197 (35) 54 (50) 251 (37)**
Lung disease 55 (10) 14 (13) 69 (10)
Diabetes 62 (11) 18 (17) 80 (12)
Ulcer or stomach disease 50 (9) 12 (11) 62 (9)
Kidney disease 14 (3) 10 (9) 24 (4)**
Liver disease 4 (1) 1 (1) 5 (1)
Anemia or other blood disease 7 (1) 6 (6) 13 (2)**
Cancer 22 (4) 5 (5) 27 (4)
Depression 46 (8) 9 (8) 55(8)
Hip or knee osteoarthritis 161 (28) 40 (37) 201 (30)
Hand osteoarthritis 113 (20) 24 (22) 137 (20)
Rheumatoid arthritis 25 (4) 8 (7) 33 (5)
Neck/shoulder complaints 302 (53) 50 (46) 352 (52)
Hip complaints 236 (42) 40 (37) 276 (41)
Knee complaints 266 (47) 47 (43) 313 (46)
Headache/migraine 89 (16) 16 (15) 105 (16)
Feet problems 155 (27) 37 (34) 192 (28)
Gout 20 (4) 7 (6) 27 (4)
Neurological problems 21 (4) 7 (6) 28 (4)
Osteoporosis 75 (13) 23 (21) 98 (14)*
* p< 0.05, ** p< 0.01
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was no significant difference in the prevalence of the following complaints between 
patients aged >55–74 and ≥75 years: hip/knee osteoarthritis, which was 28% and 37%, 
respectively; rheumatoid arthritis, which was 4% and 7%, respectively; and depression, 
which was 8% and 8%, respectively.
discussiOn
The present study reports the characteristics of 675 patients aged >55 years visiting their 
GP for back pain. Back pain severity, level of disability and duration between consultation 
and baseline measurement were somewhat higher for patients who were invited to join 
the study directly during the consultation compared with those retrospectively identi-
fied and approached within 2 weeks after the consultation. Comparison of patients aged 
>55–74 and ≥75 years shows a significant difference in disability (RDQ score 9.4 and 
12.1, respectively). Patients aged ≥75 years reported significantly higher pain severity 
at the moment of filling in the questionnaire, but the magnitude of the difference (0.6) 
was small, and no difference was found between the two groups for average back pain 
severity in the previous week. Patients aged ≥75 years more often reported other mus-
culoskeletal complaints, as well as high blood pressure, heart diseases, osteoporosis, 
kidney diseases, and anaemia or other blood diseases. Also, the older group more often 
had lower bonequality than the younger patients. 
The review of Pengel et al.8 describes the course of acute back pain patients. The 
baseline pain scores of the studies range from 12 to 65 (on a 100-point scale for pain) 
and a similar range was found for disability scores, making comparison with our results 
difficult.8 Previous research about the difference of pain severity between age groups 
of other musculoskeletal complaints, such as hip, knee and ankle pain, already indicate 
that older adults experience higher pain severity than younger adults.11 28 Although we 
found a significant difference between our two age groups for back pain severity and 
disability, the difference is very small. Several studies reported on the minimally clini-
cally important change, ranging from 2 to 8 points for the RDQ and ranging from 2 to 
4.5 points on the 11-point NRS scale.29 30 Proposed consensus for clinically meaningful 
changes for back pain patients on an 11-point NRS scale and for the RDQ are 2 and 5 
points, respectively.31 The differences between our age groups were smaller, probably 
indicating no clinically relevant differences, but it is unknown whether these differences 
will increase in case of a greater age difference between the study groups. 
The older patients in our study experience more depressive symptoms and lower 
quality of life. Other studies indicated that there is an association between pain and 
depression in older adults, but not in younger adults.32 33 This association could explain 
the difference between depressive symptoms between the age groups. In our study 
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population, the medical consumption of the back pain patients did not differ between 
the age categories. The percentage of patients who used pain medication and the per-
centage of patients who received care from a physical therapist were more or less the 
same. Other research indicated that older back pain patients more frequently received a 
medication prescription and less often a referral to physical therapy. However, these dif-
ferences increased when there was a greater difference between the age categories.34 35 
Our study population has a higher percentage of patients with a history of back pain 
compared with other back pain study populations.7 36 The age difference between the 
various study populations is a likely explanation for this finding. Other studies conducted 
among the general population comparing different age categories also found some 
similar differences, e.g., older patients in general, and older patients with musculoskeletal 
complaints, experienced more disability than younger patients.12 37 38 Increased age and 
multi-morbidity were significantly associated with lower quality of life.39 40 The number 
of co-morbidities increases with increasing age and patients with co-morbidity used 
healthcare services more often than patients with one health problem.9 41 Bone density 
and bone mass decrease with older age, especially in women.42 43 Decreased bone quality 
was associated with pain severity in older patients with hand osteoarthritis.44 All these 
differences between age categories might influence the course of back pain and should 
be taken into account when GPs consider their treatment approach. Prognostic research 
should examine whether these characteristics are predictors for recovery. 
A limitation of the present study is that patient inclusion was accomplished either 
through invitation directly during consultation or those retrospectively identified and 
approached within 2 weeks after the consultation. This resulted in small baseline differ-
ences between these groups in back pain severity and disability. This is probably due to 
the difference in the number of days between consultation and baseline measurement. 
Nevertheless, because mean age is similar in both inclusion groups and the percentage 
of patients retrospectively identified and approached within two weeks after the consul-
tation was the same (84%) in both age categories, comparison between the age groups 
within the total population is possible. Using both methods may have decreased the risk 
of recruiting a more selective sample and increased external validity. Another limitation 
is that, due to the workload of the participating GPs, not all consecutive eligible patients 
were referred to the study during consultation. However, when recruiting patients after 
the consultation, all consecutive eligible back pain patients were invited to participate. 
This resulted in a higher participation rate when patients were invited directly during 
consultation. Because there was no information available about the patients who re-
fused to participate, it is unknown if this influenced the results. 
In summary, the older patients reported more severe disabilities and co-morbidity. 
However, the clinical relevance of these differences for the course of the back pain 
episode in these older patients remains a topic for further research. 
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ABstRAct 
Background
Neuropathic symptoms are reported in 16-55.6% of patients with back pain. Studies 
were performed in various populations, however, none focused on older adults. The aim 
of the study was to assess prevalence of neuropathic pain in older adults with back pain.
methods
Prevalence of neuropathic pain, measured with the Dolour Neuropathique en 4 ques-
tions (DN4), was assessed in the BACE study (Netherlands). Patients (>55 years) consult-
ing their general practitioner with a new episode of back complaints were included. Two 
DN4-versions were used; one based on interview plus physical examination, the other 
based on interview alone. In the interview plus physical examination version, patients’ 
and complaint characteristics were compared between groups with different scores 
(0,1,2,3, and ≥4). The DN4 interview-version compared patients with negative and posi-
tive scores.
Results
Of the 261 included patients available for analysis were 250 patients (95.8%) with the 
DN4 interview plus physical examination, and 259 patients (99.2%) with the DN4 inter-
view. DN4 interview plus physical examination (n=250): 5 patients (2%) scored positive 
(score ≥4). Higher score was associated with pain radiating below the knee (p<0.001) 
and use of paracetamol (p=0.02). DN4 interview (n=259): 29 (11.2%) patients scored posi-
tive (score ≥3). Positive score was associated with higher body mass index (p=0.01), pain 
radiating below the knee (p=0.001) and use of paracetamol (p=0.002). 
conclusions
In older adults with back pain presenting with a new episode in primary care prevalence 
of neuropathic pain is low and seems to be associated with pain radiating below the 
knee, use of paracetamol and higher body mass index.
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intROductiOn 
Back pain is an important health problem in the community1-3 with the low back being 
the most affected area.4 A recent systematic review estimated the point prevalence of 
low back pain in the open population to be 11.9%.3 In older adults, benign or mild back 
pain seems to be less frequent compared to other age groups, but they experience 
more episodes with severe or disabling back pain.5 Pain in older adults is reported to 
last longer compared to younger patients with back pain.4 With the aging population it 
is likely that a greater number of people will suffer from severe back pain in the future. 
Costs related to back pain are a substantial burden on society.2 6 As the prevalence of 
seeking healthcare for back pain increases with age,2 costs will probably also increase 
in the coming decades. It is noteworthy that patients with neuropathic pain use more 
health care compared to patients with nociceptive pain.7 
Neuropathic pain is defined as pain arising as a direct consequence of a lesion or 
disease affecting the somatosensory system either at peripheral or central level.8 In 
back pain, although the mechanism of neuropathic pain is not fully understood, most 
likely different mechanisms play a role in the development of neuropathic pain. It is 
thought that back pain can be a ‘mixed’ pain consisting of nociceptive and neuropathic 
components. Neuropathic pain may be caused by lesions of nociceptive sprouts in 
the degenerated intervertebral discs, by mechanical compression of the nerve root 
or by action of inflammatory mediators from degenerated intervertebral discs.9 It is 
important to identify patients with neuropathic pain and neuropathic components 
because conventional analgesic treatment may be less effective in this population.10-12 
Thus identification of patients with neuropathic pain may guide the choice of further 
investigation and/or therapy. Various screening instruments are available to identify 
neuropathic pain, such as Dolour Neuropathique en 4 questions (DN4),13 LANSS14 and 
painDETECT.15 These screening instruments have a sensitivity ranging from 66-85% and 
specificity from 74-90%.13-18 The DN4 has shown good face validity and interrater reliabil-
ity in the general population, tested in persons with a mean age of 56 years (SD 17),13 the 
validity remained the same whether the patients had neuropathic pain or mixed pain 
syndromes. The DN4 is also validated in back pain patients aged 22 to 85 years of age. 
Neuropathic symptoms are reported in 16-55.6% of patients with low back pain, with 
and without radiating leg pain.13 19-24 The range is broad because studies were performed 
in various populations. However, none of the studies focused on older adults. In this 
cross-sectional survey we assessed the prevalence of neuropathic pain using the DN4 in 
older adults who consulted their general practitioner (GP) with a new episode of back 
complaints. Furthermore we compared two different DN4 versions and evaluated whether 
differences exist in patients’ and back complaint characteristics such as duration of back 
pain and back pain severity between the groups with and without neuropathic pain. 
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methOds 
The present study included a subpopulation from the BACE (Back Complaints in the 
Elders) study in the Netherlands.25 Patient inclusion in this Dutch BACE study (n=675) 
took place from March 2009 until September 2011. In BACE, patients aged >55 years 
were included when they consult a GP with a new episode of back complaints. Back 
complaints were defined as pain in at least a part or the whole region from the top of 
the shoulder blades to the first sacral vertebra. If a patient had not visited the GP with 
the same back complaints in the preceding six months it was considered a new episode. 
Thus, the sample also included patients with longer durations of back pain who had not 
visited their GP in the preceding six months for evaluation of this condition. Patients 
were excluded if they were unable to fill out the questionnaires due to cognitive impair-
ment (e.g. dementia or stroke) or were not able to read and write in Dutch. Patients 
who were unable to undergo physical examination (e.g. wheelchair-bound patients) 
were also excluded. For more details see the design article of the BACE study.25 The 
subpopulation used in the present study consisted of patients included from January 
2011 onwards. From this moment on neuropathic pain was measured in the participat-
ing patients during baseline measurement. 
The Medical Ethics Committee of Erasmus Medical Center in Rotterdam approved the 
study protocol.
measurements
At the entry of this study a baseline questionnaire was completed by the patients 
and physical examination of the back took place. The questionnaire included socio-
demographic characteristics, patients self-reported comorbidity, use of medication, and 
duration and localization of pain. Severity of pain was measured on an 11-point numerical 
rating scale (NRS) with 0 as ‘no pain’ and 10 representing ‘worst pain ever’.26 Disability was 
measured with the Roland Morris Disability Questionnaire (RDQ).27 The RDQ scores range 
from 0 (no disability) to 24 (severe disability). Quality of life was measured with the Short-
Form 36 (SF-36), Dutch version.28 The SF-36 measures eight dimensions: physical function, 
role-physical function, bodily pain, general health, vitality, social function, role-emotional 
function and mental health. These eight dimensions can be recoded into two summary 
scores: a physical component summary score and a mental component summary score. 
Each dimension and summary score is scored from 0-100 with a higher score representing 
better health.29 30 Summary scores were calculated with adapted Z-values, in view of the 
higher mean age of our study population.28 Depression was measured with the Center 
for Epidemiologic Studies Depression Scale (CES-D) (range 0-60). Patients with a higher 
score are more prone to depression.31 Pain catastrophizing was measured with the pain 
catastrophizing scale (PCS) (range 0-52) with a higher score representing a higher risk 
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for catastrophizing.32 Back beliefs were investigated with the back beliefs questionnaire 
(BBQ).33 Lifestyle factors included smoking and drinking alcohol. Drinking alcohol was 
measured with the Audit-C.34 35 Women were defined as possible hazardous drinkers if 
they scored ≥3 on the scale, men if they scored ≥4. During physical examination, body 
weight and height were measured and converted to body mass index (BMI). 
For this sub-study we included those patients who completed both the DN4 interview plus 
physical examination. The DN4 consists of a seven-item interview and a three item physical 
examination with a score range of 0-10. The interview consisted of questions about the pain 
characteristics (burning, painful cold, electric shocks, tingling, pins and needles sensation, 
numbness and itchiness), the physical examinations tested sensitivity to touch, pinprick and 
brush. For a more detailed description of the DN4, see appendix A. In a general population 
a score of ≥4 indicates neuropathic pain with a sensitivity of 83% and a specificity of 90%.13 
The DN4 is validated in patients with chronic low back pain in the age of 22 to 85 years36 and 
linguistically validated in Dutch.37 The interview (hereafter called the ‘DN4 interview’) can 
also be used without the physical examination. In the DN4 interview, the maximum score is 
7 and a score of ≥3 indicates neuropathic pain (sensitivity 82% and specificity 86%).38 
statistical analysis
Descriptive statistics were used to present patient characteristics in frequencies for all 
variables with categorical data and to calculate mean and standard deviation (SD) for 
continuous variables.
The DN4 interview plus physical examination, and the DN4 interview alone, were 
analyzed separately. For the DN4 interview plus physical examination patients’ and 
complaint characteristics were compared between all groups with different scores (0, 1, 
2, 3, and ≥4) with the one-way analysis of variance (ANOVA) for variables with numeri-
cal data. Patients with a score of 4 and 5 were analyzed together because of the small 
number of patients with these scores. There were no patients with a score of 6 or more. 
Groups were tested for equal variances using Levene’s test, and a Kruskal-Wallis test was 
used if assumptions for normality were not satisfied. Categorical variables were analyzed 
with the chi-square test linear by linear, in which all groups with different scores were 
compared. In the DN4 interview analysis, patients’ and complaint characteristics were 
compared between patients with a negative and a positive DN4 score using an inde-
pendent sample t-test. Levene’s test was used to test equal variances; if assumptions 
for normality were not satisfied a Mann-Whitney U test was performed. Variables with 
categorical data were analyzed using the chi-square test. If >20% of the cells contained 
an expected count of <5, the tables were reduced. If the 2x2 table still had an expected 
count <5, Fisher’s exact test was performed. Reported p-values were from 2-sided tests 
and a p<0.05 was defined as statistically significant. All analyses were performed using 
SPSS software (version 17.0 for Windows, Chicago, IL, USA).
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Results 
The present study included 261 (38.7%) of the 675 patients from the Dutch BACE study. 
All patients answered the DN4 questions, but two patients did not answer all the ques-
tions in the interview. Nine patients did not have a complete DN4 physical examination. 
Therefore, 250 patients (95.8%) were available for the DN4 interview plus physical exami-
nation analysis, and 259 patients (99.2%) were available for analysis of the DN4 interview.
table 1. Baseline patient characteristics of the study population. 
All patients (n=261)
Age in years 66.4 ± 7.6
Male, n(%) 103 (39.5)
BMI 27.7 ± 4.7
Low education level, n (%) 106 (40.6)
Smoking, n (%) 43 (16.5)
Hazardous drinkinga, n (%) 122 (46.7)
Severity of back painb 5.0 ± 2.7
Disabilityc 9.8 ± 5.7
Duration of back pain >3 months, n (%) 62 (23.8)
Time in days between consultation with general practitioner and the DN4 29.0 ± 12.8
Pain radiates to below the knee, n (%) 81 (31.0)
Pain location only lumbar, n (%) 188 (72.0)
Use of pain medication for back pain, n (%): 184 (70.5)
 Paracetamol, n (%) 100 (38.3)
 NSAID, n (%) 97 (37.2)
 Opioid, n (%) 22 (8.4)
 Benzodiazepine, n (%) 16 (6.1)
 Antidepressant or antiepileptic, n (%) 2 (0.8)
Diabetes, n (%) 41 (15.7)
Quality of life physical summary scaled 43.7 ± 9.0
Quality of life mental summary scaled 49.4 ± 10.2
Depressive symptomatologye 9.9 ± 7.8
Pain catastrophizingf 14.0 ± 11.0
Attitude and beliefs about back paing 26.4 ± 7.0
All results are presented as mean ±SD unless stated otherwise. a Hazardous drinking is measured with Audit-
C: range 0-12; ≥3 in woman and ≥4 in men is risk of hazardous drinking; b Measured with numerical rating 
scale; range 0-10; 0 is no pain, 10 is the worst pain imaginable; c Measured with the Roland Morris disability 
questionnaire range 0-24; zero is no disability; d Measured with Short Form 36, range 0-100; higher score is 
higher quality of life; e Measured with CED-D, range 0-60; higher score indicates more prone to depression; 
f Measured with pain catastrophizing scale range 0-52; higher score is more risk for catastrophizing; g Mea-
sured with back beliefs questionnaire range 9-49; higher score is more positive thoughts of recovery
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Patients
Table 1 shows the baseline characteristics of the 261 included patients. The mean age 
of the 261 patients was 66.4 ±7.6 (range 56-87) years. Mean BMI was 27.7 ±4.7. Of these 
patients, 103 (39.5%) were male, 16.5% (43 patients) smoke, and 122 patients (46.7%) 
were at risk for hazardous drinking. Chronic back pain (pain lasting more than 3 months) 
was present in 62 patients (23.8%), and 81 patients (31.0%) had pain radiating below the 
knee. Mean baseline pain severity measured with the NRS was 5.0 ±2.7. Of all patients, 
184 (70.5%) used pain medication. The most frequently used were paracetamol and 
non-steroidal anti-inflammatory drugs (NSAIDs). Mean time between consulting a GP 
and DN4 measurement was 29.0 ±12.8 days. 
dn4 interview plus physical examination
Table 2 shows a comparison of patients’ and complaint characteristics between the dif-
ferent scores of the 250 patients in the DN4 interview plus physical examination analysis. 
Only 5 patients (2%) scored positive on the DN4 interview plus physical examination (4 
patients scored 4; 1 patient scored 5). There was significantly more pain radiation in pa-
tients with a higher DN4 score. Patients with a higher DN4 score also used significantly 
more paracetamol. SF-36 physical summary score tended to be lower in patients with a 
higher DN4 score but the difference was not significant.
dn4 interview
Table 3 presents data on the comparison between patients with positive and negative 
scores on the DN4 interview. 
In the DN4 interview, 111 patients (42.9%) scored 0 points, 85 patients (32.8%) scored 
1 point, and 34 patients (13.1%) scored 2 points. A total of 25 patients (9.7%) scored 
3 points, 3 patients (1.2%) scored 4 points and 1 patient (0.4%) scored 5 points. No 
patients scored higher than 5 (total score range 0-7). Of the 259 patients, 29 (11.2%) had 
a positive score (≥3 points) on the DN4 interview, which indicated neuropathic pain. 
Patients having neuropathic pain had a significantly higher BMI compared to patients 
who did not have neuropathic pain. Patients with neuropathic pain more often had 
pain radiating below the knee and use paracetamol more frequently. Baseline back pain 
severity (NRS pain scale) was higher in neuropathic pain patients, but the difference was 
not significant.
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discussiOn 
Prevalence
In older adults with back pain the prevalence of neuropathic pain was 2% using the DN4 
interview plus physical examination and was 11.2% using the DN4 interview alone. This 
is considerably lower than the 16-55.6% reported by others.13 19-24 There are various pos-
sible reasons for this difference. First, most studies were performed in specialist centers 
(mostly in secondary/tertiary care),13 19-22 24 whereas the present study was performed in 
a primary care setting. Beith et al. analyzed primary care patients with back pain who 
table 2. Comparison of characteristics between scores of the DN4 interview and physical examination 
(n=250) 
0 (n=102) 1 (n=82) 2 (n=37) 3 (n=24) >4 (n=5) p-value
Age in years 67.0 ± 7.2 67.1 ± 8,5 64.7 ± 7.2 64.8 ± 7.0 62.8 ± 4.4 0.31
Male, n (%) 41 (40.2) 32 (39.0) 18 (48.6) 6 (25.0) 3 (60.0) 0.88
BMIa 27.3 ± 4.1 27.4 ± 4.5 28.2 ± 6.0 29.0 ± 4.2 33.2 ± 10.5 0.16
Low education level, n (%) 37 (36.6) 37 (46.3) 15 (40.5) 10 (41.7) 3 (60.0) 0.37
Smoking, n (%) 14 (13.9) 16 (20.0) 7 (18.9) 2 (8.7) 1 (20.0) 0.94
Hazardous drinkingb, n (%) 54 (54.5) 34 (43.6) 17 (45.9) 11 (47.8) 2 (40.0) 0.30
Severity of back painc 4.5 ± 2.7 5.0 ± 2.7 5.5 ± 2.7 5.9 ± 2.2 5.0 ± 3.1 0.15
Disabilityd 8.9 ± 5.6 9.7 ± 5.9 11.1 ± 5.6 11.9 ± 5.1 10.6 ± 5.3 0.10
Duration of back pain >3 months, n (%) 29 (30.9) 14 (19.2) 9 (25.7) 7 (33.3) 1 (20.0) 0.73
Time in days between consultation with 
general practitioner and the DN4
28.4 ± 13.5 28.2 ± 12.0 28.4 ± 10.5 32.1 ± 16.3 28.0 ± 4.7 0.75
Pain radiates below the knee, n (%) 22 (21.8) 24 (30.0) 15 (40.5) 14 (58.3) 3 (60.0) <0.001
Pain location only lumbar 72 (70.6) 62 (75.6) 28 (75.7) 16 (66.7) 3 (60.0) 0.84
Use of paracetamol, n (%) 35 (34.7) 29 (36.3) 14 (37.8) 17 (70.8) 2 (40.0) 0.02
Use of NSAID, n (%) 39 (38.6) 28 (35.0) 17 (45.9) 8 (33.3) 1 (20.0) 0.75
Quality of life physical summary scalee 45.2 ± 9.1 43.7 ± 8.7 40.8 ± 8.7 40.9 ± 8.3 42.0 ± 7.8 0.06
Quality of life mental summary scalee 50.6 ± 9.9 48.8 ± 10.6 47.7 ± 10.6 48.2 ± 10.4 47.8 ± 9.3 0.54
Depressive symptomatologyf 8.8 ± 7.9 10.5 ± 7.6 12.3 ± 8.9 9.6 ± 6.6 13.8 ± 8.2 0.15
Pain catastrophizing g 13.4 ± 10.7 13.8 ± 11.1 15.4 ± 11.3 15.9 ± 11.7 11.4 ± 12.3 0.48
Attitude and beliefs about back painh 26.8 ± 7.0 26.1 ± 6.7 24.9 ± 7.1 27.0 ± 7.3 22.8 ± 6.5 0.77
All results are presented as mean ±SD unless stated otherwise. Bold values indicate a p-value <0.05. 
a Analyzed with the Kruskal Wallis test; b Hazardous drinking is measured with Audit-C: range 0-12; ≥3 in 
woman and ≥4 in men is risk of hazardous drinking; c Measured with numerical rating scale; range 0-10; 0 is 
no pain, 10 is the worst pain imaginable; d Measured with the Roland Morris disability questionnaire range 
0-24; zero is no disability; e Measured with Short Form 36, range 0-100; higher score is higher quality of life; 
f Measured with CED-D, range 0-60; higher score indicates more prone to depression; g Measured with pain 
catastrophizing scale range 0-52; higher score is more risk for catastrophizing; h Measured with back beliefs 
questionnaire range 9-49; higher score is more positive thoughts of recovery
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were referred for physiotherapy, 95% of whom were referred by a GP;23 they reported a 
neuropathic pain prevalence of 16% which is more in line with our findings. 
The screening tools used to measure neuropathic pain may also explain the different 
prevalences. Different tools including the DN4, Leeds Assessment of Neuropathic Symp-
toms and Signs (LANNS),14 Self-report Leeds Assessment of Neuropathic Symptoms and 
Signs (S-LANNS)18 and PainDETECT15 were used. One study compared S-LANNS and DN4 
and obtained a different prevalence for patients with neuropathic pain using these 
different screening tools.21 This difference in prevalence might be due to the absence 
of physical examination in the S-LANSS, resulting in a lower prevalence (33 vs. 42%). 
table 3. Comparison of patients scoring positive or negative on the DN4 interview 
characteristics
negative dn4 
(n=230, 88.8%)
Positive dn4 
(n=29, 11.2%)
mean difference 
(95% ci) p-value
Age in years 66.7 ± 7.7 64.4 ± 6.6 2.3 (-0.6 – 5.2) 0.13
Male, n (%) 93 (40.4) 9 (31.0) 0.33
BMI 27.4 ± 4.5 29.7 ± 5.8 -2.4 (-4.2 – -0.5) 0.01
Low education, n (%) 93 (41.0) 13 (44.8) 0.87
Smokinga 40 (17.6) 3 (10.7) 0.44
Hazardous drinkingb, n (%) 108 (48.4) 13 (46.4) 0.84
Severity of back painc,d 4.9 ± 2.7 5.7 ± 2.3 -0.9 (-1.9 – 0.17) 0.10
Disabilitye 9.5 ± 5.8 11.7 ± 5.0 -2.1 (-4.4 – 0.1) 0.06
Duration of back pain >3 months n (%) 54 (25.7) 8 (30.8) 0.58
Time in days between consultation with 
general practitioner and the DN4
28.7 ± 12.5 31.4 ± 15.0 -2.8 (-7.7 – 2.2) 0.28
Pain radiates below the knee, n (%) 63 (27.8) 17 (58.6) 0.001
Pain location only lumbar, n (%) 169 (73.5) 19 (65.5) 0.09
Use of paracetamol, n (%) 81 (36.0) 19 (65.5) 0.002
Use of NSAID, n (%) 87 (38.7) 9 (31.0) 0.43
Quality of life physical summary scalef 44.0 ± 9.1 41.1 ± 8.1 2.9 (-0.6 – 6.4) 0.10
Quality of life mental summary scalef 49.5 ± 10.3 48.1 ± 10.1 1.4 (-2.5 – 5.4) 0.48
Depressive symptomatologyg 9.8 ± 7.9 10.4 ± 7.0 -0.5 (-3.6 – 2.6) 0.73
Pain catastrophizingh 13.8 ± 10.9 15.1 ± 11.7 -1.2 (-5.6 – 3.1) 0.57
Attitude and beliefs about back paini 26.3 ± 6.9 26.2 ± 7.2 0.1 (-2.6 – 2.8) 0.94
All results are presented as mean ±SD unless stated otherwise. Bold values indicate a p-value <0.05. 
a Analyzed using Fisher’s exact test; b Hazardous drinking is measured with Audit-C: range 0-12; ≥3 in wom-
an and ≥4 in men is risk of hazardous drinking; c Analyzed using the Mann-Whitney U test; d Measured with 
numerical rating scale; range 0-10; 0 is no pain, 10 is the worst pain imaginable; e Measured with the Roland 
Morris disability questionnaire range 0-24; zero is no disability; f Measured with Short Form 36, range 0-100; 
higher score is higher quality of life; g Measured with CED-D, range 0-60; higher score indicates more prone 
to depression; h Measured with pain catastrophizing scale range 0-52; higher score is more risk for catastro-
phizing; i Measured with back beliefs questionnaire range 9-49; higher score is more positive thoughts of 
recovery
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We found a higher prevalence in the DN4 interview group. Physical examination in our 
study was always performed on the spine. Another research group recently suggested 
that physical examination as a part of DN4 should also be performed on other painful 
areas such as the leg.36 This might also explain the lower prevalence of our patients scor-
ing positive on the DN4 interview plus physical examination. On the other hand, the 
tests performed in physical examination may not be as sensitive in older adults. 
A third difference is the duration of back pain. Most earlier studies included patients 
if they had suffered back pain for at least 3 months (chronic pain),13 19 20 22 24 whereas we 
included all patients with back pain irrespective of the duration. In our population mean 
duration ±SD of back pain was 8.1 ±31.9 months (median 1.1 month Interquartile range 
0.7-3.3 months) (data not shown). In our population, 23.8% of the patients had chronic 
back complaints. It is possible that the neuropathic component of back pain emerges 
after a longer period of back pain, which might explain this difference in neuropathic 
pain prevalence. 
interpretation of findings
Use of paracetamol was more frequent in patients with a positive neuropathic pain 
score. Torrace et al.39 reported that patients with neuropathic pain in primary care took 
stronger painkillers, although they did not report ‘over-the-counter’ medications these 
people used. In the present study almost all patients were treated with conventional 
analgesics rather than with anti-neuropathic drugs; this is in line with the results from 
a Belgian study.40 Also, a rat study showed that paracetamol has peripheral antial-
lodynic and antihyperalgesic effects,41 mechanism which might contribute to pain 
relief in patients with neuropathic pain. It is likely that patients with neuropathic pain 
experience pain relief after taking paracetamol and therefore continue to use them. On 
the other hand conventional analgesic treatment is also reported to be less effective in 
neuropathic pain.10-12 Patients might also use more paracetamol because they did not 
experience sufficient pain relief. 
In the present study, pain radiating below the knee was associated with neuropathic 
pain, which is in line with other reports36 38 and with the belief that neuropathic mecha-
nisms play a greater role in leg pain than in non-radiating back pain.15 24 42 
The physical summary score of the SF-36 tended to be lower in patients with a higher 
score on the DN4, but the difference was not significant. In the community, neuropathic 
pain is associated with lower scores on all dimensions of the SF-36 (7, 43). These results 
were also observed in a study investigating primary care patients.23 Probably, our study 
was not sufficiently powered to show significant difference between the groups. 
Severity of back pain measured with the NRS tended to be higher in patients with 
a positive DN4 score, but the difference was not significant. Although some studies 
reported an association between neuropathic pain and pain severity,23 38 43-45 only one of 
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these studies was performed in back pain patients.23 Another study showed no associa-
tion between neuropathic pain and back pain severity.20 It is possible that older adults 
experience pain differently from younger persons, as demonstrated in back pain.4 5 Also, 
our lack of association between pain severity and a positive score on the DN4 might be 
due to the small number of patients scoring positive on the DN4. 
We found no associations between neuropathic pain and age, gender and duration 
of back pain. Recent literature shows conflicting results concerning these characteris-
tics. Some data are in line with ours,20 40 whereas others found associations with higher 
age19 22 38 44 and gender.19 22 38 44 45 However, those studies were performed in a general 
population or in secondary care, while our study was performed in primary care. The 
studies that found an association with age included a younger group than ours, and 
their mean age remained under 55 years; in view of the 10-year difference in mean age 
the effect they found may no longer present at older age (55 years and over). Only Bou-
hassira et al.38 reported that neuropathic pain increases with age, peaking at 50-64 years 
in a general population. It is possible that we found no association with age because our 
patients were over 55 years of age and the age range of our population was too small. 
Some studies reported an association between neuropathic pain and the duration 
of pain,38 44 but was not present in a study on patients with back pain.36 Also, we found 
no association between neuropathic pain and duration of pain; however, this might be 
because the studies which found an association were performed in the general popula-
tion. Also, in the present study, older patients may not precisely recall how long they 
experienced pain. However, to reduce such recall bias, patients with cognitive problems 
were excluded. 
We also examined depression and disability, because these have also been associated 
with neuropathic pain.7 23 46 However, other studies reported no difference in disability 
and depression between patients with and without neuropathic pain.21 47 In our patients, 
although disability tended to be higher in the positive group the difference was not 
significant and may be due to insufficient power. 
strength and limitations
The present study evaluated neuropathic pain in older adults reporting back pain in 
general practice. Other studies analyzed neuropathic pain in older adults pooled with 
patients of all ages. Our study provides additional information about neuropathic pain 
specific to older adults, which might be important because these patients might experi-
ence pain differently.4 5 
We found a low prevalence of neuropathic pain in older adults with back pain using 
two versions of the DN4. Due to this low number of patients scoring positive on the 
DN4, it is difficult to make statements about the differences between patients with and 
without neuropathic pain. Before we can make any firm statements about the found 
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associations in this study, similar research should be performed in a larger population 
of older adults. Statistical power of this study would have increased if all patients of 
the Dutch BACE cohort had filled in the DN4. However, because we decided to include 
the DN4 measurement about halfway through the inclusion-period of the BACE-study, 
less patients could be included. However, because we continued to include consecutive 
patients for this sub-study it is unlikely that we introduced selection-bias. Furthermore, 
we analyzed multiple variables in a small population which could have led to findings 
by chance. 
It is thought that neuropathic pain is not just positive or negative, but can be more or 
less neuropathic.47-49 This is why we analyzed all scores separately and pooled patients 
scoring 4 or 5 on the DN4 interview plus physical examination. Still most patients scored 
low on the DN4. Because specific symptoms were examined in DN4 this does not mean 
that their pain could not have a neuropathic component, but it makes it less likely. 
conclusions and clinical implications
This study shows a low prevalence of neuropathic pain in older adults with a new 
episode of back pain (2% on the DN4 interview plus physical examination and 11% on 
the DN4 interview alone). Neuropathic pain seems to be associated with pain radiating 
below the knee, increased use of paracetamol and higher BMI. Patients with neuropathic 
pain could benefit from different treatment options. Although the prevalence is low, it is 
important that clinicians are aware of the possibility of neuropathic pain in older adults 
with back pain presenting in general practice. 
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APPendix A
dn4 Questionnaire
Please complete this questionnaire by ticking one answer for each item in the 4 ques-
tions below:
inteRView Of the PAtient
Question 1: Does the pain have one or more of the following characteristics?
Yes No
1 – Burning
2 – Painful cold
3 – Electric shocks 
Question 2: Is the pain associated with one or more of the following symptoms in the 
same area?
Yes No
4 – Tingling
5 – Pins and needles
6 – Numbness
7 – Itching
exAminAtiOn Of the PAtient
Question 3: Is the pain located in an area where the physical examination may reveal one 
or more of the following characteristics?
Yes No
8 – Hypoesthesia to touch
9 – Hypoesthesia to prick
Question 4: In the painful area, can the pain be caused or increased by:
Yes No
10 – Brushing
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ABstRAct
Background
The aim of the current study was to determine the course of back pain in older patients 
and identify prognostic factors for non-recovery at 3 months’ follow-up.
methods
We conducted a prospective cohort study (the BACE study) of patients aged >55 years 
visiting a general practitioner (GP) with a new episode of back pain in the Netherlands. 
The course of back pain was described in terms of self-perceived recovery, pain severity, 
disability, pain medication, and GP visits at 6 weeks’ and 3 months’ follow-up. Prognostic 
factors for non-recovery at 3 months’ follow-up were derived from the baseline ques-
tionnaire and physical examination. Variables with a prognostic value were identified 
with multivariable logistic regression analysis (method backward), and an area under 
the receiver operating curve (AUC) was calculated for the prognostic model.
Results
A total of 675 back pain patients (mean age 66.4 (SD 7.6) years) participated in the BACE 
cohort study. At 6 weeks’ follow-up 64% of the patients reported non-recovery from 
back pain. At 3 months’ follow-up 61% still reported non-recovery, but only 26% of these 
patients had revisited the GP. Longer duration of the back pain, severity of back pain, 
history of back pain, absence of radiating pain in the leg below the knee, number of 
comorbidities, patients’ expectation of non-recovery, and a longer duration of the timed 
‘Up and Go’ test were significantly associated with non-recovery in a multiple regression 
model (AUC 0.79). 
conclusion
Longer duration of the back pain, severity of back pain, history of back pain, absence of 
radiating pain in the leg below the knee, number of comorbidities, patients’ expectation 
of non-recovery, and a longer duration of the timed ‘Up and Go’ test were significantly 
associated with non-recovery . This information can help GPs identify older back pain 
patients at risk for non-recovery.
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intROductiOn
In clinical guidelines the course of back pain is often described as favorable for most 
patients, although it is also often emphasized that recurrence of back pain is com-
mon.1-3 Recovery rates vary widely between studies because of different study popula-
tions and outcomes.4 5 The course of back pain may also differ between patients, because 
individual factors (e.g. age, duration of back pain, or general health) can influence the 
course.6 7 
Information on the course and prognostic factors for non-recovery of back pain is help-
ful for clinicians to better inform their patients. It might also be useful to select (effec-
tive) treatment when modifiable prognostic factors for non-recovery are found. Hayden 
et al. reported that many inconsistent findings exist between reviews on prognostic 
factors for back pain.4 Variables consistently reported as prognostic factors for different 
unfavorable outcomes were older age, poor general health, increased psychological or 
psychosocial stress, poor relations with colleagues, physically heavy work, worse func-
tional disability at baseline, sciatica, and the presence of work compensation.4 Although 
older age is frequently reported as a prognostic factor for non-recovery,6-8 information 
on demographic and clinical factors associated with non-recovery during follow-up for 
older back pain patients is lacking.9 The course of back pain and factors associated with 
non-recovery might differ between younger and older adults, because 1) older age is 
often reported as a prognostic factor for non-recovery, 2) older age is also considered a 
'red flag' in patients with back pain, i.e. indicating possible underlying pathology, which 
could influence the course of back pain,1 10 and 3) older people have more comorbidi-
ties.11 
Therefore, the aim of the present study is to describe the course of back pain patients 
aged >55 years recruited in general practice, and to identify prognostic factors for non-
recovery of back pain in these patients at 3 months’ follow-up.
methOds
study design
This is a prospective cohort study including back pain patients aged >55 years consult-
ing their general practitioner (GP) with a new episode of back pain (the BACE study). An 
episode was defined as ‘new’ if the patient had not visited a GP during the preceding 
6 months for the same back complaint. Back pain was defined as pain in the region 
from the top of the scapulae to the first sacral vertebra. Exclusion criteria were language 
problems, cognitive disorders, or being unable to complete the physical examination 
(e.g. wheelchair-bound patients). Eligible back pain patients were invited to participate 
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in the BACE study by their GP either directly during consultation, or in writing within 2 
weeks after consultation. After inclusion in the BACE study and having signed informed 
consent, the baseline measurements included a questionnaire and a physical examina-
tion of the back. The follow-up period of this study was 3 months, with two follow-up 
measurements: at 6 weeks and at 3 months. The study protocol was approved by the lo-
cal Medical Ethics Committee. The BACE study design is described in detail elsewhere.12
measurements
The questionnaires are based on the Multinational Musculoskeletal Inception Cohort 
Study (MMICS) statement.13 This is a consensus statement designed to improve the qual-
ity of back pain prognosis research by recommending a core set of measurements. The 
baseline questionnaire and physical examination included measurements of potential 
prognostic factors for non-recovery. Follow-up questionnaires at 6 weeks and 3 months 
included the following outcome measurements: 1) self-perceived recovery measured 
with the Global Perceived Effect (GPE) on a 7-point scale ranging from ‘completely 
recovered’ to ‘worse than ever’,14 2) average severity of back pain during the previous 
week measured on an 11-point numeric rating scale (NRS) ranging from 0 ‘no pain’ to 
10 ‘worst pain ever’,15 3) disability, measured with the Roland Disability Questionnaire 
(RDQ), ranging from 0 points (no disabilities) to 24 points,16 4) medication used for back 
pain: a dichotomous variable asking if the patient took pain medication in the 3 months 
preceding the follow-up questionnaire, and 5) a GP visit in the 3 months preceding the 
follow-up questionnaire (yes/no). 
The potential prognostic factors for non-recovery selected for this study were those 
factors that had been identified as prognostic factors in the previous literature and/or 
deemed clinically relevant. These factors were divided into two categories: 
(1) History taking: including patients’ characteristics and characteristics of the back 
disorder. The following patient characteristics were included: age, sex, education level, 
body mass index (BMI), patients’ expectation of recovery, quality of life; physical and 
mental summary scales of the Short Form-36 (SF-36),17 depressive symptomatology 
measured with the Center for Epidemiologic Studies Depression Scale (CES-D),18 kinesio-
phobia measured with the Fear-Avoidance Beliefs Questionnaire (FABQ) physical activity 
subscale,19 pain catastrophizing measured with the Pain Catastrophizing Scale (PCS),20 
comorbidity of musculoskeletal symptoms (neck, shoulder, knee or hip symptoms) 
and the number of comorbidities measured with the Self-Administered Comorbidity 
Questionnaire (SCQ).21 The symptoms measured with the SCQ were heart disease, high 
blood pressure, lung disease, diabetes, ulcer or stomach disease, kidney disease, liver 
disease, anemia or other blood disease, cancer, depression, osteoarthritis, rheumatoid 
arthritis, neck/shoulder complaint, headache, foot problems, and neurological disorder. 
The following characteristics of the back disorder were included: duration of the back 
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pain at baseline, severity of back pain at baseline measured on an 11-point NRS, baseline 
disability measured with the RDQ, history of back pain, the presence of radiating pain in 
the leg below the knee, and perceived cause of the back pain. 
(2) Physical examination: including anteflexion (finger-floor distance in cm), difference 
in quadriceps strength between the right and left leg, Lasègue test,22 timed ‘Up and Go’ 
test,23 and bone quality measured using Lunar Achilles InSight (quantitative ultrasound 
measurement of the heel).24 Low bone quality is defined as a score of >2.5 standard de-
viations (SD) lower than the population mean. Information regarding red flags (indica-
tors for possible underlying pathology) were also collected in the BACE study. However, 
the prognostic value of these factors was not the subject of this study. The prevalence of 
these factors and their diagnostic value will be described elsewhere.
statistical analysis
Descriptive analysis was used to report the characteristics of the participants and the 
course of back pain over the 3-month follow-up period.
To identify prognostic factors, an unfavorable outcome was defined as non-recovery, 
i.e. a score a score of ‘somewhat improved’, ‘stayed the same’, ‘somewhat worsened’, 
‘strongly worsened’ or ‘worse than ever’ on the GPE scale. Recovery was defined as a 
score of ‘completely recovered’ or ‘strongly improved’. Imputation of missing data of 
the baseline prognostic variables was carried out by multiple imputation, creating 
five imputed databases.25 Bivariate logistic regression analysis was performed to gain 
insight into the association between the baseline variables and outcome. A multivariate 
logistic regression analysis (method backward, entry P < 0.05, removal P > 0.10) was first 
performed with the history-taking variables on all five imputed databases. If a variable 
was selected in at least three of the five imputed databases in the multivariate analysis, 
it was included in the final model (method enter). To determine the discriminative abil-
ity of the model, the area under the receiver operating curve (AUC) was calculated. An 
AUC of 0.5–0.7 is considered as moderate discrimination, and an AUC ofP0.7 as good. 
After selection of these variables, the same analysis of the multivariate (backwards) 
regression analysis was performed with the variables of the physical examination added 
to the history-taking model in order to examine the additional value of the physical 
examination. Sensitivity analysis was performed for the method of patient recruitment 
in the study.
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All patients with back complaints,
aged >55 years, consulting  their 
general practitioner
 
Patients invited to participate (n= 1402)
- A: Direct during consultation (n=141)
- B: In writing after consultation (n=1261)
 
Exclusion reason:
- Patients did not meet inclusion criteria
 
 
Exclusion reason (n= 727):
- Patients not willing to participate (n=291)
- Patients did not meet inclusion criteria (n=118)
- Reason unknown (n=318)
Inclusion (n=675)
- Via A: direct during consultation (n=105)
- Via B: In writing after consultation (n=570)
 
 
Lost to follow-up (n=9):
- No longer interested to participate (n=3)
- Patient deceased (n=1)
- Cognitive impairment (1)
- Reason unknown (n=4)
Baseline measurements (n=675)
- Returned questionnaire (n=669)
- Physical examination (n=670)
 
6 weeks follow-up (n=666)
- Returned questionnaire (n=639)
 
3 months follow-up (n=662)
- Returned questionnaire (n=626)
 
Lost to follow-up (n=4):
- No longer interested to participate (n=3)
- Health issues (n=1)
figure 1. Flow chart of patient recruitment and follow-up
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table 1. Baseline characteristics of the study population.
study population
n=675
Number of days between consultation and baseline physical examination: median (IQR) 23 (16-31)
history taking
Age in years: mean ± SD 66.4 ± 7.6
Male: n (%) 274 (41)
body mass index: mean ± SD 27.5 ± 4.7
Education level low: n (%) 279 (41)
Marital status married: n (%) 479 (71)
Employed (paid job): n (%) 177 (26)
Patients’ expectation to recover of back pain: n(%) 291 (43)
Quality of life: SF-36 Physical summery scale: mean ± SD 43.2 ± 8.9
Quality of life: SF-36 Mental summery scale: mean ± SD 49.6 ± 10.3
Depressive symptomatology (CES-D): mean ± SD 10.0 ± 7.7
Kinesiophobia (FABQ): mean ± SD 13.4 ± 5.8
Pain catastrophizing (PCS): mean ± SD 14.1 ± 10.6
Co-morbidity musculoskeletal complaints: n (%) 519 (77)
Co-morbidity (number of other complaints): mean ± SD 2.3 ± 1.9
Duration of back pain in days: median (IQR) 35 (20-100)
Duration of back pain > 3 months: n (%) 156 (23)
Severity of back pain (NRS): mean ± SD 5.2 ± 2.7
Pain radiating in the leg below the knee: n (%) 205 (30)
Disability: (RDQ): mean ± SD 9.8 ± 5.8
History of back pain: n (%) 579 (86)
Perceived cause: accident or trauma: n (%) 28 (4)
Physical examination
Finger-floor distance (in cm): mean ± SD 10.9 ± 11.9
Quadriceps strength difference: n (%) 78 (12)
Positive test of Lasègue: n (%) 100 (15)
Timed 'Up and Go' test (in sec): mean ± SD 11.1 ± 3.9
Low bone quality: n (%) 77 (11)
IQR: interquartile range (presented as 25%-75% IQR), SD: standard deviations, SF-36: Short Form-36 (range 
0 ‘low quality of life’ -100 points), CES-D: Center for Epidemiologic Studies Depression Scale (range 0 ‘no 
depressive symptomatology ‘ – 60 points), FABQ: Fear-Avoidance Beliefs Questionnaire (physical act. sub-
scale) (range 0 ‘no fear and avoidance beliefs’-28 points), PCS: Pain Catastrophizing Scale (range 0 no pain 
catastrophizing -52 points), NRS: numeric rating scale (range 0 ‘no pain’-10 ‘worst pain ever’), RDQ: Roland 
disability questionnaire (range 0 no disabilities – 24 points).
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Results
Population characteristics
The flowchart of the study is presented in figure 1. A total of 675 back pain patients par-
ticipated in the study. During follow-up, 639 (95%) patients returned the 6-week follow-
up questionnaire and 626 (93%) patients returned the 3-month follow-up questionnaire. 
The baseline characteristics of the study population are presented in table 1. The mean 
age of the patients was 66.4 years (SD 7.6; range 56–91 years). Forty-one percent of the 
patients were male. Of all patients, 41% had a low level education, 26% had a paid job 
and 71% were married. The median duration of the back pain at baseline was 35 days 
(IQR 20–100 days); 23% of the patients reported back pain lasting ≥3 months. Thirty 
percent of the patients had pain radiating in the leg below the knee.
course of back pain 
The baseline assessment and outcomes at 6 weeks’ and 3 months’ follow-up are pre-
sented in table 2. At baseline, the mean back pain severity was 5.2 (SD 2.7); at 6 weeks 
this had decreased to a mean of 3.7 (SD 2.8); and at 3 months’ follow-up to a mean of 3.6 
(SD 2.8). The average disability score, measured with the RDQ, was 9.8 (SD 5.8) at base-
line and was 7.8 (SD 6.2) at 3 months’ follow-up. At 6 weeks’ and at 3 months’ follow-up, 
non-recovery was reported by 409 patients (64%) and 380 patients (61%) respectively. In 
total 39% of the back pain patients reported use of pain medication for their back pain 
in the 3 months after baseline measurement, whereas only 26% of the patients reported 
that they had revisited their GP in these 3 months.
table 2. Outcomes at 6 weeks and 3 months follow-up of older back pain patients in general practice.
Baseline
(n=675)
n(%)
6 weeks follow-up
(n=639)
n(%)
3 months follow-up
(n=626)
n(%)
Poor recovery (GPE)a - 409 (64) 380 (61)
Severity of back pain (NRS) 5.2 ± 2.7 3.7 ± 2.8 3.6 ± 2.8
Disability (RDQ); mean ±SD 9.8 ± 5.8 - 7.8 ± 6.2
Taking pain medication for back pain 483 (72) - 246 (39)
Re-visiting GP within 3 months - - 161 (26)
GPE: Global Perceived Effect, NRS: numeric rating scale (range 0 ‘no pain’-10 ‘worst pain ever’), SD: standard 
deviations, RDQ: Roland disability questionnaire (range 0 no disabilities – 24 points)
a GPE 7-point Likert scale, dichotomized in 1,2: recovered, 3-7: poor recovery,
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Prognostic factors for poor recovery
Missing values of the baseline prognostic variables ranged from 0% to 12%. The two 
variables that missed more than 5% were item rheumatoid arthritis of the SCQ (5.3%) 
table 3. Pooled bivariate association between baseline characteristics and poor recovery at 3-months 
follow-up (n=619). 
Poor recovery
OR (95% ci) p value
history taking
Age 1.0 (1.0-1.1) 0.02
Male sex 0.6 (0.4-0.8) <0.01
Low education 1.7 (1.2-2.4) <0.01
Body mass index 1.1 (1.0-1.1) <0.01
Patients’ expectation to recover 0.3 (0.2-0.4) <0.01
Quality of life: SF-36 Physical summery scale 0.9 (0.9-1.0) <0.01
Quality of life: SF-36 Mental summery scale 1.0 (1.0-1.0) 0.06
Depressive symptomatology (CES-D) 1.1 (1.0-1.1) <0.01
Kinesiophobia (FABQ, physical act. subscale) 1.1 (1.0-1.1) <0.01
Pain catastrophizing (PCS) 1.0 (1.0-1.0) <0.01
Co-morbidity musculoskeletal complaints 2.6 (1.8-3.9) <0.01
Co-morbidity (number of other complaints) 1.4 (1.3-1.5) <0.01
Duration of the back pain:
0-6 weeks Reference cat.
6-12 weeks 1.7 (1.1-2.6) 0.02
>3 months 5.5 (3.4-9.1) <0.01
Severity of back pain (NRS) 1.2 (1.2-1.3) <0.01
Disability (RDQ) 1.1 (1.1-1.1) <0.01
History of back pain (yes) 1.8 (1.1-2.9) 0.02
Radiating pain in the leg below the knee 1.2 (0.8-1.7) 0.34
Perceived cause: accident or trauma 1.4 (0.6-3.5) 0.43
Physical examination
Finger-floor distance (in cm) 1.0 (1.0-1.0) 0.42
Quadriceps strength difference 1.8 (1.1-3.1) 0.03
Positive test of Lasègue 1.6 (1.0-2.6) 0.05
Timed ‘Up and Go’ test (in sec) 1.1 (1.1-1.2) <0.01
Low bone quality 1.1 (0.7-1.9) 0.64
SF-36: Short Form-36 (range 0 ‘low quality of life’ -100 points), CES-D: Center for Epidemiologic Studies De-
pression Scale (range 0 ‘no depressive symptomatology ‘ – 60 points), FABQ: Fear-Avoidance Beliefs Ques-
tionnaire (physical act. subscale) (range 0 ‘no fear and avoidance beliefs’-28 points), PCS: Pain Catastrophiz-
ing Scale (range 0 no pain catastrophizing -52 points), NRS: numeric rating scale (range 0 ‘no pain’-10 ‘worst 
pain ever’), RDQ: Roland disability questionnaire (range 0 no disabilities – 24 points).
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and ‘duration of the back pain’ (12% missing). However, for statistical analysis, imputa-
tion of missing data was carried out by multiple imputation. Table 3 shows the pooled 
bivariate associations between baseline characteristics and non-recovery at 3 months' 
follow-up. The characteristics which were associated with non-recovery in the bivari-
ate regression analysis were older age, male sex, low education, patients' expectation 
of non-recovery, low quality of life, physical and mental summary score, depressive 
symptoms, kinesiophobia, pain catastrophizing, the number of comorbidities and mus-
culoskeletal comorbidities, longer duration of the back pain, higher back pain severity, 
more disabilities, history of back pain, difference in quadriceps strength, a positive test 
of Lasègue and longer completing duration of the timed 'Up and Go' test. 
table 4. Multivariable association between baseline characteristics and poor recovery at 3 months follow-
up (n=619).
Poor recovery
Pooled OR (95% ci) p value Auc
history taking 0.78
Patients’ expectation to recover 0.4 (0.3-0.6) <0.01
Quality of life: SF-36 Physical summery scale 1.0 (0.9-1.0) 0.03
Co-morbidity (number of other complaints) 1.2 (1.1-1.4) <0.01
Duration of the back pain:
0-6 weeks ref. category
6-12 weeks 1.9 (1.2-3.1) 0.01
>3 months 4.4 (2.5-7.7) <0.01
Severity of back pain (NRS) 1.2 (1.1-1.3) <0.01
History of back pain (yes) 1.7 (1.0-3.0) 0.06
Radiating pain in the leg below the knee 0.6 (0.4-1.0) 0.05
history taking and physical examination 0.79
Patients’ expectation to recover 0.4 (0.3-0.6) <0.01
Co-morbidity (number of other complaints) 1.2 (1.1-1.3) <0.01
Duration of the back pain:
0-6 weeks ref. category
6-12 weeks 1.8 (1.1-3.0) 0.02
>3 months 4.3 (2.5-7.5) <0.01
Severity of back pain (NRS) 1.2 (1.1-1.3) <0.01
History of back pain (yes) 1.8 (1.0-3.2) 0.04
Radiating pain in the leg below the knee 0.7 (0.4-1.0) 0.06
Timed ‘Up and Go’ test (in sec) 1.1 (1.0-1.2) 0.01
SF-36: Short Form-36 (range 0 ‘low quality of life’ -100 points), NRS: numeric rating scale (range 0 ‘no pain’-
10 ‘worst pain ever’).
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Table 4 shows the pooled multivariate associations between baseline characteristics 
and non-recovery. The history-taking model was calculated with all variables of the 
categories patients’ characteristics and characteristics of the back disorder. The variables 
remaining in the final history-taking model were patients’ expectations of non-recovery, 
low quality of life, physical summary score of the SF-36, the number of comorbidities, 
longer duration of back pain (6–12 weeks or >3 months), higher severity of back pain, 
history of back pain, and absence of radiating pain in the leg below the knee. This model 
had a discriminative ability of AUC of 0.78. 
When the variables of the physical examination were added to this model, the AUC 
remained quite similar (0.79) and the variables associated with non-recovery were pa-
tients’ expectation to recover [odds ratio (OR) 0.4; 95% confidence interval (CI): 0.3–0.6], 
number of comorbidities (OR 1.2; 95% CI: 1.1–1.4), duration of the back pain 6–12 weeks 
(OR 1.8; 95% CI: 1.1–3.0), duration of the back pain >3 months (OR 4.3; 95% CI: 2.5–7.5) 
(0–6 weeks as reference category), severity of back pain (OR 1.2; 95% CI: 1.1–1.3), history 
of back pain (OR 1.8; 95% CI: 1.0–3.2), radiating pain in the leg below the knee (OR 0.7; 
95% CI: 0.4–1.0), and duration of the timed ‘Up and Go’ test (OR 1.1; 95% CI: 1.0–1.2). 
We performed an exploratory sensitivity analysis on the method of patient recruit-
ment. We divided the patient population in two groups: the patients who were invited 
to participate direct during consultation and the patients who were invited in writing. 
Multiple regression analysis (method enter) for the last model (the history-taking and 
physical examination model) was performed for both groups. The magnitude of the 
associations did not change. 
discussiOn
This study presents the 3-month course of back pain in older patients visiting their GP 
and identifies factors associated with non-recovery at 3 months’ follow-up. The mean 
age of the population was 66.4 (SD 7.6) years, range 56–91 years. Pain severity of this 
BACE population decreased from a mean of 5.2 (SD 2.7) at baseline to 3.6 (SD 2.8) at 3 
months’ follow-up. At 3 months’ follow-up 61% of the back pain patients reported non-
recovery. Using a multiple backwards regression model, baseline variables associated 
with non-recovery at 3 months’ follow-up were longer duration of the back pain, severity 
of back pain, history of back pain, absence of radiating pain in the leg below the knee, 
number of comorbidities, patients’ expectation of non-recovery, and a longer duration 
of the timed ‘Up and Go’ test (AUC 0.79). 
When these results were compared with the review by Pengel, which described the 
course of back pain in the total adult population, some similarities and differences were 
found. In their review, Pengel et al. reported that the level of pain decreased rapidly in 
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the first month and continued to decrease, but more slowly, until 3 months’ follow-up.7 A 
similar pattern was found in the present study, i.e. pain severity mainly decreased during 
the first 6 weeks and then only slightly between 6 weeks and 3 months. The studies 
reviewed by Pengel et al. reported a pain reduction of 12–84% from baseline to 1-month 
follow-up.7 In the present study there was a 15% decrease in pain during the first 6 weeks, 
which is less than the pain reduction reported by most of the studies described in the 
review. Pengel et al. only reviewed those studies that included patients with back pain 
lasting less than 3 weeks.7 Acute back pain patients have a more favorable prognosis 
than patients with pain of longer duration.6 However, possible variation in the course 
of back pain may also be attributed to the fact that our study population consisted of 
patients aged >55 years, whereas the included study populations of the review were 18 
years and over.
To our knowledge, this is the first study that examined prognostic factors for non-
recovery of older back pain patients. Most of the variables which were described in the 
literature to be prognostic factors for non-recovery were also bivariately associated with 
non-recovery at 3 months in this study (the work-related variables were not relevant for 
our study population).4 8 Although age is often reported to be a prognostic factor, and 
older age was associated with non-recovery in the bivariate regression analysis, it was 
not a predictor in our multiple regression model. In patients aged >55 years, age might 
lose its predictive power. Furthermore, the presence of radiating pain in the leg below 
the knee was not statistically significant associated with non-recovery in the bivariate 
regression analysis. But in the multiple regression analysis the absence of radiating pain 
in the leg below the knee was associated with non-recovery. The difference between 
binary and multiple logistic analysis could be the result of the influence of other vari-
ables included in the model. Factors reported as prognostic factors in the literature, 
but not significantly associated with the outcome in our population, were perceived 
causes of back pain accident/trauma, and finger–floor distance. Low bone quality was 
included in the analysis because we hypothesized that this variable could be clinically 
relevant; however, it was not associated with non-recovery at 3 months’ follow-up in 
our study population. Furthermore the AUC of the multiple regression model remained 
quite similar when the variables of the physical examination were added to the history-
taking multiple regression model. This indicates that the additional value of the physical 
examination with regard to the discriminative value of the model was small.
A limitation of the study is the missing data in some baseline prognostic variables, 
but imputation is a valid method to address this issue. The summary scores of question-
naires (e.g. the FABQ and CES-D) and the total number of comorbidities had the high-
est percentage of missing values (3.0–16.4%), because this value was already missing 
when one of the items of these questionnaires had not been completed. Therefore, we 
imputed the separate items of the questionnaire (percentage missing 1.0–5.3%) instead 
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of the summary scores, in order to obtain most of the patients’ information. Besides 
these summary scores, the only variables with a missing percentage of >5% were ‘item 
rheumatoid arthritis of the SCQ’ (5.3%) and ‘duration of the back pain (11.9% missing). A 
second limitation is that patients were either included directly during the GP consulta-
tion, or in writing within 2 weeks after the consultation. The time between the consulta-
tion and baseline measurement was longer in the group of patients that were invited in 
writing. Therefore we performed a sensitivity analysis including these latter patients, but 
no large differences in associations were found. 
This present study identified prognostic factors which were associated with non-
recovery at 3 months’ follow-up in older back pain patients. Validation in another group 
of older back pain patients is the next step before these results can be implemented 
in GP practice. Validation is possible in other studies of the BACE consortium; this is a 
collaboration between different research groups which perform cohort studies with the 
same methods and design as used in the present study.
In summary, 61% of these older back pain patients reported non-recovery at 3 months’ 
follow-up. Baseline characteristics associated with non-recovery have been identified. 
This information could serve as a guideline for GPs to better inform back pain patients 
about their prognosis. However, additional studies are needed to validate our results 
before implementation in GP practice is possible.
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ABstRAct
Background
In a small proportion of patients experiencing unspecified back pain, a specified under-
lying pathology is present. The purposes of this study were: (1) to identify the prevalence 
of physician-specified causes of back pain and (2) to assess associations between 'red 
flags' and vertebral fractures, as diagnosed by the patients’ general practitioner (GP), in 
older adults with back pain.
methods
The Back Complaints in the Elders (BACE) study is a prospective cohort study. Patients 
(aged >55 years) with back pain were included when consulting their GP. A question-
naire was administered and a physical examination and heel bone densitometry were 
performed, and the results determined back pain and patient characteristics, including 
red flags. Participants received a radiograph, and reports were send to their GP. The final 
diagnoses established at 1 year were collected from the GP’s patient registry.
Results
Of the 669 participants included, 6% were diagnosed with a serious underlying pathol-
ogy during the 1-year follow-up. Most of these participants (n=33, 5%) were diagnosed 
with a vertebral fracture. Multivariable regression analysis showed that age of ≥75 
years, trauma, osteoporosis, a back pain intensity score of ≥7, and thoracic pain were 
associated with a higher chance of getting the diagnosis of a vertebral fracture. Of these 
variables, trauma showed the highest positive predictive value for vertebral fracture of 
0.25 (95% confidence interval = 0.09, 0.41) and a positive likelihood ratio of 6.2 (95% 
confidence interval = 2.8, 13.5). A diagnostic prediction model including the 5 red flags 
did not increase these values. Low prevalence of vertebral fractures could have led to 
findings by chance.
conclusions
In these older adults with back pain presenting in general practice, 6% were diagnosed 
with serious pathology, mainly a vertebral fracture (5%). Four red flags were associated 
with the presence of vertebral fracture.
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intROductiOn
Most patients with back pain experience unspecified back pain, although in a minority 
of the cases, a specified underlying pathology is present.1-3 Of these specified causes, 
vertebral fractures, malignancies, infection, cauda equina syndrome, and ankylosing 
spondylitis are considered serious pathologies and are estimated to account for 1% to 5% 
of low back pain in primary care.4 5 Vertebral fractures are the most common underlying 
serious pathology in patients with back pain.2 These fractures particularly are more com-
mon in older patients.1 In patients with vertebral fractures, disability is more common 
than in patients with unspecified back pain.6 Identifying patients with vertebral fractures 
is necessary because vertebral fractures can also be an indicator for osteoporosis.7 In 
turn, treatment of osteoporosis can prevent future vertebral fractures.8 9
To identify specified causes of back pain, most clinical guidelines recommend the 
use of 'red flags'.10 11 These alarming symptoms, derived from history taking or physical 
examination, or both, are suggested to have an association with serious pathology as 
a cause of back pain. The prevalence of serious pathology as a cause of back pain rises 
with age, and red flags, consequently, may be more important in patients aged >55 
years.12 Guidelines differ in their recommendations regarding which red flags should be 
used and what the consequence should be when red flags are present. For example, the 
Dutch guideline for general practitioners (GPs) makes no statement about the direct 
consequences if red flags are present, and further diagnostic actions are at the discre-
tion of the patient’s GP.13 The guideline of the American Pain Society advises diagnostic 
imaging and testing if, based on the presence of red flags, a serious underlying pathol-
ogy is suspected.4 A recent systematic review showed that only a limited number of red 
flags are of diagnostic value. The variables older age, corticosteroid use, and significant 
trauma are red flags for a vertebral fracture.14 15 Most individual red flags show poor 
diagnostic accuracy. There are indications that predictive performance can be improved 
when combinations of red flags are used. A first step in combining red flags was a diag-
nostic model for detecting vertebral fractures in primary care, described by Henschke 
et al.2 However, this diagnostic model has not yet been evaluated in other populations. 
The aims of this study were: 1) to identify the prevalence of physicianspecified causes 
(eg, vertebral fractures) of back pain, as identified by the patients’ GP, in older adults with 
back pain and 2) to assess the associations between red flags and vertebral fracture in a 
subgroup of patients diagnosed with vertebral fracture by their GP.
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methOds
Data of the Back Complaints in the Elders (BACE) study, a prospective observational 
cohort in the Netherlands, was used for this study. Patient inclusion (n=675) took place 
between March 2009 and September 2011 in a representative sample of 49 general 
practices in and around Rotterdam. Patients aged >55 years were included when they 
consulted a GP with a new episode of back pain. Back pain was defined as pain in at least 
a part or the whole region from the top of the shoulder blades to the first sacral vertebra, 
with or without pain radiation to the leg. If a patient had not visited a GP with the same 
back pain in the preceding 6 months, this was considered a new episode. Patients were 
invited to join the study by their GP during the consultation or in writing within 2 weeks 
after the consultation. Patients were excluded if they were unable to fill out the ques-
tionnaires due to cognitive impairment, were not able to read and write in Dutch, or 
were unable to undergo physical examination (eg, patients using wheelchairs). Details 
of the BACE study design are described elsewhere.16
data collection
After inclusion in the BACE study and providing written informed consent, baseline 
measures included a questionnaire, a structured physical examination of the back, a ra-
diograph of the back, and heel bone densitometry. The questionnaire asked about par-
ticipant characteristics, features of the back pain, and the presence of red flags. Red flags 
for vertebral fractures were assessed in a questionnaire during the physical examination 
and were retrieved from the GP’s patient registry. The red flags for vertebral fractures 
were age, sex, trauma, sudden decrease in height, acute onset of pain, osteoporosis, 
and prolonged corticosteroid use. Red flags were chosen based on those reported in 
clinical guidelines.4 11 13 17 18 Corticosteroid use in the year before consulting the GP with 
back complaints was retrieved from the GP’s patient registry because this red flag was 
not included in the questionnaire. Other determinants that were considered important 
for diagnosing vertebral fractures were percussion tenderness of the spine,19 disability, 
back pain intensity score, osteoarthritis in the hip or knee, and thoracic pain. These 
variables also were assessed in the questionnaire or during the physical examination.
A radiograph of the lumbar spine was performed. If participants had back pain in the 
region of the thoracic spine, a thoracic radiograph also was performed. The radiographic 
findings reported by the radiologist were sent only to the GPs, who could use this in-
formation in their final diagnoses. Diagnoses were established by the GPs as they do in 
regular daily practice using the clinical guidelines for GPs regarding back pain.13 20
The final diagnosis regarding the back pain was determined at 1-year follow-up from 
the GP’s patient registry. For each patient included in the cohort, the corresponding di-
agnosis was retrieved via the associated International Classification of Primary Care (ICPC) 
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code (L03–unspecified low back pain without radiating pain, L86–unspecified low back 
pain with radiating pain, L76–fracture of the musculoskeletal system, L71–malignancy 
of the musculoskeletal system, L84–osteoarthritis and spondylosis) and by searching 
in the free-text field. All GPs checked the collected diagnoses of their participating 
patients. The final diagnoses were mostly manifest shortly after consulting the GP; 
however, the 1-year follow-up was decided on for the present study to ensure that all 
diagnoses would be evident at that time.
Diagnoses collected were categorized as unspecified back pain and specified back 
pain. Of the specified back pain diagnoses, vertebral fracture, spinal malignancy, an-
kylosing spondylitis, vertebral infection, and cauda equina syndrome were considered 
serious pathologies. 
Participants’ perceived severity of back pain averaged over the previous week was 
measured on an 11-point numeric rating scale (NRS),21 with 0 representing 'no pain' and 
10 representing 'worst pain ever.' Severe pain was defined as an NRS pain score of ≥7, 
as it is shown to be a discriminative cutoff value of severe pain in patients with back 
pain.22 Disability was measured with the Roland-Morris Disability Questionnaire (RDQ).23 
The RDQ scores range from 0 to 24, and a score of ≥17 was defined as severe disability. 
Quality of life was measured with the 36-Item Short-Form Health Survey (SF-36), Dutch 
version.24 The SF-36 measures 8 dimensions: physical function, role–physical function, 
bodily pain, general health, vitality, social function, role– emotional function, and 
mental health. These 8 dimensions can be recoded into 2 summary scores: a physical 
component summary score and a mental component summary score. Each dimension 
and summary score is scored from 0 to 100, with a higher score representing better 
health.25 26 Summary scores were calculated with adapted z-score values, in view of the 
higher mean age of our study population.24
Depression was measured with the Center for Epidemiologic Studies Depression Scale 
(CES-D) (range: 0–60 points). Patients with a higher score are more prone to depression.27 
Pain catastrophizing was measured with the Pain Catastrophizing Scale (PCS) (range: 0–52 
points), with a higher score representing a higher risk for catastrophizing.28 Back beliefs 
were investigated with the Back Beliefs Questionnaire (BBQ) (range: 9–49 points), with a 
higher score representing more positive thoughts on recovery.29 Lifestyle factors included 
smoking (yes/no) and drinking alcohol. Alcohol consumption was measured with the 
Alcohol Use Disorders Identification Test (AUDITC).30 31 Women were defined as possible 
hazardous drinkers if they scored ≥3 on the scale, and men were considered possible 
hazardous drinkers if they scored ≥4. During the physical examination, body weight and 
height were measured and converted to body mass index (BMI). Low education level was 
present if the participant had no education or if the highest level of education was primary 
school or lower vocational education. Trauma, sudden decrease in height, acute onset of 
pain, and osteoarthritis in the hip or knee were self-reported. Corticosteroid use was de-
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fined as oral or inhalation corticosteroid use for more than 90 days. Percussion tenderness 
of the spine was assessed in the physical examination. Heel bone densitometry was per-
formed using Achilles quantitative ultrasound assessment as a proxy for identification of 
osteoporosis. In every participant available for the physical examination, both heel bones 
were measured, a T-score of ≤2.5 on at least one side was considered as osteoporotic.32
data analysis
Descriptive statistics were used to present prevalence of back pain, participant char-
acteristics, back complaint characteristics, psychological factors, and red flags, using 
frequencies for categorical data and mean and standard deviation for continuous 
variables. Analyses were performed using complete cases. To assess the associations 
between red flags and vertebral fractures, red flags and other determinants that were 
considered important for diagnosing vertebral fractures were separately included in a 
univariable logistic regression analysis, with diagnosis at 1-year follow-up as outcome. 
Variables scoring a P value of <.05 were examined for correlation using the Pearson test; 
if variables were correlated (r>.6), only one variable (after consensus) was entered in 
the multivariable logistic regression analysis (backward Wald method, entry .05, removal 
.10). The multivariable regression analysis was used to find the best fitted model for 
vertebral fractures in our study population. 
For all red flags, the sensitivity, specificity, positive and negative predictive values, 
and positive and negative likelihood ratios were calculated to establish diagnostic ac-
curacy. Reported P values were from 2-sided tests, and a P value of <.05 was defined as 
statistically significant. All analyses were performed using SPSS software (version 20 for 
Windows, SPSS Inc, Chicago, Illinois).
Results
Participant characteristics
Of the 1,402 invited patients, 675 were included in the BACE study; 118 patients did not 
meet the inclusion criteria, 291 patients were not willing to participate, and 318 patients 
did not respond to the invitation. Six patients (0.9%) were excluded from the analyses 
because they moved to another city during the 1-year follow-up and, due to a change of 
GP practice, the diagnosis could not be retrieved. 
Table 1 presents the baseline characteristics of the 669 included participants. The 
age of the included participants ranged from 55 to 91 years (X=66, SD=7.7); 40% of 
the participants (n=269) were male; mean severity of back pain was 5 (SD=2.7); and 87 
participants (13%) reported that they experienced a first episode of back pain. Of all 669 
participants, 95% underwent a radiograph of the back.
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table 1. Baseline characteristics of the 669 included patients aged >55 years.
Patients with diagnosis (n=669)
Patient characteristics
Age in years, mean (SD) 66 (7.7)
Male 269 (40)
Body mass index, mean (SD) 27 (4.7)
Low education level 278 (42)
Smoking 120 (18)
Hazardous drinkinga 329 (49)
Back pain characteristics
Severity of back painb, mean (SD) 5 (2.7)
First episode of back pain 87 (13)
Duration of back pain >3 months 154 (23)
Pain radiates below the knee 205 (30)
Use of pain medication for back pain 480 (72)
Psychological factors
Quality of life physical summary scalec, mean (SD) 43 (8.9)
Quality of life mental summary scalec, mean (SD) 50 (10.3)
Depressive symptomatologyd, mean (SD) 10 (7.8)
Pain catastrophizinge, mean (SD) 14 (10.6)
Attitude and beliefs about back painf, mean (SD) 26 (7.2)
Red flags
Prolonged corticosteroid useg 53 (8)
Trauma 28 (4)
Osteoporosish 86 (13)
Sudden decrease in height 23 (3)
Percussion tenderness spine 127 (19)
Severe disabilityi 85 (13)
Acute onset of pain 232 (35)
Back pain intensity score ≥7 255 (38)
Osteoarthritis in hip/knee 199 (30)
All data are presented as numbers (%) unless stated otherwise; Missing values ranged from 0-12%; a Hazard-
ous drinking is measured with Audit-C: range 0-12; ≥3 in woman and ≥4 in men is risk of hazardous drink-
ing; b Measured with a numerical rating scale as an average of the previous week; range 0-10; 0 indicates 
no pain, 10 indicates the worst pain imaginable; c Measured with the Short Form-36, range 0-100; higher 
score indicates higher quality of life; d Measured with the CED-D, range 0-60; higher score indicates more 
prone to depression; e Measured with pain catastrophizing scale range 0-52; higher score indicates more 
risk for catastrophizing; f Measured with back beliefs questionnaire range 9-49; higher score indicates more 
positive thoughts of recovery; g Oral or inhalation corticosteroid use >90 days; h Measured with heel bone 
densitometry; i Measured with the Roland-Morris disability questionnaire; range 0-24; zero indicates no 
disability, a cut-off value of 17 was used to indicate severe disability. 
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Of all 669 participants, unspecified back pain with or without radiation below the knee 
was diagnosed in 384 of them (57%) (table 2). Serious pathology was present in 6% 
of our study population; vertebral fracture was the most common diagnosis and was 
seen in 33 participants (5%), of whom 30 were diagnosed with an osteoporotic vertebral 
fracture. Four participants (1%) were diagnosed with a spinal malignancy, and no spinal 
infections or cauda equina syndrome were diagnosed. Of the other specified diagnoses 
that were not defined as serious pathology, vertebral osteoarthritis was the most com-
mon (173 patients, 26%); disk herniation was present in 5% of the participants (table 2).
Association between red flags and vertebral fracture
In the univariable analyses, age of ≥75 years, prolonged corticosteroid use, trauma, 
osteoporosis, severe disability, a back pain intensity score of ≥7, and thoracic pain were 
individually associated with the diagnosis of vertebral fractures (table 3). These variables 
were included in the multivariable regression analysis. In this model, age of ≥75 years, 
trauma, osteoporosis, a back pain intensity score of ≥7, and thoracic pain were associ-
ated with the diagnosis of vertebral fractures.
Table 4 shows the diagnostic value of the red flags. Age had a positive predictive 
value of 0.14 (95% confidence interval (CI)=0.07, 0.20) and a positive likelihood ratio of 
3.1 (95% CI=2.0, 4.7). Osteoporosis had a similar positive predictive value of 0.14 (95% 
CI=0.07, 0.21) and likelihood ratio of 3.2 (95% CI=1.9, 5.2). The positive predictive value 
and the positive likelihood ratio of trauma were 0.25 (95% CI=0.09, 0.41) and 6.2 (95% 
CI=2.8, 13.5), respectively. These values for trauma were the highest among all variables 
and raise the probability from .05 to .25 when the test is positive. The negative likelihood 
ratio for trauma was 0.8 (95% CI=0.5, 1.3), which lowers the probability of a vertebral 
table 2. GPs diagnosis within one year of follow-up, n=669 
Patients, n (%)
Unspecified back pain without pain radiating below the knee 291 (43)
Unspecified back pain with pain radiating below the knee 93 (14)
Back osteoarthritis 173 (26)
Discopathy 58 (9) 
Spondylolisthesis 5 (1)
Disc herniation 35 (5)
Spinal stenosis 21 (3)
Vertebral fracture 33 (5)
Spinal malignancy 4 (1)
Ankylosing spondylitis 1 (0.1)
All data are presented as numbers (%), more than one diagnosis per patient could be reported
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fracture if there was no trauma from .05 to .04. A diagnostic prediction model with 4 red 
flags combined did not increase these diagnostic values.
discussiOn 
summary of results
The present study assessed the prevalence of physician-specified underlying patholo-
gies of back pain, as identified by the participants’ GP, in older adults with back pain 
seen in primary care and the associations of red flags with vertebral fracture. Based on 
the final diagnoses of back pain retrieved at 1-year follow-up, 57% of the participants 
were diagnosed with unspecified back pain with or without radiation below the knee, 
and 6.1% of the participants were diagnosed with serious pathology (vertebral fracture, 
spinal malignancy, and ankylosing spondylitis). Vertebral fractures were the most com-
mon serious pathology (5% of the participants). Red flags associated with vertebral 
fractures were age of ≥75 years, trauma, osteoporosis, a back pain intensity score of ≥7, 
and thoracic pain. However, the positive predictive value and positive likelihood ratio of 
the combined red flags did not increase more than the values for trauma alone.
table 3. Univariable and multivariable association of red flags with vertebral fractures in patients aged >55 
year with back pain 
Red flag
All 
patients 
(n=669)
Patients 
with fracture 
(n=33)
univariable 
OR (95% ci)c P-value
multivariable 
OR (95% ci) P-value
Age ≥75 years 109 15 4.8 (2.3-9.9) <0.001 3.5 (1.5-8.6) 0.01
Female gender 400 22 1.4 (0.7-2.9) 0.41
Prolonged corticosteroid usea 53 6 2.8 (1.1-7.1) 0.031 - -
Trauma 28 7 7.6 (3.0-19.4) <0.001 7.8 (2.7-22.5) <0.001
Osteoporosis 86 12 4.5 (2.1-9.5) <0.001 2.5 (1.0-6.2) 0.05
Sudden decrease in height 23 3 3.1 (0.9-11.2) 0.08
Percussion tenderness spine 127 7 1.2 (0.5-2.7) 0.74
Severe disabilityb 85 9 2.9 (1.3-6.5) 0.01 - -
Acute onset of pain 232 10 0.8 (0.4-1.6) 0.48
Back pain intensity score ≥7 255 22 3.4 (1.6-7.6) 0.001 3.1 (1.4-7.2) 0.01
Osteoarthritis in hip or knee 199 5 0.4 (0.2-1.1) 0.07
Thoracic back pain 152 14 2.6 (1.3-5.4) 0.008 2.1 (0.9-4.9) 0.09
All data are presented as numbers unless stated otherwise; Missing values ranged from 0-13%; a >90 days 
use of inhalation or oral corticosteroids; b Measured with the Roland-Morris disability questionnaire; range 
0-24; >17 was indicated severe disability; c variables with a p value <0.05 were included in the multivariable 
model; OR = Odds ratio, CI = confidence interval. Nagelkerke R2 20.3
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interpretation of findings
In our study population, vertebral fractures, malignancies, and ankylosing spondylitis 
accounted for 6% of the causes of back pain presented to the GP. Vertebral infection 
and cauda equina syndrome were not identified in our study population. The 6% preva-
lence in our study is similar to prevalences found in other studies performed in primary 
care, namely 1% to 5% (1, 2, 4). Most studies on specified causes of back pain describe 
only serious causes of back pain. Only one study performed in primary care reported 
all specified diagnosis of back pain.1 Comparing our distribution of specified causesof 
back pain with the previous findings, it appears that the prevalences of herniated disk, 
spinal stenosis, vertebral fractures, and spondylolisthesis are about the same in both 
populations. Only the prevalence of unspecified back pain was somewhat higher in the 
study by Deyo and Weinstein,1 and the prevalence of degenerative pathology, such as 
osteoarthritis, was higher in our study population. These findings were due mainly to 
our older study population because spine degeneration increases with age.33 The find-
ing of osteoarthritis might not alter the management of back pain in general practice 
because there is no specific treatment for this group of patients. 
In our multivariable model, age of ≥75 years, trauma, osteoporosis, and a back pain 
intensity score of ≥7 were associated with vertebral fractures in our population of older 
patients with back pain. Various cutoff points have been used to determine older age 
in studies investigating red flags in low back pain. We used the cutoff value of 75 years 
of age because a recent Cochrane review showed this cutoff value to be the most infor-
mative for detecting vertebral fractures in patients with back pain.15 The finding that 
patients with older age are more likely to have a vertebral fracture is consistent with 
other studies.2 33 Also, the result that trauma, as a red flag, is associated with a vertebral 
fracture is in line with other studies in primary care.14 15 However, only 21% of our partici-
pants with a fracture reported a trauma. 
A back pain intensity score of ≥7 has not been shown in research on red flags to be 
associated with vertebral fractures. In tertiary care, the presence or absence of pain has 
been studied,34-37 although the use of a cutoff value in patients with back pain has not 
previously been tested. This finding should be further evaluated in other populations 
with back pain and might be of diagnostic value in patients with back pain seen in 
primary care.
Prolonged use of corticosteroids appeared to be related with a higher risk of vertebral 
fractures in older patients with back pain. Oral and inhalation corticosteroids were ana-
lyzed because both are associated with an increased risk of vertebral fracture.38-40 Other 
topical applications of corticosteroids (injection, dermal, nasal, ocular, and auricular) 
have not been reported to increase the risk of vertebral fracture.40 41 In the present study, 
prolonged use was defined as 3 months of corticosteroid use in the year previous to con-
sulting a GP for back complaints. Two previous studies on corticosteroids as a red flag 
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in primary care showed likelihood ratios of 4.034 and 48.5,2 whereas the likelihood ratio 
was only 2.5 in our study. In our study population, corticosteroid use showed an associa-
tion with vertebral fractures in the binary analysis, but this variable was not included in 
the final model. Osteoporosis is thought to be a mediator in the relationship between 
prolonged use of corticosteroids and fractures. It is possible that corticosteroids cause 
osteoporosis; however, in our population of older adults, it is plausible that osteoporosis 
also was present without the prolonged use of corticosteroids. The diagnostic predic-
tion model reported by Henschke et al2 also was assessed in our study population. 
We used the same red flags (age of >70 years, female sex, trauma, and prolonged use 
of corticosteroids) but could not reproduce the results as reported. When 2 red flags 
were present, the positive likelihood ratio in the study by Henschke et al was 15.5 (95% 
CI=7.2, 24.6), although we found a positive likelihood ratio of only 2.6 (95% CI=1.9, 3.7). 
Therefore, we used the red flags emerging from the multivariable regression analysis 
in our study population. The diagnostic values were somewhat better, but the positive 
likelihood ratios in this new diagnostic model were not as high as the likelihood ratios 
reported by Henschke et al.2 The differences between these diagnostic models might 
be due to the low prevalence of vertebral fractures in both studies or to the somewhat 
different population of older patients in our study.
strengths and limitations
To our knowledge, this is the first study assessing the diagnostic value of red flags in 
older patients with back pain seen in primary care. Older patients may be more prone 
to a specified cause of back pain, so it is important to evaluate whether red flags are 
present in this population and predict the most common type of serious pathology (ie, 
vertebral fractures).
If serious pathology is not identified at the first consultation, disease manifestation 
may become clearer over time. Also, almost all participants underwent a radiograph of 
the spine, and these reports were sent to the GPs. We assumed that specified diagnoses, 
even those not detectable on the radiograph of the spine, became evident within 1 year 
and were incorporated in the GP registry. Therefore, we identified the final diagnoses 
regarding specified causes of back pain in the registry of the participants’ GP after the 
1-year follow-up and assumed that, in this way, we retrieved the most reliable specified 
diagnoses. 
One limitation of the study is the low prevalence of vertebral fractures. Because only 
33 participants were diagnosed with a fracture and multiple variables were tested, this 
limitation could have led to findings by chance. The diagnoses of 6 participants were 
not available for follow-up, but we expect that they were random missing patients and 
did not have an important impact on the results of this study. Furthermore, incorpora-
tion bias could have occurred. We wanted to know if the red flags are useful to predict 
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vertebral fractures, but they also could have been used by the GP to determine if a 
patient had a vertebral fracture. In that case, the strength of the associations could be 
overestimated. Although almost all of our study participants underwent a radiograph 
and the findings were sent to their GP, it is more likely that the diagnosis of vertebral 
fractures was obtained from the radiographic findings rather than from the red flags at 
baseline.
It is possible that patients with a vertebral fracture were missed, because not all in-
cluded patients received a radiograph of the back and no standardized imaging protocol 
was used. The radiographs of the back were made at patients’ nearest hospital as usual 
in normal daily practice. Any additional investigation for the back pain during follow-up 
was up to the GP; therefore, it is possible that we underestimated the prevalence of 
vertebral fractures. A final limitation might be that the diagnosis of vertebral fractures 
was obtained from radiographic findings, and it could have occurred that the fracture 
found on the radiograph was not linked to this episode of back pain.
clinical impact
In older adults with back pain seen in primary care, red flags alone and combined in a di-
agnostic predication model were not very accurate in predicting vertebral fracture. Also, 
in this population of older adults, prevalence of vertebral fractures was low. Patients with 
a traumatic vertebral fracture need to be identified as soon as possible. These patients 
had a trauma; therefore, if this red flag is present, further diagnostic analysis should be 
performed. The fractures missed using this red flag alone were all osteoporotic fractures, 
which do not require immediate treatment, besides pain medication. A wait-and-see 
policy in the patients without a trauma can be justified, and further diagnostic testing 
can still be considered if pain lasts longer.
In these older adults with back pain seen in general practice, 43% were diagnosed 
with specified back pain and 6% with a serious underlying pathology. Most of these 
patients were diagnosed with a vertebral fracture (5%), and red flags associated with 
vertebral fracture were age of ≥75 years, trauma, osteoporosis, and a back pain intensity 
score of ≥7. The red flag of trauma had the highest diagnostic value, and a diagnostic 
prediction model did not increase this value.
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ABstRAct
Background
Although back pain is a frequently recurring disorder, the course of back pain remains 
uncertain. Therefore, this study aimed to identify different trajectories in older adults 
with back pain who presented in general practice and to determine which baseline 
characteristics are associated with these trajectories. 
methods
The BACE study is a prospective cohort study including 675 patients (aged >55 years) 
with back pain who consulted a general practitioner; patients were followed for 3 years. 
Latent class growth analysis was used to identify different trajectories in back pain sever-
ity measured at eight different time points. A multinomial regression analysis was used 
to assess variables associated with membership of an identified trajectory.
Results
Using the different indices of fit and the usefulness of the different trajectories in clinical 
practice, a 3-class cubic model was determined to be the best model. The three trajec-
tories were defined as ‘low pain trajectory’, ‘high pain trajectory’ and ‘intermediate pain 
trajectory’. Baseline variables associated with a higher chance of being in the intermedi-
ate or high trajectory were: female gender, higher body mass index, chronic back pain 
(at baseline), more disability, lower scores on the SF-36 physical summary scale, and 
negative expectations of recovery.
conclusions
Three different back pain trajectories were identified in older adults presenting with back 
pain in general practice. Various baseline characteristics were associated with a higher 
chance of being in the high or intermediate back pain trajectory. These characteristics 
might help identify patients at risk for a less favourable outcome.
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intROductiOn
Back pain is a major problem worldwide; in women and in patients aged 40-80 years the 
prevalence of back pain is the highest.1 Due to its high prevalence and the association 
of back pain with increased disability, it is a leading cause of years lived with disability.2 
With the ageing population it is likely that back pain will become more prevalent and 
lead to an even higher burden on society and health care. 
Most guidelines make a distinction between patients with acute and with chronic 
nonspecific back pain based on the duration of the episode concerned.3 However, back 
pain is often recurrent and many patients do not recover within the first three months 
of their episode of back pain.4 5 Since back pain frequently recurs, it is proposed not to 
focus on a single episode but to consider patterns of back pain on the longer term to 
better describe the course of back pain.6 The course of back pain over time can provide 
additional information and this might be more suitable to identify patients at risk for a 
non-favourable course. If different groups of patients can be identified, this may help to 
select the most appropriate interventions for these patients. Understanding the course 
of back pain also is important to inform both clinicians and patients and, if patients 
with a less favourable course are identified, to eventually treat these patients different 
to avoid such a course of back pain. 
Studies in various populations have identified different trajectories using diverse 
statistical methods.7-13 Most studies created trajectories based on back pain scores of 
patients and, despite the use of different pain measurements, most found four dif-
ferent trajectories.7 8 10 13 A recent study using pain as outcome measure identified six 
trajectories in older adults with back pain;9 these trajectories consisted of four stable 
trajectories and two trajectories with substantial improvement over time. Another study 
had a 7-year follow-up of patients allocated to different trajectories;14 during follow-up, 
it appeared that most participants remained in the same trajectory and the allocation of 
trajectories was stable over time.
Older age is one of the factors associated with a longer time to recovery, or to non-
recovery.15 16 It is possible that these older adults are more often present in the trajecto-
ries of non-recovery and that previously defined trajectories for all age groups do not 
adequately fit this group of older adults with back pain. Therefore, this study aimed to 
identify different trajectories in older adults with back pain who presented in general 
practice and to determine which baseline characteristics are associated with member-
ship of a particular trajectory. 
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methOds 
study population
Data used in the present study were from the BACE cohort study, a prospective observa-
tional cohort.17 Patient inclusion took place between March 2009 and September 2011 
in a representative sample of 49 general practices located around the city of Rotterdam 
(the Netherlands). 
Patients aged >55 years were included when they consulted a general practitioner 
(GP) with a new episode of back complaints. Back complaints were defined as pain in at 
least a part or the whole region from the top of the shoulder blades to the first sacral ver-
tebra, with or without pain radiation to the leg. If a patient had not visited a GP with the 
same back complaints in the preceding 6 months it was considered to be a new episode. 
Patients were invited to participate in this study by their GP during the consultation, or 
in writing within 2 weeks after the consultation. 
Patients were excluded if they were unable to fill out the questionnaires due to cogni-
tive impairment or were unable to read and write in Dutch. Patients who were unable to 
undergo physical examination (e.g. wheelchair-bound patients) were also excluded. The 
Medical Ethics Committee of Erasmus Medical Center (Rotterdam) approved the study 
protocol. Full details of the BACE study design are described elsewhere.17 
data collection
After inclusion in the BACE study and having signed informed consent, patients filled 
in questionnaires at baseline, 6 weeks, 3, 6 and 9 months, and at 1, 2 and 3 years. The 
questionnaires asked about patient characteristics and features of the back complaint 
including patients’ perceived severity of back pain averaged over the previous week 
measured on an 11-point numerical rating scale (NRS)18 with 0 as ‘no pain’ and 10 rep-
resenting ‘worst pain ever’. Disability was measured with the Roland Morris Disability 
Questionnaire (RDQ).19 The RDQ scores range from 0 (no disability) to 24 (severe dis-
ability). Quality of life was measured with the Short-Form 36 (SF-36), Dutch version.20 
The SF-36 measures eight dimensions: physical function, role-physical function, bodily 
pain, general health, vitality, social function, role-emotional function and mental health. 
These eight dimensions can be recoded into two summary scores: a physical component 
summary score and a mental component summary score. Each dimension and summary 
score is rated on 0-100 scale, with higher scores representing better health.21 22 In view 
of the higher mean age of our study population, summary scores were calculated with 
adapted Z-values (20). Depression was measured with the Center for Epidemiologic 
Studies-Depression (CES-D; range 0-60); patients with a higher score are more prone to 
depression.23 Pain catastrophizing was measured with the Pain Catastrophizing Scale 
(PCS; range 0-52) with higher scores representing a higher risk for catastrophizing.24 
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Back beliefs were investigated with the back beliefs questionnaire (BBQ; range 9-49) 
with a higher score representing more positive thoughts on recovery.25 Lifestyle factors 
included smoking (yes/no) and drinking alcohol. Drinking alcohol was measured with 
the Audit-C.26,27 Women were defined as possible hazardous drinkers if they scored ≥3 
on the scale, men if they scored ≥4. Patients were scored as having low education if they 
had no education or the highest education was middle school or any other education 
in level 2, according to the International Standard Classification of Education (ISCED) 
2011.28 Expectations about recovery in the coming three months were asked on a 1-5 
scale, with 1 representing the most positive and 5 the most negative thoughts about 
recovery. During the physical examination at baseline, body weight and height were 
measured and converted to body mass index (BMI). 
statistical analysis
To identify possible trajectories in these older adults with back pain latent class growth 
analysis (LCGA) was used.29 The analysis was based on patients’ reported severity of back 
pain averaged over the previous week measured on an 11-point NRS. All questionnaires 
during the 3-year follow-up were used in the analysis. First, a latent class analysis (LCA) 
was performed for 2-7 trajectories to get an indication as to how many trajectories 
would fit the data best, and whether the course of pain would be best described by 
linear, quadratic or cubic trajectories. Then, the LCGA was performed for 2-5 trajectories 
and assessed as to whether the course of back pain was best described by quadratic or 
cubic trajectories. 
Model of fit was determined by different indices of fit:30 31 the Bayesian information 
criteria (BIC) in which a lower number represents a better model of fit; The Vuong-Lo-
Mendell-Rubin likelihood ratio test (LRT), and the bootstrap likelihood ratio test (BLRT), 
in which a test result of <0.05 indicates that the fit of the model with k groups is better 
than the model of k-1 groups; and Entropy (a value between 0 and 1) which indicates 
separation of the trajectories, with values approaching 1 indicating a clear delineation 
of the trajectories formed.32 
After determining the number of trajectories and the best fitting trajectory analysis, 
a multiple imputation was performed and a multinomial regression analysis (3-step 
approach) used which takes the probability of the membership of the trajectory per 
patient into account.33 34 
Description of the baseline characteristics was performed using SPSS software (ver-
sion 21 for Windows, Chicago, IL, USA). Mplus Version 7.3 (Mutén and Muthén, Los An-
geles, CA, USA) was used for the LCGA, for multiple imputation, and for the multinomial 
regression analysis. 
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identification of trajectories
Of the 1402 back pain patients invited by 103 GPs to participate in this cohort study, 675 
patients (48%) were included and 727 patients were excluded. Reasons for exclusion 
were as follows: not willing to participate (n = 291), not meeting the inclusion criteria (n 
= 118) or the patient did not respond (n = 318). Of these 675 included patients, mean age 
was 66.4 (standard deviation: SD 7.6) years and 41% were male (table 1). Mean severity 
of back pain in all patients was 5.2 (SD 2.7). 
Using the different indices of fit and the usefulness of the trajectories in practice, 
the cubic model with three trajectories was determined to best fit this population. The 
smallest group contained 168 patients, which was 25% of the total number of patients. 
The entropy of the total model was 0.84, which shows a good discriminative value (32). 
The Vuong-Lo-Mendell-Rubin LRT showed that a model with four trajectories was no 
better than the three trajectory model; the BIC and the bootstrap LRT added no informa-
tion to this model. 
The three trajectories were defined as: i) ‘low pain trajectory’, i.e. patients (n=254) with 
a mean baseline back pain score of 3.8 (SD 2.9) and a mean back pain score pattern of 0 
or 1 from 6 months onwards; ii) ‘high pain trajectory’, i.e. patients (n=168) with relatively 
high pain scores during follow-up, these patients had a mean baseline pain score of 7.3 
(SD 1.6) and showed a relatively stable mean pain score over time; and iii) ‘intermediate 
pain trajectory’, i.e. patients (n=250) with a mean baseline pain score of 5.1 (SD 2.1) and 
a slight decrease in pain score over time. Three patients failed to report any pain score 
and were not included in the latent class growth analysis.
Figure 1 presents estimated means and the individual values of all three trajectories as 
measured with a NRS at eight time points during the 3-year follow-up. Although there is 
a stable mean without fluctuation on the group level, individual patterns show a fluctua-
tion in back pain scores. The average SD of the estimated means in the intermediate 
trajectory was somewhat higher than the SD of mean in the two other trajectories (2.1 
vs. 1.7 and 1.6, respectively). Although these differences are small, it is unlikely that the 
intermediate trajectory included more patients with fluctuating back pain patterns than 
the other two trajectories. Patients in the high pain class seem to have more or less 
constant pain over time and patients barely report pain scores under 4. Patients in the 
intermediate pain class show pain scores over the whole range at all time points. And 
patients in the low pain class seem to report most pain in the first months and over time 
the pain gradually decreases. 
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table 1. Baseline characteristics of older patients with back pain presenting in general practice.
All patients
(n=675)*
low pain 
trajectory
(n=254)
intermediate 
pain trajectory
(n=250)
high pain 
trajectory
(n=168)
Age, years 66.4 (7.6) 65.1 (7.1) 66.6 (7.6) 68.1 (8.2)
Male gender, n (%) 274 (41) 130 (51) 87 (35) 55 (33)
Body mass index 27.5 (4.7) 26.8 (4.1) 27.6 (4.4) 28.3 (5.7)
Low education, n (%) 279 (41) 89 (35) 98 (39) 92 (55)
Smoking, n (%) 122 (18) 38 (15) 54 (22) 30 (18)
Hazardous drinkinga, n (%) 333 (49) 142 (56) 121 (48) 70 (42)
Back complaint characteristics
Severity of back painb 5.2 (2.7) 3.8 (2.9) 5.1 (2.1) 7.3 (1.6)
Duration of back pain > 3months, n (%) 156 (23) 21 (8) 76 (30) 59 (35)
Pain radiating below the knee, n (%) 205 (30) 55 (22) 77 (31) 73 (44)
Medication use, n (%) 483 (72) 176 (69) 170 (68) 137 (82)
History of back pain, n (%) 579 (86) 209 (82) 217 (89) 150 (89)
Disabilityc 9.8 (5.8) 7.0 (5.7) 10.2 (5.1) 13.5 (4.8)
Psychological factors
Quality of life physical summary scaled 43.2 (8.9) 47.3 (8.3) 42.5 (8.2) 38.1 (8.0)
Quality of life mental summary scaled 49.6 (10.3) 51.3 (9.1) 49.4 (10.4) 47.1 (11.2)
Depressive symptomatologye 10.0 (7.8) 7.7 (6.9) 10.0 (6.8) 13.5 (9.0)
Pain catastrophizingf 14.1 (10.6) 11.1 (8.9) 13.4 (10.3) 19.8 (11.2)
Attitude and beliefs about back paing 26.4 (7.2) 29.1 (6.4) 26.3 (7.0) 22.4 (6.8)
Expectations regarding recoveryh, n (%)
- Completely pain free 113 (17) 83 (33) 23 (9) 7 (4)
- Strong improvement 178 (26) 70 (28) 72 (29) 36 (21)
- The same as now 349 (52) 94 (37) 147 (59) 108 (64) 
- Strong worsening 15 (2) 1 (0.4) 2 (0.8) 12 (7)
- More pain than ever 3 (0.4) 0 (0) 0 (0) 3 (2)
*Three patients failed to report any pain score and are not included in this latent class growth analysis. All 
results are presented as mean (SD) unless stated otherwise. Missing values ranged from 0-22%; a Hazardous 
drinking is measured with Audit-C: range 0-12; ≥3 in women and ≥4 in men is risk of hazardous drinking; 
b Measured with a numerical rating scale as an average of the previous week; range 0-10; 0 indicates no 
pain, 10 indicates the worst pain imaginable; c Measured with the Roland-Morris Disability Questionnaire; 
range 0-24; zero indicates no disability. d Measured with the Short Form-36, range 0-100; higher score in-
dicates higher quality of life; e Measured with the CED-D, range 0-60; higher score indicates more prone to 
depression; f Measured with the Pain Catastrophizing scale, range 0-52; higher score indicates more risk for 
catastrophizing; g Measured with the Back Beliefs Questionnaire, range 9-49; higher score indicates more 
positive thoughts of recovery; h Asked on a 1-5 scale, with 1 as the most positive and 5 as the most negative 
expectations regarding recovery in the coming 3 months.
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A: High pain trajectory
B: Intermediate pain trajectory
C: Low pain trajectory
figure 1. Plot of class means and individual back pain scores at follow-up in the three different trajectories
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multinomial regression analysis
The low pain trajectory was chosen as reference category (table 2). Compared to the 
low pain trajectory, patients in the intermediate trajectory were more likely to be female 
(odds ratio: OR 2.04; 95% CI 1.23-3.37), had a higher body mass index (OR 1.07; 95% CI 
1.01-1.14), more often had a back pain duration > 3 months at baseline (OR 4.87; 95% 
CI 2.29-10.37), had lower scores on the SF-36 physical summary scale (OR 0.94; 95% CI 
0.90-0.98) and more negative expectations of recovery (OR 2.02; 95% CI 1.40-2.91). Some 
of these variables were also associated with membership of the trajectory with high 
pain scores. These associations were even stronger (with higher ORs) in the high pain 
trajectory: duration of back pain > 3 months at baseline (OR 7.70; 95% CI 3.34-17.74), 
disability (OR 1.15; 95% CI 1.06-1.25), SF-36 physical summary scale (OR 0.92; 95% CI 
0.86-0.97) and negative expectations of back pain (OR 3.48; 95% CI 2.08-5.80). 
table 2. Results of the multinomial regression analysis (reference class is ‘low pain trajectory’). 
intermediate pain trajectory high pain trajectory
OR 95% ci p-value OR 95% ci p-value
Age 1.02 0.98-1.06 0.31 1.02 0.97-1.06 0.47
Gender, female 2.04 1.23-3.37 0.01 1.55 0.80-3.01 0.19
Body mass index 1.07 1.01-1.14 0.03 1.07 0.99-1.15 0.09
Low education 0.73 0.43-1.22 0.22 0.99 0.51-1.90 0.97
Smoking 1.90 0.89-4.05 0.10 1.34 0.52-3.41 0.55
Hazardous drinkinga 1.10 0.67-1.83 0.70 0.90 0.48-1.70 0.74
Duration of back pain >3 months 4.87 2.29-10.37 <0.0001 7.70 3.34-17.74 <0.0001
Pain radiating below the knee 1.01 0.58-1.78 0.96 1.18 0.60-2.31 0.63
Medication use 0.79 0.43-1.42 0.43 1.05 0.50-2.22 0.89
History of back pain 1.10 0.57-2.12 0.78 2.05 0.67-6.28 0.21
Disabilityb 1.06 1.00-1.14 0.07 1.15 1.06-1.25 0.001
Quality of life physical summary scalec 0.94 0.90-0.98 0.01 0.92 0.86-0.97 0.004
Quality of life mental summary scalec 0.98 0.94-1.02 0.30 0.98 0.94-1.02 0.30
Depressive symptomatologyd 1.00 0.95-1.06 0.97 1.01 0.95-1.07 0.83
Pain catastrophizinge 0.99 0.95-1.02 0.52 1.01 0.98-1.05 0.51
Attitude and beliefs about back painf 0.99 0.94-1.03 0.48 0.95 0.90-1.00 0.08
Expectations of recoveryg 2.02 1.40-2.91 <0.0001 3.48 2.08-5.80 <0.0001
a Hazardous drinking is measured with Audit-C: range 0-12; ≥3 in women and ≥4 in men is risk of hazardous 
drinking; b Measured with the Roland-Morris Disability Questionnaire; range 0-24; zero indicates no disabil-
ity. c Measured with the Short Form-36, range 0-100; higher score indicates higher quality of life; d Measured 
with the CED-D, range 0-60; higher score indicates more prone to depression; e Measured with the Pain 
Catastrophizing scale, range 0-52; higher score indicates more risk for catastrophizing; f Measured with the 
Back Beliefs Questionnaire, range 9-49; higher score indicates more positive thoughts of recovery; g Asked 
on a 1-5 scale, with 1 as the most positive and 5 as the most negative expectations regarding recovery in 
the coming three months;
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summary of results
In older adults presenting in primary care with back pain, LCGA was performed to 
identify different trajectories regarding the course of back pain. A 3-class cubic model 
fitted best and low, intermediate and high back pain trajectories were identified. The 
low trajectory (254 patients; 38%), was the most favourable trajectory with patients 
recovering over time and with a mean back pain score of 1/10 during follow-up. Patients 
in the intermediate and the high trajectory did not seem to recover during follow-up. 
Baseline characteristics associated with a higher risk of being in the intermediate pain 
trajectory were female gender, higher body mass index, chronic (>3 months) back pain 
(measured at baseline), lower scores on the SF-36 physical summary scale, and more 
negative expectations of recovery. For the high pain trajectory these characteristics 
were chronic back pain, more disability, lower scores on the SF-36 physical summary 
scale, and more negative expectations of back pain. 
interpretation of findings
In various populations with back pain, 3-12 trajectories have been reported,7-13 with 
most studies describing four trajectories.7 8 10 13 Most of these studies were performed in a 
primary care setting, whereas three studies included patients from general practice,10-12 
as in our study. One of these studies in general practice found three trajectories as the 
model best fitting their population.12 All other studies found at least four trajectories as 
best fitting. One study among older adults found six trajectories with pain as outcome.9 
The differences between these studies might be due to differences in study populations, 
or to the use of varying statistical methods. None of the previous studies used LCGA to 
incorporate growth over time in the model. Although most of the studies used severity 
of back pain as outcome measure,8-13 bothersomeness was also used.7 In most studies 
the follow-up was one year,8 10-13 compared to three years in the present study. Only one 
study included a trajectory that showed increasing pain over time.8 Most studies show 
trajectories with estimated means that were stable over time,10 13 or had both stable and 
decreasing trajectories.7 9 12
Various characteristics associated with an increased probability of having a less fa-
vourable trajectory have also been examined. In the present study, female gender was 
associated with a higher risk of being in the intermediate pain trajectory, but was not 
associated with being in the high pain trajectory. In only one other study was female 
gender also found to be associated with a less favourable trajectory.9 It is interesting that 
female gender was not associated with the high pain trajectory. In the present popula-
tion, chronic back complaints were associated with membership of a less favourable 
trajectory (intermediate pain trajectory vs. low pain trajectory OR 3.93, and high pain 
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trajectory vs. low pain trajectory OR 7.18). A longer duration of back pain (at baseline) 
was previously reported to be associated with an unfavourable course of back pain.7 9-11 
Also, negative patients’ expectations about the course of back pain was also reported to 
be associated with a less favourable course.9 11 In other studies, only quality of life was 
not mentioned as a variable associated with a less favourable outcome. In the present 
study, a lower quality of life on the physical summary scale was associated with mem-
bership of the intermediate and high trajectory. 
The present study included 168 patients in the high pain trajectory (i.e. 25% of the 
patients). In studies with younger populations, about 10-20% of the patients were 
included in the most severe trajectory.10-13 In only one study was the majority of pa-
tients included in the most severe trajectory, despite the younger population in that 
study.8 Older patients tend to experience more severe back pain compared to younger 
patients.35 Since older age is often associated with a less favourable outcome it is likely 
that, in the present population of older adults, more patients were included in the high-
est pain trajectory.
Because of the recurrent character of back pain it is suggested to examine the course 
of back pain, rather than investigate single episode. Defining different pain trajectories 
and establishing which characteristics are associated with trajectories with a high pain 
level, allows to better inform our patients or eventually even treat patients different in 
each trajectory. Other variables associated with allocation to a high pain trajectory were 
more disability and lower scores on the SF-36 physical summary scale; however, these 
latter variables are more likely attributable to the high level of pain on the longer term, 
rather than being the actual cause of pain. Another possibility is that patients with more 
disability are less likely to stay active and, therefore, either do not make a good recovery 
or do not recover at all. 
strengths and limitations
In this study the probability of membership to a class was included in the multinomial 
analysis which makes the analysis more robust and less likely to be biased. This is not 
done in previous studies on trajectories. Bias can occur because a patient with a prob-
ability of 0.56 of being in the high pain class and a probability of 0.44 of being in the 
middle pain class, would be accounted fully to the high pain class in the same way as a 
patient with a probability of 1.00 when this probability is not taken into account. 
In previous studies the trajectories of pain were mostly categorized due to non-
normality. In contrast, in the present study we measured severity of back pain on a 0-10 
scale to obtain the most accurate pain data in the model. Non-normality is not a prob-
lem using LCGA, because latent variables can be normal if the predictor variable is not 
normally distributed. Furthermore, 675 patients were included in the present analysis. A 
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simulation study showed that non-normality in a maximum likelihood approach is not 
a problem when a population includes ≥ 500 patients and produces unbiased results.36 
It is difficult to assess whether our patients in the intermediate trajectory have more 
fluctuating pain than patients in the low and high pain score trajectories. We assessed 
the SDs of the estimated mean of the back pain score; this resulted in scores indicating 
an intermediate trajectory that did not fluctuate more than the other two trajectories, 
even though these results were indirect evidence for this hypothesis. 
A limitation is that the first year of follow-up has six points of measurement compared 
with only two in the final two years of follow-up. Because these latter measurements 
may have provided little information, more measurement points during the last two 
years would have been more informative; e.g. in order not to miss back pain flares, 
measurements could have been made (at least) every 3 months. 
clinical implications
In our study, different trajectories were identified with different pain patterns. Although 
the mean of the trajectories remains stable, it is important to note that individual pain 
patterns do fluctuate over time. Although fluctuation is around the mean of the trajec-
tory, patients seem (overall) to fit well into this three trajectory model. Variables associ-
ated with the intermediate and high trajectory were chronic back pain (at baseline), 
lower scores on the SF-36 physical summary scale, and more negative expectations of 
recovery in the coming 3 months. These variables might help identify patients at risk for 
a less favourable outcome; however the models and the variables need to be externally 
validated and predictive values of variables should be assessed, before being applied in 
clinical practice. 
conclusion
This study identified three different back pain patterns in older adults with back pain: 
low, intermediate and high pain groups. Baseline characteristics associated with a 
greater chance of being in the intermediate trajectory were female gender, higher body 
mass index, chronic back pain (at baseline), lower scores on the SF-36 physical summary 
scale, and more negative expectations of recovery in the coming 3 months. Chronic 
back pain, more disability, lower scores on the SF-36 physical summary scale and more 
negative expectations of back pain were more frequently present in the high pain trajec-
tory. These characteristics might help to identify patients at risk for a less favourable 
outcome.
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ABstRAct
Background
Older patients with back pain are more likely to visit their general practitioner (GP) and 
are more likely to be prescribed analgesics. To assess analgesic use in older adults with 
back pain in general practice. 
methods
The BACE study in the Netherlands is a prospective cohort study. Patients (aged >55 
years) with back complaints were recruited when consulting their GP or shortly thereaf-
ter. Measurements took place at baseline and at 3- and 6-month follow-up. For medica-
tion use, patients were asked if they had used any medication for their back pain in the 
previous 3 months and, if so, to specify the medication name, dosage used, frequency 
of usage, and whether the medication was prescribed or purchased over-the-counter. 
Results
Of the 1,402 patients who were approached to enter the study, 675 were included. 
Of these patients, 484 (72%) reported medication use at baseline. Nonsteroidal 
anti-inflammatory drugs (NSAIDs) (57%) were more often used than paracetamol (49%). 
Paracetamol was mostly obtained over-the-counter (69%), and NSAIDs were mostly 
obtained by prescription (85%). At baseline, patients with severe pain (numerical rat-
ing scale score ≥7) used more paracetamol, opioids, and muscle relaxants. Patients 
with chronic pain (back pain >3 months) used more paracetamol, while patients with 
a shorter duration of pain used more NSAIDs. During follow-up there was an overall 
decline in medication use; however, at 3- and 6-month follow-up, 36% and 30% of the 
patients, respectively, still used analgesics.
conclusions
In these older adults consulting their GP with back pain, 72% used analgesics at baseline. 
Despite a decrease in medication use during follow-up, at 3 and 6 months a consider-
able proportion still used analgesics.
Analgesic use in older adults with back pain 105
intROductiOn
Back pain is a major health problem with a reported lifetime prevalence of up to 84%.1 In 
the Netherlands, about 30–45% of patients with back pain visit their general practitioner 
(GP).2 3 A recent study in the UK showed that older patients (>70 years) with low back 
pain are more likely to visit their GP and more likely to receive analgesics compared 
with younger adults with back pain.4 With regard to analgesic options, international 
guidelines for low back pain usually recommend paracetamol as first choice, followed 
by nonsteroidal anti-inflammatory drugs (NSAIDs).5 Selecting analgesic medication for 
back pain is important, not only for effective pain relief but also because each class of 
medication is associated with particular (serious) adverse reactions, especially in older 
adults.
NSAIDs, for example, are associated with adverse reactions such as gastrointestinal 
and cardiovascular events.6 7 An Australian study reported that since NSAIDS such as 
ibuprofen became available 'over-the-counter,' fewer people were using them appro-
priately and according to the instructions.8 Three percent of patients participating in the 
study used more than the maximum dose of NSAIDs, 7.5% used more than one NSAID, 
and 13% were at risk of an interaction with another medication that they took.
Adverse reactions from opioids are most commonly dry mouth, nausea, vomiting, 
dizziness, and constipation.9 10 Dizziness can cause increased incidence of falls and frac-
tures.11 12 A frequently used opioid, codeine, can even elevate risk of all-cause mortality 
after only 30 days’ usage.13
Most studies on analgesic use only report prescribed medication.14-16 This can give a 
wrong impression of medication use, because paracetamol and NSAIDs are often used 
without prescription. Furthermore, previous studies assessing analgesic use in older 
adults were mostly performed in settings other than general practice,4 17 18 and most of 
these studies were cross-sectional.4 16 19 In the present study we examine both 'over-the-
counter' and prescribed analgesic use in older adults with back pain in general practice. 
Medication use was assessed over 6 months of follow-up and compared between 
patients with (1) different ages (55–74 years vs ≥75 years), (2) different durations of pain 
(<3 months vs ≥3 months), and (3) different pain scores for baseline severity of back pain 
(<7 vs ≥7; range 0–10).
methOds
The Back Complaints in the Elders (BACE) study in the Netherlands is a prospective ob-
servational cohort study. Patient inclusion (N = 675) took place between March 2009 and 
September 2011 in a representative sample of 49 general practices around Rotterdam. 
106 Chapter 7
Patients aged >55 years were recruited when they consulted a GP with a new episode of 
back complaints. Back complaints were defined as pain in at least a part of or the whole 
region from the top of the shoulder blades to the first sacral vertebra, with or without 
pain radiation to the leg. If a patient had not visited a GP with the same back complaints 
in the preceding 6 months, it was considered a new episode. Patients were invited to 
participate in the study by their GP during the consultation or in writing within 2 weeks 
after the consultation. 
Patients were excluded if they were unable to fill out the questionnaires due to cogni-
tive impairment or were not able to read and write in Dutch. Patients who were unable 
to undergo physical examination (e.g., wheelchair-bound patients) were also excluded.
The Medical Ethics Committee of Erasmus University Medical Center, Rotterdam, ap-
proved the study protocol. Details of the BACE study design are described elsewhere.20 
data collection
Baseline measurement included a questionnaire and physical examination of the 
back. Follow-up measurements took place at 3 and 6 months post-baseline by means 
of questionnaires. The questionnaires asked about patient characteristics, features of 
the back complaint, and use of pain medication. Patients’ perceived severity of back 
pain averaged over the previous week was measured on an 11-point numerical rating 
scale (NRS),21 with 0 as 'no pain' and 10 representing 'worst pain imaginable.' Disability 
was measured with the Roland–Morris Disability Questionnaire (RDQ).22 RDQ scores can 
range from 0 (no disability) to 24 (severe disability). Quality of life was measured with 
the Dutch version of the Short Form—36 (SF-36).23 The SF-36 measures eight dimen-
sions: physical function, physical role function, bodily pain, general health, vitality, social 
function, emotional role function, and mental health. Scores on these eight dimensions 
can be summarized by two summary scores: a physical component summary score and 
a mental component summary score. Each dimension and summary score is scored 
from 0 to 100, with a higher score representing better health.24 25 Summary scores were 
calculated with adapted Z-values in view of the higher mean age of our study popula-
tion.23 Depression was measured with the Center for Epidemiologic Studies Depression 
Scale (range 0–60). Patients with a higher score are more prone to depression.26 Pain 
catastrophizing was measured with the Pain Catastrophizing Scale (range 0–52), with 
a higher score representing a higher risk for catastrophizing.27 Patients’ beliefs about 
their back pain were investigated with the Back Beliefs Questionnaire (range 9–49), 
with a higher score representing more positive thoughts on recovery.28 Lifestyle factors 
assessed included smoking habits (yes/no) and alcohol consumption. Alcohol consump-
tion was measured with the Alcohol Use Disorders Identification Test – Consumption 
questions.29 30 Women were defined as possible hazardous drinkers if they scored ≥3 on 
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the scale, men if they scored ≥4. During physical examination, body weight and height 
were measured and converted to body mass index (BMI).
For medication use, patients were asked if they had used any medication for their 
back pain in the previous 3 months and, if so, to specify the medication name, used dos-
age, frequency of usage, and whether the medication was prescribed or purchased as 
'over-the-counter' medication. The exact question asked is shown in the Appendix. The 
medications reported by the patients were recorded in a database and classified by an 
MD by group: paracetamol, NSAID, opioid, muscle relaxant, antidepressant, anticonvul-
sant, and other. Nonpharmacologic treatments were also recorded; patients were asked 
if they had visited their GP, physiotherapist, or medical specialist in the past 3 months.
statistical Analysis
Descriptive statistics are used to present patient and back complaint characteristics in 
patient counts for all variables with categorical data and as mean and standard devia-
tion (SD) for continuous variables. Patients using medication for back pain at baseline 
were compared with the patients not using any medication for their back pain. For 
continuous variables, an independent sample t-test was used. Variables with categorical 
data were analyzed using the chi-square test. If >20% of the cells contained an expected 
count of <5, a Fisher’s exact test was performed. Patients using medication for back 
pain at baseline, 3 months, or 6 months were selected, and medication use was further 
analyzed. Patient counts were used to describe which medication types were most com-
monly used and the frequency of medication use.
Patients using medication were divided into groups according to age (>55–74 years vs 
≥75 years), to whether pain was acute or chronic (<3 months vs >3 months), and to the 
severity of back pain at baseline (NRS <7 vs NRS ≥7). Differences were analyzed using the 
chi-square test. If >20% of the cells contained an expected count of <5, a Fisher’s exact 
test was performed. Reported P values were from two-sided tests, and a P value < 0.05 
was defined as statistically significant. All analyses were performed using SPSS software 
(version 20 for Windows, Chicago, IL, USA).
Results
Figure 1 shows that 1,402 patients were invited to participate and that 675 patients were 
eventually included. 
Characteristics of all patients included in the BACE study are presented in table 1. 
Mean age was 66 ± 7.6 years, and 274 of the patients were male (41%). For all included 
patients, the mean severity of baseline back pain was 5.2 ± 2.7 (NRS). Pain severity was 
higher in patients using pain medication at baseline compared with those who did not 
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use analgesics for their back pain (5.5 ± 2.7 vs 4.4 ± 2.4 respectively). For 87 patients 
(13%), this episode of back pain was the first in their life. Mean disability measured with 
the Roland-Morris Disability Questionnaire was 9.8 ± 5.8; disability score was higher in 
patients using analgesics for their back pain compared with those who did not take 
analgesics (10.6 ± 5.7 vs 7.7 ± 5.6, respectively). Chronic back complaints (duration >3 
months) were reported by 156 patients (23%). Patients who did use pain medication 
were less likely to have chronic back complaints compared with those who did not use 
analgesics. Furthermore, patients using pain medication for their back pain had a lower 
mean quality of life on the SF-36 physical summary scale, scored higher regarding pain 
catastrophizing, and had less positive thoughts regarding recovery.
Out of all patients, 72% (484 patients) reported using pain medication in the 3 months 
prior to baseline (table 2). In patients using analgesics, NSAIDs (57%) were more often 
used than paracetamol (49%). Most patients (69%) using paracetamol purchased it 
over-the-counter, while NSAIDs were more frequently obtained via a prescription (85%). 
A relatively large proportion of the patients used opioids (17%), and 8% used muscle 
relaxant. Used opioids were morphine, codeine, and tramadol. The muscle relaxants 
were mostly benzodiazepines (92%). Overall, the frequency of taking pain medication 
Patients invited to participate (n= 1402)
- A: Direct during consult (n=141)
- B: In writing after consult (n=1261)
 
Exclusion reason (n= 727):
- Patients not willing to participate (n=291)
- Patients did not meet inclusion criteria (n=118)
- Reason unknown (n=318)
Inclusion (n=675)
- Via A: direct during consult (n=105)
- Via B: In writing after consult (n=570)
 
Lost to follow-up (n=13):
- No longer interested to participate (n=5)
- Diseased (n=1)
- Cognitive impairment (n=1)
- Health issues (n=1)
- Reason unknown (n=5)
Baseline measurements (n=675)
- Returned questionnaire (n=667)
- Physical examination (n=670)
 
3 months follow-up (n=662)
- Returned questionnaire (n=623)
- Short questionnaire (n=3)
- Missing (n=36)
 
 
figure 1. Flow chart of patient inclusion
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was mostly daily (67%); only a small proportion (7%) of all medication was used less than 
once a week. Most patients (49%) used one kind of medication; 120 patients (18%) used 
two types, and only 35 patients (5%) used three types (figure 2). Medications reported 
in the 'other' category were hydrocortisone (2 patients), NSAID cream (2 patients), 
glucosamine (2 patients), homeopathic cream (2 patients), nefopam (1 patient), Harpag-
ophytum procumbens (1 patient), and menthol gel (1 patient).
At 3-month follow-up, medication use was lower compared with baseline (table 2). Of 
the 245 patients (36%) using medication at 3-month follow-up, 214 also used medication 
at baseline. At 3-month follow-up, paracetamol was used more often than NSAIDs (51% 
vs 43%). Although most patients still used analgesics on a daily basis, this proportion 
table 1. Baseline characteristics of the patients in the BACE study.
All 
patients 
(n=675)
Patients using 
pain medication 
(n=484)
Patients not using 
pain medication 
(n=191) p-value
Age in years, mean ±SD 66 ±7.6 66 ±7.7 66 ±7.6 0.58
Male 274 (41) 188 (39) 86 (45) 0.14
BMI, mean ±SD 27.5 ±4.7 27.3 ±4.7 27.9 ±4.7 0.19
Low education level 279 (41) 205 (42) 74 (39) 0.57
Smoking 122 (18) 87 (18) 35 (18) 0.80
Hazardous drinkinga 333 (49) 242 (50) 91 (48) 0.88
Severity of back painb, mean ±SD 5.2 ±2.7 5.5 ±2.7 4.4 ±2.4 <0.001
Disabilityc, mean ±SD 9.8 ±5.8 10.6 ±5.7 7.7 ±5.6 <0.001
First episode of back pain 87 (13) 61 (13) 26 (14) 0.69
Duration of back pain >3 months 156 (23) 104 (21) 52 (27) 0.04
Pain radiates to below the knee 205 (30) 155 (32) 50 (26) 0.20
Pain location only lumbar 450 (67) 313 (65) 137 (72) 0.19
Quality of life physical summary scaled, 
mean ±SD
43.2 ±8.9 41.7 ±8.5 47.2 ±8.8 <0.001
Quality of life mental summary scaled, 
mean ±SD
49.6 ±10.3 49.8 ±10.4 48.9 ±9.9 0.32
Depressive symptomatologye, mean ±SD 10.0 ±7.8 10.3 ±7.8 9.2 ±7.7 0.09
Pain catastrophizingf, mean ±SD 14.1 ±10.6 15.1 ±10.8 11.5 ±9.5 <0.001
Attitude and beliefs about back paing, 
mean ±SD
26.4 ±7.2 25.8 ±7.2 28.0 ±7.1 0.001
All data are presented as numbers (%) unless stated otherwise; Missing values ranged from 0-12%
a Hazardous drinking is measured with Audit-C: range 0-12; ≥3 in woman and ≥4 in men is risk of hazard-
ous drinking; b Measured with a numerical rating scale as an average of the previous week; range 0-10; 0 
indicates no pain, 10 indicates the worst pain imaginable; c Measured with the Roland-Morris disability 
questionnaire; range 0-24; zero indicates no disability; d Measured with the Short Form-36, range 0-100; 
higher score indicates higher quality of life; e Measured with the CED-D, range 0-60; higher score indicates 
more prone to depression; f Measured with pain catastrophizing scale range 0-52; higher score indicates 
more risk for catastrophizing; g Measured with back beliefs questionnaire range 9-49; higher score indicates 
more positive thoughts of recovery 
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(56%) was smaller compared with baseline (67%). At 3-month follow-up, paracetamol 
had been obtained over-the-counter by 84 patients (67%), and NSAIDs were obtained 
by prescription by 82 patients (77%). Nevertheless, among medication users, 178 (73%) 
reported the use of one type of analgesic (figure 2). 
At 3-month follow-up medications reported in the 'other' category were glucosamine 
(2 patients), prednisone (2 patients), hydroxychloroquine (1 patient), cold cream (2 
patients), NSAID cream (1 patient), and menthol cream (1 patient). 
At 6-month follow-up there was a further (albeit small) decline in medication use (204 
patients; 30%) (table 2). The frequency of medication use at 6-month follow-up was simi-
lar to the usage at 3-month follow-up. Other medications reported at 6-month follow-up 
were glucosamine (2 patients), prednisolone (1 patient), and NSAID cream (4 patients).
Of the 484 patients who reported use of pain medication for their back pain at base-
line, 146 patients still reported use of pain medication at 3- and 6-month follow up. 
Of the 191 patients not using pain medication at baseline, 31 had started using pain 
medication for their back pain at 3-month follow-up. Of these 31 patients, 11 patients 
still used pain medication at 6-month follow-up. 
Among patients using paracetamol at baseline, 7% also reported use of paracetamol 
at 3- and 6-month follow-up. A similar percentage was found in patients reporting NSAID 
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figure 2. Number of types of medications used by the patients during the study period
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use. Of these patients, 14 reported daily use of paracetamol and 9 reported daily use of 
NSAIDs. Also, 15 patients (2%) reported opioid use at all three measurement points, 7 of 
whom reported daily use. 
Medication use at baseline was compared between the age groups (table 3). 
Paracetamol was more often used by patients aged ≥75 years (60%) compared with 
relatively younger patients (46%), while NSAIDs were more often used by patients aged 
55–74 years (61% vs 40%). Patients with severe back pain (NRS ≥7) more often used 
table 3. Analgesic use at baseline and at 3 and 6-months follow-up classified by severity of back pain (<7 
vs. >7), age (55-74 vs. >75 years), and duration of back pain (<3 vs. ≥3 months).
No severe 
pain
Severe 
pain p-value
55-74 
years
≥75 
years p-value
<3 
months
≥3 
months p-value
Baseline
n=484 n=265 n=216 n=404 n=80 n=331 n=104
Paracetamol 235 (49) 119 (45) 116 (54) 0.04 187 (46) 48 (60) 0.02 149 (45) 60 (58) 0.03
NSAID 277 (57) 157 (59) 117 (54) 0.48 245 (61) 32 (40) <0.001 203 (61) 45 (43) <0.01
Opioid 82 (17) 34 (13) 48 (22) <0.01 67 (17) 15 (19) 0.59 62 (19) 13 (13) 0.13
Muscle relaxant 37 (8) 14 (5) 23 (11) 0.02 34 (8) 3 (4) 0.16 31 (9) 4 (4) 0.07
Antidepressant 5 (1) 2 (1) 3 (1) 0.66* 3 (1) 2 (3) 0.19* 2 (1) 2 (2) 0.24*
Anticonvulsant 4 (1) 3 (1) 1 (1) 0.63* 3 (1) 1 (1) 0.51* 1 (1) 2 (2) 0.14*
Other 10 (2) 5 (2) 5 (2) 0.76* 7 (2) 3 (4) 0.21* 9 (3) 1 (1) 0.46*
3-months follow-up
n=245 n=119 n=125 n=197 n=48 n=136 n=76
Paracetamol 126 (51) 58 (49) 68 (54) 0.45 100 (51) 26 (54) 0.64 67 (49) 39 (51) 0.71
NSAID 106 (43) 57 (47) 48 (38) 0.16 87 (44) 19 (40) 0.71 66 (49) 27 (36) 0.06
Opioid 51 (21) 17 (14) 34 (27) 0.01 40 (20) 11 (23) 0.69 28 (21) 18 (24) 0.60
Muscle relaxant 11 (5) 2 (2) 9 (7) 0.04 8 (4) 3 (6) 0.44* 10 (7) 0 (0) 0.02*
Antidepressant 7 (3) 4 (3 3 (2) 0.72* 6 (3) 1 (2) 1.00* 4 (3) 3 (4) 0.70*
Anticonvulsant 4 (2) 2 (2) 2 (2) 1.00* 2 (1) 2 (4) 0.17* 1 (1) 3 (4) 0.13*
Other 10 (4) 4 (3) 6 (5) 0.75* 8 (4) 2 (4) 1.00* 4 (3) 3 (4) 0.70*
6-months follow-up
n=204 n=99 n=104 n=156 n=48 n=112 n=64
Paracetamol 115 (56) 54 (55) 60 (58) 0.71 84 (54) 31 (65) 0.20 62 (55) 35 (55) 0.88
NSAID 89 (44) 48 (49) 40 (39) 0.15 71 (46) 18 (38) 0.44 49 (44) 25 (39) 0.57
Opioid 35 (17) 10 (10) 25 (24) <0.01 27 (17) 8 (17) 1.00 19 (17) 13 (20) 0.58
Muscle relaxant 12 (6) 4 (4) 8 (8) 0.28 9 (6) 3 (6) 1.00* 9 (8) 2 (3) 0.33*
Antidepressant 4 (2) 2 (2) 2 (2) 1.00* 4 (3) 0 (0) 0.58* 1 (1) 3 (5) 0.14*
Anticonvulsant 5 (3) 2 (2) 3 (3) 1.00* 3 (2) 2 (4) 0.32* 2 (2) 3 (5) 0.36*
Other 7 (3) 5 (5) 2 (2) 0.27* 6 (4) 1 (2) 1.00* 3 (3) 2 (3) 1.00*
All results are presented as numbers (%); *Fisher’s exact test; Missing values ranged from 0-14%; Bold num-
bers indicate a p-value <0.05
Analgesic use in older adults with back pain 113
paracetamol, opioids, and muscle relaxants. Patients with chronic pain (≥3 months) 
more often used paracetamol (58% vs 45%), while patients with acute complaints more 
often used NSAIDs (61% vs 43%). 
At 3-month follow-up, there were no longer any differences between the age groups 
in analgesic usage. However, patients with severe back pain (NRS ≥7) at baseline still 
more often used opioids (27% vs 14%) and muscle relaxants (7% vs 2%) at 3-month 
follow-up compared with patients with less severe back pain. 
At 6-month follow-up, no difference in muscle relaxant usage was reported; however, 
opioids were still used more often by patients with severe back pain at baseline com-
pared with those with less severe back pain at baseline.
Fifty-four percent of all patients also reported at least one (additional) visit to their 
GP, a physiotherapist, or a medical specialist in the 6 months after baseline. Of the 
484 patients reporting medication use at baseline, 33% visited their GP vs 22% of the 
patients who did not use analgesics at baseline (P < 0.001), and 40% of the 484 visited 
a physiotherapist; in the patients who did not use medication at baseline, the rate was 
69% (p 0.74). Medical specialists were visited by 17% of the patients taking medication 
at baseline and by 8% of those who did not use any medication at baseline (P < 0.01).
discussiOn
summary of Results
The present study explores over-the-counter and prescribed analgesic use in older 
adults with back pain in general practice; ≥70% of these patients reported the use of 
analgesics. Medication use declined during the 6 months post-baseline. At baseline, 
NSAIDs were more often used by the relatively younger patients (55–74 years); this may 
indicate that GPs take into account possible adverse drug reactions related to NSAIDs, 
especially among older adults. Nevertheless, 40% of those aged ≥75 years used NSAIDs 
at baseline and at 3- and 6-month follow-up. Patients with severe back pain at baseline 
more frequently used paracetamol, opioids, and muscle relaxants at baseline and at 
3-month follow-up compared with patients with less severe pain at baseline; there was 
no difference in NSAID use between these groups. All differences in medication use 
between the age groups and between groups with different durations of complaints 
had disappeared at 3 months post-baseline.
interpretation of findings
Previous studies reported that NSAIDs are the most often prescribed medication for 
low back pain;16 31 however, these studies did not take into account over-the-counter 
medication. We hypothesized that because patients frequently use over-the-counter 
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paracetamol, it was probably underrepresented in these types of studies. However, the 
present study showed that (at baseline) NSAIDs were the most frequently used analge-
sics in older patients (85% obtained by prescription and 11% over-the-counter). During 
the study period, paracetamol was mostly obtained over-the-counter (69%). The Dutch 
guidelines for acute low back pain recommend that when medication is prescribed, it 
should be done on a time contingency basis, with paracetamol as first-choice medica-
tion. If there is insufficient pain relief with paracetamol alone, the second step is the 
use of NSAIDs.32 33 This is in line with international guidelines.5 However, patients in the 
present study most often used NSAIDs, which may not be in line with guideline recom-
mendations. For patients with chronic back pain, the Dutch and European guidelines 
recommend NSAIDs and (weak) opioids for short-term pain relief.32-34 The European 
guideline complements this with the recommendation to consider antidepressants as 
comedication.34 In the present study, most patients with chronic pain at baseline used 
paracetamol, followed by NSAIDs and then by opioids. Antidepressants were used by 
very few patients (2%) with chronic back pain. In the present study, because details on 
comorbidity, comedication and other considerations possibly taken into account by the 
GPs were unknown, it is difficult to draw conclusions about whether analgesic use was 
in line with current guideline recommendations.
The finding that over 70% of our patients consulting their GP reported use of anal-
gesics is similar to that of Cherkin et al., who reported that about 80% of patients used 
medication after visiting their GP.31 Cherkin et al. also reported a similar (but slightly 
greater) decrease; after 7 weeks, only 13% of their patients used any medication, whereas 
in our study, after 3 months, 36% of the patients reported analgesic usage. However, 
patients in the study of Cherkin et al. were younger (mean age 43 years) than our study 
population.
In a study by Luo et al., older adults (≥65 years) were also less likely to be prescribed 
traditional NSAIDs compared with younger patients, while there was no prescription 
difference in cyclooxygenase-2 (COX-2) inhibitors.15 Federman et al. found that patients 
aged ≥75 years in an outpatient setting were more likely to use NSAIDs, but mostly used 
COX-2 inhibitors.14 However, Federman et al. excluded patients with a contraindication 
for NSAIDs, which might explain the difference compared with the study of Luo et al. and 
with the present study. Federman et al. also reported that opioids were less frequently 
used by older adults,14 whereas we found no difference in opioid use between our 
younger and older age categories.
An Australian study in the open population found that analgesics (opioids and com-
bination analgesics) were more often used in those with the highest scores for low back 
pain.35
Another study showed that patients (in primary and secondary care settings) with 
chronic low back pain who reported increased severity of back pain had increased num-
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bers of prescriptions for opioids and decreased numbers of prescriptions for NSAIDs.18 
This is similar to our finding that there was no difference in NSAID use between the 
subgroups, while there was a difference in opioid use between the subgroups. 
Older patients with back pain are more likely to be prescribed analgesics than younger 
patients.4 16 This is remarkable, because older patients are more prone to adverse drug 
reactions, especially in the case of comedication or of comorbidities such as liver or 
kidney failure. An Australian study found that for over-the-counter medication, 1.9% 
of paracetamol users and 23.1% of ibuprofen users had contraindications for these 
analgesics.36 In another open population, it was shown that 10% of older patients with 
low back pain used NSAIDs while they were also using a diuretic and an angiotensin-
converting enzyme inhibitor or angiotensin II receptor antagonist;35 such patients are at 
increased risk of acute renal failure.37 In our study population, we did not ask about other 
types of medication use and therefore cannot judge whether our patients were at risk 
for adverse drug reactions. Also, because we did not ask about the analgesic dose, we 
could not determine whether the dosage used might potentially cause an adverse drug 
reaction. We did record that 5 patients at baseline and 3 patients at 3-month follow-up 
used NSAIDs obtained both by prescription and over-the-counter. However, because we 
asked about medication use during the previous 3 months, we cannot evaluate whether 
these medications were used simultaneously. Nevertheless, it should be noted that 
patients are not always aware of the risks of using over-the-counter medication.8 
strengths and limitations
We used questionnaires to ask patients which analgesics they used for their back pain; 
this enabled us to report on both prescribed and over-the-counter analgesics. Although 
this provides more information than data derived from medical records alone, there is a 
possibility of recall bias. However, it has been reported that patients with chronic disease 
(including low back pain) generally show good concordance between self-reported 
medication use and data in the patient’s medical record.38 For ethical reasons, we could 
not ask patients who did not participate in the study any questions. Therefore, we could 
not make any comparisons between patients who did and did not participate in the 
study regarding generalizability.
conclusions
In this group of patients aged ≥55 years who consulted their GP with back pain, 72% 
used analgesics at baseline, paracetamol and NSAIDs being the most frequently used. 
Although a decrease in medication use was seen during follow-up, a substantial propor-
tion of these older adults still used analgesics at 3- and 6-month follow-up (36% and 
30%, respectively).
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Background  
Chronic back pain is an important health problem. Non-steroidal anti-inflammatory 
drugs (NSAIDs) are widely used in the treatment of low back pain. Particularly patients 
with acute back pain can receive NSAIDs for their back pain, but also in chronic back 
pain patients short term NSAID use is recommended for pain relief. There are two types 
of NSAIDs available and used in the treatment of back pain: non-selective NSAIDs and 
selective COX-2 NSAIDs. In 2008 a Cochrane review was performed and identified a small 
but significant effect from NSAIDs compared to placebo in patients with chronic back 
pain. This is an update of the Cochrane review published in 2008 focusing on chronic 
low back pain.
Objectives  
The aim of the study was to determine if NSAIDs are more efficacious than various com-
parison treatments for non-specific chronic low-back pain and if so, which type of NSAID 
is most efficacious.
search methods  
The MEDLINE, EMBASE, CENTRAL, PubMed and two clinical trials registry databases were 
searched for randomized controlled trials reported in English, German or Dutch until 
June 2015. We also screened references given in relevant reviews.
selection criteria  
Randomised controlled trials (double-blind and single-blind) of NSAIDs in the treatment 
of chronic low back pain were included.
data collection and analysis  
Two review authors independently selected the trials to be included in the systematic 
review according to the inclusion criteria. One review author extracted the data, and a 
second review author checked the data. Two authors independently evaluated the risk 
of bias of all included articles. If data were considered clinically homogeneous, a meta-
analysis was performed and quality of evidence was assessed using GRADE.
Results  
Thirteen trials were included in this review. Ten of these studies scored ‘low risk of bias’ 
and were considered high quality research. Six studies compared NSAIDs with placebo. 
There is low quality evidence that NSAIDs are more effective than placebo, with a mean 
difference in pain intensity score from baseline of -3.30 (95% CI -5.33 to -1.27) on a 0-100 
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visual analogue scale (VAS) with a median follow-up of 56 days (IQR 13-91 days). Dis-
ability was measured in three studies with the Roland Morris Disability Questionnaire. 
There is low quality evidence that NSAIDs are more effective than placebo on disability, 
with a mean difference from baseline of -0.85 (95% CI -1.30 to -0.40) on a scale from 0 to 
24 with a median follow-up of 84 days (IQR 42-105 days). Adverse events were also re-
ported in all six studies, the pooled RR for adverse events was 1.04 (95% CI 0.92 to 1.17), 
suggesting that adverse events are not statistically significant more frequent in patients 
using NSAIDs compared to placebo. Due to relatively small sample size and relatively 
short follow-up in most studies, it is likely that the proportion of patients experiencing 
an adverse event is underestimated. Therefore it is not possible to make firm statements 
about the occurrence of adverse events. 
There were two studies which compared different types of non-selective NSAIDs, 
namely ibuprofen compared to diclofenac and piroxicam compared to indomethacin. 
No differences between these types of NSAIDs were found, but sample size in both stud-
ies were small. One study reported no differences on pain intensity between selective 
and non-selective NSAIDs. One other study compared diflunisal with paracetamol and 
showed no difference in improvement from baseline on pain intensity score. One study 
showed a better global improvement in favour of celecoxib compared to tramadol.
NSAIDs were compared in one study with ‘home-based exercise’. Disability improved 
more in patients doing exercises compared to patients receiving NSAIDs, but pain scores 
were similar.
Authors’ conclusions  
The evidence of six of the thirteen included studies showed that NSAIDs are more effec-
tive than placebo on pain intensity. NSAIDs are slightly more effective than placebo with 
regard to disability. However, the magnitude of the effects are small, and the quality of 
evidence is low. When only studies with low risk of bias are included, the differences in 
effect between NSAIDs and placebo are reduced. We identified no difference in efficacy 
between different types of NSAIDs, including selective versus non-selective NSAIDs. Due 
to selection of RCTs, the relatively small sample sizes, and relatively short follow-up in 
most studies, it is not possible to make firm statements about the occurrence of adverse 
events or whether NSAIDs are safe for long-term use.
122 Chapter 8
intROductiOn
description of the condition  
Back pain is a major health problem with a reported lifetime prevalence of up to 84%.1 2 
More than one quarter of North Americans reported to have experienced low back pain 
within the previous three months3 and low back pain is a leading cause of years lived 
with disability.4 In the first three months recovery occurs in a substantial part of the 
patients, but the majority of patients still experience pain after one year.5 Having chronic 
back pain is associated with more disability and these patients make a great demand 
on the health-care system.6 Also, of patients experiencing any chronic pain, back pain is 
the most common7 and patients with chronic back pain have a higher healthcare utiliza-
tion compared to patients with acute back pain.8 For treatment, guidelines recommend 
staying active and exercising, if necessary with the use of analgesics. Non-steroidal 
anti-inflammatory drugs (NSAIDs) are one of the most frequently used analgesics in 
the management of back pain.9 10 Particularly patients with acute back pain can receive 
NSAIDs for their back pain, but also in chronic back pain patients short term NSAID use 
is recommended for pain relief.11
description of the intervention  
Most guidelines on treatment of back pain recommend using paracetamol as first 
choice, followed by NSAIDs if paracetamol is not sufficient.12 NSAIDs are widely available 
in several types and brands and both over-the-counter and on prescription. The NSAID 
treatment is based on the analgesic and anti-inflammatory mechanisms of the drug, but 
is also associated with adverse events, such as gastro-intestinal13 14 and cardiovascular 
events.15 
how the intervention might work  
Cyclooxygenase one (COX-1) and two (COX-2) are key enzymes in the synthesis of pros-
taglandins, which contribute to inflammation, pain, and fever. NSAIDs inhibit the COX 
enzyme and therefore the production of prostaglandins will be inhibited. Consequently 
this can reduce the inflammation, pain and fever. COX-1 produces prostaglandins that 
also support platelets and protect the stomach lining. It also helps to maintain kidney 
function. Inhibition of COX-1 can raise the risk of renal insufficiency and gastro-intestinal 
adverse-events such as gastritis or stomach bleeding.
There are two types of NSAIDs: non-selective NSAIDs which inhibit both COX-1 and 
COX-2 enzymes and selective NSAIDs which inhibit only the COX-2 enzyme. Both selec-
tive and non-selective NSAIDs are available for the treatment of pain, and the choice of 
NSAID is mostly based on the different possible known adverse events, convenience of 
use, and cost.
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Nonselective or traditional NSAIDs have a higher risk compared to the selective 
NSAIDs on gastro-intestinal adverse events13 due to the inhibition of both COX en-
zymes. However, aside from these gastro-intestinal benefits of selective NSAIDs, there 
is a known cardiovascular risk in these types of NSAIDs. Cardiovascular risks are also 
present in nonselective NSAIDs and should be taken into account when prescribing any 
NSAIDs.16 17
why it is important to do this review  
This Cochrane review is one of a series of Cochrane reviews of non-steroidal anti-inflam-
matory drugs for low back pain and is an update of a Cochrane review first published 
in 2008.18 The original review consisted of 65 randomized controlled trials on acute 
back pain, chronic back pain and sciatica. Many articles were available for update, and 
therefore we decided to make a series of Cochrane reviews regarding NSAID use for 
acute back pain, chronic back pain and sciatica. Also, efficacy of treatment with NSAIDs 
can differ among these different types of back pain. This review focusses on NSAIDs for 
chronic low back pain.
Objectives  
The objective of this systematic review was to determine if NSAIDs are more efficacious 
than various comparison treatments for non-specific chronic low-back pain and if so, 
which type of NSAID is most efficacious. Comparisons of NSAIDs with reference treat-
ments that were investigated are NSAIDs versus placebo, NSAIDs versus other drugs 
(e.g. acetaminophen/paracetamol, pregabalin, narcotic analgesics or muscle relaxants), 
NSAIDs versus NSAIDs (e.g. traditional NSAIDs versus selective COX-2 inhibitors), and 
NSAIDs versus non-drug treatment.
methOds  
criteria for considering studies for this review  
Types of studies  
Randomised controlled trials (double-blind and single-blind) were included. Only Eng-
lish, German and Dutch studies were included in the review, since this was stated in the 
original protocol.
Types of participants  
Subjects age 18 years or older, treated for non-specific chronic low-back pain were 
included. Chronic back pain was defined as at least twelve weeks. If the duration of 
back pain was not described, but back pain was labelled as chronic, the study was also 
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included. If a study included mixed populations (like chronic back pain and subacute or 
acute back pain), studies were only included if data of chronic back pain was presented 
separately. Subjects with sciatica and subjects with specific low-back pain caused by 
pathological entities such as infection, neoplasm, metastasis, osteoporosis, rheumatoid 
arthritis, or fractures were excluded.
Types of interventions  
Studies assessing one or more types of NSAIDs were included. Additional interventions 
were allowed if there was a contrast for NSAIDs in the study. For example, studies com-
paring NSAIDs plus muscle relaxants versus muscle relaxants alone were included, while 
studies comparing NSAIDs plus muscle relaxants versus paracetamol were not.
NSAIDs which were no longer available on the market, like rofecoxib, were excluded 
from the review.
Types of outcome measures  
Primary outcomes  
Primary outcome measures were: 1) pain intensity (e.g. Visual Analog Scale or Numeri-
cal Rating Scale), 2) global measure (e.g. overall improvement, proportion of patients 
recovered), 3) back pain-specific functional status (e.g. Roland Disability Questionnaire, 
Oswestry Scale), 4) return to work (e.g. return to work status, number of days off work), 
and 5) adverse events (proportion of patients experiencing adverse events).
Secondary outcomes  
Secondary outcome measures were physiological outcomes (e.g. range of motion, spi-
nal flexibility, degrees of straight leg raising or muscle strength) and generic functional 
status (e.g. SF-36, Nottingham Health Profile, Sickness Impact Profile). Other symptoms 
such as health care consumption were also considered.
search methods for identification of studies  
Electronic searches  
RCTs meeting our inclusion criteria were identified by a search of the following data-
bases on June 24th, 2015:
·	 Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 
5 of 12, May 2015)
·	 MEDLINE (OvidSP, 1946 to June Week 2 2015)
·	 MEDLINE In-Process & Other Non-Indexed Citations (OvidSP, June 23, 2015)
·	 EMBASE (OvidSP, 1980 to 2015 Week 25)
·	 ClinicalTrials.gov
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·	 World Health Organization (WHO) International Clinical Trials Registry Platform 
(ICTRP)
·	 PubMed
For this update, the searches were conducted annually between May 2012 and June 
2015. The trials registers were added in 2013, MEDLINE In-Process & Other Non-Indexed 
Citations was added in 2014, and PubMed was added in 2015 to identify studies not 
in MEDLINE using the strategy recommended by Duffy et al.19 Search strategies are 
presented in Appendix 1; Appendix 2; Appendix 3; Appendix 4;and Appendix 5 (online 
available only).
The searches were devised and run by a research librarian from the Cochrane Back and 
Neck Review Group according to their guidelines.20
Searching other resources  
After the electronic search, systematic reviews regarding NSAIDs for chronic low back 
pain were screened. Articles included in the previous version of this review18 were also 
included.
data collection and analysis  
Selection of studies  
All search results were screened independently by two authors (BK and PR or PR and 
WE). Clearly ineligible studies were excluded based on title and abstract. Full text articles 
were retrieved for all remaining studies and these were again screened independently 
by two authors for inclusion. Disagreements regarding inclusion were resolved via 
consensus
Data extraction and management  
One review author (WE) extracted the data, a second review author (PR) checked the 
data. Data were extracted on type and dose of NSAIDs, type of reference treatment, 
follow-up time, duration of current symptoms, and the outcomes described above. If 
data were not available for data extraction due to different format, authors of the trial 
were contacted for further information. Any disagreement was resolved through con-
sensus.
Assessment of risk of bias in included studies  
Two authors (WE and PR) independently evaluated the risk of bias of all included articles, 
using the criteria list recommended by the Cochrane Back Review Group20 and described 
in Appendix 6 (online available only). The criteria were scored as ‘low risk’, ‘high risk’ or 
‘unclear’. If the criteria were scored as unclear, authors were not followed up to provide 
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extra information. Disagreements were resolved by consensus and a third review author 
was consulted if disagreements persisted.
Measures of treatment effect  
The primary outcome pain intensity was measured with the Visual Analogue Scale 
(VAS) or Numerical Rating Scale (NRS) on a scale from 0 to 100 and 0 to 10 respectively. 
Global improvement was measured by the proportion of patients recovered. Disability 
was measured on different disability scales, (e.g. Roland Morris Disability Questionnaire 
(RDQ) on a 0 to 24 scale). Adverse events were measured by the proportion of patients 
experiencing any adverse event.
Dealing with missing data  
Data that were not reported in the article were not included in the review and were 
considered missing. If data were not described in the text, but were shown in graphs, 
data were collected from the graphs.
Assessment of heterogeneity  
Clinical heterogeneity was assessed for all included studies that reported similar out-
comes. The studies were judged on setting, participants and intervention. If studies were 
clinically heterogeneous, they were not pooled. Statistical heterogeneity was assessed 
by chi-square test and I2. If values of I2 were higher than 50% substantial heterogeneity 
could be present21 and pooling was performed using a random effects model. When no, 
low or moderate heterogeneity was suspected a fixed effects model was used.
Assessment of reporting biases  
Funnel plots were used to investigate reporting bias, when at least four trials were 
included in a particular comparison.
Data synthesis  
Dichotomous outcomes were analysed by calculating the relative risk (RR). Continu-
ous outcomes were analysed by calculating the mean difference (MD) when the same 
instrument was used to measure outcomes or the standardized mean difference (SMD) 
when different instruments were used to measure the outcomes. The uncertainty was 
expressed with 95% confidence intervals (95% CI). The outcome measures from the indi-
vidual trials were combined through meta-analysis where possible (clinical comparabil-
ity of population, intervention and outcomes among trials) using a fixed-effect model 
unless there was significant statistical heterogeneity, in which case a random-effects 
model was used. A P value of the Chi2 test that is less than 0.05 indicates a significant 
Non-steroidal anti-inflammatory drugs for chronic low back pain 127
statistical heterogeneity. If a meta-analysis was not possible, the results from clinically 
comparable trials were described in the text.
We assessed the overall quality of the evidence for each outcome using the GRADE ap-
proach, as recommended in The Handbook21 and adapted in the updated CBRG method 
guidelines.20  Factors that may decrease the quality of the evidence were: study design 
and risk of bias, inconsistency of results, indirectness (not generalizable), imprecision 
(sparse data) and other factors (e.g. reporting bias). The quality of the evidence for a 
specific outcome was reduced by a level, according to the performance of the studies 
against these five factors.
- High quality evidence: there are consistent findings among at least 75% of RCTs 
with low risk of bias, consistent, direct and precise data and no known or suspected 
publication biases. Further research is unlikely to change either the estimate or our 
confidence in the results.
- Moderate quality evidence: one of the domains is not met. Further research is likely 
to have an important impact on our confidence in the estimate of effect and may 
change the estimate.
- Low quality evidence: two of the domains are not met. Further research is very likely 
to have an important impact on our confidence in the estimate of effect and is likely 
to change the estimate.
- Very low quality evidence: three of the domains are not met. We are very uncertain 
about the results.
- No evidence: no RCTs were identified that addressed this outcome
Subgroup analysis and investigation of heterogeneity  
Subgroup analyses were performed on analysis where both non selective and selective 
NSAIDs were present. These results were split into results for non-selective and selective 
NSAIDs.
Sensitivity analysis  
A sensitivity analysis was performed on the comparison between NSAIDs and placebo. 
Studies with high risk of bias (less than six positive items on the risk of bias table) or 
studies with a ‘flare design’ were not included in this analysis. A study with a ‘flare design’ 
only included patients who previous used NSAIDs and showed an aggravation of the 
back complaints during a wash out period.
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Results  
description of studies  
Results of the search  
The search update for this review identified a total of 2158 potential articles in the elec-
tronic search (figure 1). After screening the titles and abstracts, full texts were assessed 
and thirteen articles were identified for inclusion in this review. Amongst these were 
seven of the nine articles on chronic low back pain from the previous review. Two studies 
reported on rofecoxib which was withdrawn from the market and were excluded from 
this review.22 23
Included studies  
The sample size of the thirteen included studies ranged from 28 to 1593 patients, with 
a total of 4807 included patients in all studies. In six studies NSAIDs were compared 
with placebo.24-29 Three studies compared two different types of NSAIDs.30-32 One study 
compared NSAIDs versus paracetamol,33 one study compared NSAIDs versus tramadol,34 
and one study compared NSAIDs versus pregabalin.35 Exercise therapy was compared to 
NSAIDs in one study.36
Excluded studies  
Excluded studies are described in ‘Characteristics of excluded studies’ (online available 
only). Most studies were excluded because there was an unclear period of back pain or 
the study was not an RCT.
Risk of bias in included studies  
Risk of bias assessment is presented in figure 2 and 3. Of twelve items on risk of bias, the 
included studies ranged from four to nine items meeting criteria for low risk of bias. Ten 
of the thirteen studies scored low risk of bias on at least six items and were considered 
high quality studies.25-30 32-34 36
Allocation (selection bias)  
Of the thirteen included studies, six reported a randomization procedure24 26 27 33 34 36 and 
of these six studies only four also described concealment of treatment allocation.26 33 34 36 
Most studies did not report the method of randomization or allocation concealment 
and were scored ‘unclear’ on these items.
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Blinding (performance bias and detection bias)  
Blinding of patients, care providers and outcome assessors was reported in seven of the 
thirteen studies.25 26 30-34 The other studies did not blind patients, and/or care providers, 
and/or outcome assessors or they did not report on blinding.
Incomplete outcome data (attrition bias)  
Six of the studies reported low drop-out rates.25 31-33 35 36 The seven other studies reported 
drop-out rates higher than 20%.24 26-30 34
An intention to treat analysis was performed in only three studies.27 28 34
figure 1. Study flow diagram
130 Chapter 8 Non-steroidal anti-inflammatory drugs for chronic low back pain 131
figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included 
study
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figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as percent-
ages across all included studies
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Selective reporting (reporting bias)  
Only two studies were registered in an accessible clinical trial registry28 29 and were listed 
as having low risk of reporting bias.
Other potential sources of bias  
Most studies showed similarity of baseline characteristics; only three studies did not 
report this.24 31 33
Regarding co-interventions, only paracetamol as rescue medication was allowed; 
other types of medication were not. All but two studies avoided co-interventions25 26 
and one study did not state anything about co-interventions.36
Compliance was reported in nine studies, and in five studies compliance was accept-
able.24 27 28 32 35 In four other studies compliance was not acceptable.25 26 30 34
Timing of outcome assessment was similar between the study groups in almost all 
studies.
Funnel plots were created to assess risk of publication bias and were used for the 
analysis of NSAIDs versus placebo (figure 4-6). We could not identify publication bias. No 
funnel plots were created for other comparisons, since there were less than four studies 
available for this analysis.
figure 4. (analysis 1.1) Funnel plot of comparison: 1 NSAIDs versus placebo, outcome: 1.1 Change in Pain 
Intensity from baseline on 100mm VAS. Follow-up <=12 weeks
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figure 5. (analysis 1.2) Funnel plot of comparison: 1 NSAIDs versus placebo, outcome: 1.2 Change in Dis-
ability from baseline
figure 6. (analysis 1.3) Funnel plot of comparison: 1 NSAIDs versus placebo, outcome: 1.3 Proportion of 
patients experiencing adverse events. Follow-up <=16 weeks
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A potential conflict of interest was reported in half of the studies. Three studies re-
ported support from a pharmaceutical company26 32 33 and in four studies authors had 
affiliations with a pharmaceutical company.27-29 34 The remaining six studies did not 
report any potential conflict of interest.
effects of interventions  
See: Table 1. Summary of findings
Efficacy of NSAIDs compared to placebo
Six studies24-29 compared NSAIDs with placebo. Median follow-up was 56 days (IQE 13-91 
days). Half of these studies reported short-term outcomes of four weeks or less.24 25 27 The 
other three studies had a duration of follow-up of 12 or 16 weeks.26 28 29 Naproxen was the 
most common type of NSAID,25 28 29 but also piroxicam patch, etoricoxib and valdecoxib 
were compared to placebo.
All studies reported pain intensity on a 100mm VAS or 11-point numerical rating 
scale (figure 7). The Chi2 value for homogeneity of the mean difference (MD) was 66.26 
(p=<0.0001) and I2 92%, which could represent substantial statistical heterogeneity. This 
might be due to different types of NSAIDs used in the studies and a random effects 
model was used to pool these data. The pooled mean difference in pain intensity score 
from baseline was -3.30 (95% CI -5.33 to -1.27), indicating a statistically significant ef-
figure 7. (analysis 1.1) Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.1 Change in Pain 
Intensity from baseline on 100mm VAS. Follow up <=16 weeks
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table 1. Summary of findings
nsAids for chronic low back pain compared to placebo
Patient or population: patients with chronic low back pain
Intervention: NSAIDs
Outcomes illustrative comparative risks* (95% ci)
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Assumed risk corresponding risk
control nsAids
change in Pain intensity from 
baseline.
100mm VAS
Follow-up: 9-112 days
not estimable The mean change in pain 
intensity from baseline. in the 
intervention groups was 3.30 
lower (5.33 to 1.27 lower)
1354
(6 studies)
⊕	⊕	 	
low1,2,3
change in disability from 
baseline
Roland Morris Disability 
Questionnaire 0-24
Follow-up: 4-16 weeks
not estimable The mean change in disability 
from baseline in the intervention 
groups was 0.85 lower (1.30 to 
0.40 lower)
1161
(4 studies)
⊕	⊕	 	
low3,4,5
Proportion of patients 
experiencing adverse events. 
Follow-up: 9-112 days
Study population RR 1.04 
(0.92 to 
1.17)
1354
(6 studies)
⊕	⊕	 	
low1,2,3410 per 1000 427 per 1000 (378 to 480)
Moderate
477 per 1000 496 per 1000 (439 to 558)
sensitivity analysis change in 
Pain intensity from baseline.
100mm VAS
Follow-up: 2-16 weeks
not estimable The mean sensitivity analysis 
change in pain intensity from 
baseline. in the intervention 
groups was 1.73 lower
(3.77 lower to 0.31 higher)
728
(3 studies)
⊕	⊕	⊕	
moderate6
sensitivity analysis change in 
disability from baseline
Roland Morris Disability 
Questionnaire 0-24
Follow-up: 6-16 weeks
not estimable The mean sensitivity analysis 
change in disability from baseline 
in the intervention groups was 
0.41 lower
(1.04 lower to 0.23 higher)
654
(2 studies)
⊕	⊕	⊕	
moderate7
sensitivity analysis Proportion 
of patients experiencing 
adverse events. follow-up 
<=16 weeks.
Follow-up: 2-16 weeks
Study population RR 0.93 
(0.81 to 
1.07)
728
(3 studies)
⊕	⊕	⊕	
moderate6536 per 1000 498 per 1000 (434 to 573)
Moderate
522 per 1000 485 per 1000 (423 to 559)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The 
corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative 
effect of the intervention (and its 95% CI).
ci: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
high quality: Further research is very unlikely to change our confidence in the estimate of effect.
moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and 
may change the estimate.
low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is 
likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Allocation concealment was uncertain in the majority of studies, and randomization was uncertain in half of the studies, 
therefore selection bias is likely. High drop-out rates were present in five out of six studies, so attrition bias is likely.
2 In two out of six studies, cointerventions were allowed. Two studies included a ‘flare design’.
3 See funnel plot, publication bias could not be detected
4 Allocation concealment was uncertain in the majority of studies. High drop-out rates were present in all four studies, so 
attrition bias is very likely.
5 In one study cointerventions were allowed. One study included a ‘flare design’.
6 Allocation concealment and randomization was uncertain in all studies, therefore selection bias is likely. High drop-out rates 
were present in two out of three studies, so attrition bias is likely.
7 Allocation concealment and randomization was uncertain in both studies, therefore selection bias is likely. High drop-out 
rates were present in both studies, so attrition bias is likely.
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fect in favour of patients receiving NSAIDs compared to patients receiving placebo. The 
quality of this evidence defined by GRADE is low (Summary of findings table 1). When 
results were split into selective and non-selective NSAIDs versus placebo, there was still 
a substantial statistical heterogeneity among the studies considering non-selective 
NSAIDs, although three out of four studies used naproxen as study medication. There 
was statistical homogeneity among the studies on selective NSAIDs. The effect of selec-
tive NSAIDs became somewhat larger and the effect of non-selective NSAIDs became 
smaller and not significant (-2.04, 95% CI -4.09 to 0.01).
Four studies compared NSAIDs with placebo, with disability as outcome measure, 
measured with the Roland Morris Disability Questionnaire on a 0 to 24 scale (figure 
8).26-29 Median follow-up was 84 days (IQR 42-105 days). The Chi2 value for homogeneity 
of the mean difference (MD) was 5.53 (P = 0.14) and I² 46%, indicating that there could 
be moderate statistical heterogeneity among these studies. The pooled mean difference 
in disability from baseline was -0.85 (95% CI -1.30 to -0.40). The quality of this evidence 
defined by GRADE is low (Summary of findings table 1).
Adverse events were also reported in all studies. The Chi2 value for homogeneity of the 
RR for adverse events in all studies was 6.22 (P = 0.28) and I² 20%, indicating statistical 
homogeneity among the studies. The pooled RR for adverse events was 1.04 (95% CI 0.92 
to 1.17) (figure 9), indicating that adverse events are not statistically significant more pres-
ent in patients using NSAIDs compared to placebo. Quality of evidence of these studies 
was low using the GRADE approach (Summary of findings table 1). Results do not change 
when specified into selective and non-selective NSAIDs, although adverse events in selec-
tive NSAIDs show a trend in favour of placebo. However, RCTs have low power in detecting 
uncommon and delayed adverse events. Sample sizes of most studies were relatively small 
and duration of follow-up was relatively short. It is possible that not all adverse events 
have emerged, especially since most important adverse events are rare and can take 
weeks or months to evolve. Therefore, it is not possible to make firm statements about the 
difference in occurrence of adverse events between different types of NSAIDs.
Of the studies that compared NSAIDs with placebo, three studies were considered 
high risk of bias.24 26 27 The latter two had used of a ‘flare design’. A sensitivity analysis was 
figure 8. (analysis 1.2) Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.2 Change in Dis-
ability from baseline
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performed with the three low risk of bias studies.25 28 29 The difference between NSAIDs 
and placebo on pain intensity score on 0-100mm VAS and the disability measured with 
RDQ 0-24 became smaller and was no longer statistically significant (figure 10-12); dif-
ference between NSAIDs and placebo for pain intensity score of -1.73 (95% CI -3.77 to 
0.31) and disability of -0.41 (95% CI -1.04 to 0.23). The quality of this evidence defined by 
GRADE is moderate (Summary of findings table 1).
figure 9. (analysis 1.3) Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.3 Proportion of 
patients experiencing adverse events. Follow up <=16 weeks
figure 10. (analysis 1.4) Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.4 Sensitivity analy-
sis Change in Pain Intensity from baseline on 100mm VAS. Follow up <=16 weeks
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Efficacy of selective versus non-selective NSAIDs and non-selective versus non-selective 
NSAIDs
Two studies30 31 compared two types of non-selective NSAIDs. Driessens et al compared 
ibuprofen 1600mg/day and diclofenac 100mg/day for two weeks,30 Videman et al 
compared piroxicam 20mg/day and indomethacin 75mg/day for six weeks.31 Both stud-
ies found no significant difference between the two types of non-selective NSAIDs. It 
is possible that these studies were underpowered, since the sample size was 62 and 
28 patients in both studies, respectively. Adverse events in the study of Driessens et al 
were statistically significant more present in the diclofenac group. In the study of Vide-
man et al there was no statistically significant difference in experienced adverse events 
between the two study groups. One other study compared a non-selective NSAID with 
a COX-2 inhibitor (diclofenac 150mg/day versus etoricoxib 60mg/day for four weeks).32 
In this study 440 patients were included in the analysis and no significant difference in 
change in pain intensity from baseline between the NSAIDs and COX-2 inhibitors was 
found. Adverse events in general and specific gastrointestinal adverse events were also 
examined, but no differences between the two study groups were found.
Efficacy of NSAIDs versus other drugs
NSAIDs compared to other drug types are shown in figure 13 and 14. These studies were 
not pooled, because different types of medication were used as comparison. One study 
with 30 included patients compared NSAIDs (diflunisal 1000mg/day) with paracetamol 
(4000mg/day), in this single study NSAIDs were not significantly better than paracetamol 
and adverse events were not significantly more present in one study group.33
Another study compared NSAIDs (celecoxib 400mg/day) with tramadol (200mg/day) 
for six weeks in a trial of 1593 patients. Results of global improvement (RR 1.26 (95% CI 
1.16 to 1.38) and adverse events (RR 0.83 (95% CI 0.75 to 0.91) after six weeks were both 
in favour of celecoxib.34
The study of Romano et al35 compared celecoxib with pregabalin and scored change 
in pain intensity from baseline to four weeks on a VAS score. There was no significant 
difference found between the two study groups and also adverse events were similar in 
both celecoxib and pregabalin study groups.
figure 11. (analysis 1.5) Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.5 Sensitivity analy-
sis Change in Disability from baseline
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Efficacy of NSAIDs versus non-drug treatment
One study compared NSAIDs with ‘home-based exercise’.36 Improvement of patients 
between baseline and 8 weeks was significantly better in exercise patients then patients 
receiving NSAIDs measured with the RDQ. There was no difference in pain measured 
with a 0-100mm VAS.
discussiOn  
summary of main results  
In this review we included 13 randomized controlled trials that assessed the efficacy 
of NSAIDs for the management of chronic low back pain. Studies comparing NSAIDs 
with placebo showed a pooled effect of NSAIDs that was better than placebo in both 
outcomes on pain intensity score and disability. When only low risk of bias trials are ana-
lysed, the difference between NSAIDs and placebo was no longer significant. Adverse 
events were not significant more present in the NSAIDs or placebo study group, but this 
figure 12. (analysis 1.6) Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.6 Sensitivity analy-
sis Proportion of patients experiencing adverse events. Follow up <=16 weeks
figure 14. (analysis 2.2) Forest plot of comparison: 2 NSAIDs versus other drug treatment, outcome: 2.1 
Proportion of patients experiencing global improvement. Follow-up <=6 weeks
figure 13. (analysis 2.1) Forest plot of comparison: 2 NSAIDs versus other drug treatment, outcome: 2.2 
Proportion of patients experiencing adverse events. Follow-up <=6 weeks
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can be due to the selection of RCTs, a short duration of use and a short follow-up period 
in most studies.
Studies comparing non-selective versus selective NSAIDs or comparing different types 
of non-selective NSAIDs were also limited available. All three studies included showed 
no significant effect between the different types of NSAIDs.
Whether NSAIDs are more effective than other drugs or non-drug therapies for chronic 
low-back pain still remains unclear. A limited number of studies compared NSAIDs ver-
sus other drug treatments and all studies included different kind of drug treatments to 
compare with NSAIDs. Celecoxib was compared to tramadol in a large study. Results of 
global improvement and adverse events were both in favour of celecoxib after six weeks.
Overall completeness and applicability of evidence  
In two studies a ‘flare design’ was used. Patients who responded well to NSAIDs were in-
cluded when they showed a worsening in back pain during a wash-out period. Because 
these patients already responded well to NSAIDs, these studies are likely to overestimate 
the effect of NSAIDs. It may also reduce the external validity since this is a select group 
of patients. When these studies are excluded from the analysis together with one other 
study with high risk of bias the results changed. The magnitude of effect of NSAIDs 
became smaller and the difference was not statistically significant anymore.
Outcomes were operationalized differently in some studies and not all studies includ-
ed disability as outcome. Return to work or other work outcomes were not mentioned 
in any of the studies, although this might be an important outcome in daily practice.
Adverse events are mentioned in almost all studies. Most studies reported overall 
number of adverse events, some studies also mentioned specific gastrointestinal 
adverse events. Cardiovascular adverse events are rarely mentioned. However, these 
studies were powered to investigate treatment effects of the primary outcomes. As 
most important adverse events are rare and can take weeks or months to evolve, it is 
likely that sample sizes were too small and follow-up periods too short to draw clear 
conclusions from these studies regarding the risks for gastrointestinal and other adverse 
events of NSAIDs. 
Quality of the evidence  
Three of the included studies did not reach six positive items in the risk of bias tool. Many 
other RCTs have other methodological shortcomings such as no clear description of the 
randomization procedure, high drop-out rates and low or unclear compliance in the 
study groups. Uncertain or low compliance makes it difficult to interpret the measured 
effect in the study and can both under- and overestimate the results found.
Follow-up was at least four weeks in most studies, only three studies had follow-up 
times less than four weeks, ranging from nine days to two weeks.
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Included RCTs had different study population sizes, four studies included less than 
50 patients and may lack statistical power to detect differences in effects. Pooling may 
overcome this problem, but due to different comparisons and outcomes in the studies, 
pooling was not always possible.
The quality of evidence using the GRADE approach was low due to similar issues. Most 
important reasons for downgrading evidence were ‘risk of bias’ and ‘imprecision’.
A sensitivity analysis with a moderate quality of evidence according the GRADE ap-
proach showed that the positive effect of NSAIDs compared to placebo was reduced 
and no longer statistically significant when only low risk of bias studies were included 
in the analysis.
Specific outcomes were not always mentioned in text or tables, but only shown in 
graphs. For the Roland Morris Disability questionnaire, specific results were shown in 
graphs for three studies.26-28 Data were extracted from the graphs to calculate mean 
differences. P-values for differences between the treatment groups were mentioned in 
the text of these three trials. This was also the case in two other studies where a pain on 
a VAS scale25 and pain on a scale of 0 to 3131 was shown in graphs.
Potential biases in the review process  
In this review we used strict inclusion criteria on the duration of back pain, meaning 
that only studies which reported results on chronic low back pain were included. This 
has led to less included studies in this review, but makes the results of the review more 
distinct for patients with non-specific chronic low back pain. We also only included trials 
published in English, German or Dutch. This could have led to exclusion of trials which 
could have contribute to the data and conclusions of this review.
Only one reviewer extracted the data and the second reviewer controlled the data. 
This could have led to a higher risk of wrong data extraction.
NSAIDs come in different types and chemical entities and it makes it difficult to com-
pare different NSAIDs. In the comparison of NSAIDs versus placebo both selective and 
non-selective NSAIDs were included. An analysis of two separate comparisons showed 
no differences in directions of the findings when selective and non-selective NSAIDs 
were compared separately with placebo.
Publication bias may have occurred, but was difficult to assess due to the limited 
number of studies. Especially in the comparisons of different types of NSAIDs or NSAIDs 
compared to other types of drugs this could not be examined using a funnel plot. Al-
though half of the studies were supported by or included authors from pharmaceutical 
companies. Clinical trials sponsored by pharmaceutical companies are less likely to be 
published and are more likely to have outcomes in favour of the sponsor37 and could 
have caused publication bias.
142 Chapter 8
Agreements and disagreements with other studies or reviews  
The previous Cochrane review18 reviewed NSAIDs for sciatica, acute and chronic back 
pain based on literature from September 1998 to June 2007. They found a change in 
pain intensity in favour of NSAIDs compared to placebo. In this review we found similar 
results, but the magnitude of the results in our review was smaller than found in 2008. 
Adverse events were statistically more present in the NSAID group in the review of 2008, 
but in our review we did not find a statistical significant difference. This could be due 
to the included study in this review with mostly a small sample size and/or short-time 
follow-up. A large meta-analysis on adverse events in RCTs16 and observational data38 
showed that adverse events are more present in patients using NSAIDs.
After 2008 multiple (systematic) reviews were published regarding NSAID as thera-
peutic option in the treatment of chronic low back pain. Pain score between NSAIDs and 
placebo were often reported. In 2013 a review on NSAIDs showed that COX-2 selective 
NSAIDs were significantly more effective in reducing VAS score and disability measured 
with RDQ.39 Four studies were included in these analysis of which two were not included 
in our review. One study40 was excluded in the previous version of this review because it 
is additional information to an earlier reported study that was included in this review.26 
The other study23 reported on rofecoxib and therefore it was excluded in this review. Kui-
jpers et al41 found in a similar systematic review similar results as Chung et al.39 Regard-
ing VAS scores, they conclude that there is low quality evidence that NSAIDs are more 
effective than placebo. This is comparable to our findings in this review. Disability was 
also assessed in the Chung et al review and results were comparable to findings in this 
review.39 These reviews use comparable studies in their analysis, only the magnitude of 
the effect of NSAIDs is larger than found in this review. Some studies were not included 
in the previous reviews due to timing of publications. Furthermore these reviews did 
not perform a sensitivity analysis without studies with high risk of bias as was done in 
this review.
Chung et al also evaluated selective and non-selective NSAIDs and found no differ-
ences in efficacy between these two groups.39 Two studies were analysed in this review, 
one of those was also examined in this review and found the same results. The other 
study used in the review of Chung 2013 et al was excluded in this review due to the use 
of rofecoxib. Adverse events were more present in nonselective NSAIDs according to 
the two studies, but in our review where only one study compared these two types of 
NSAIDs, no difference in adverse effects was found.
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AuthORs’ cOnclusiOns  
implications for practice  
For patients with chronic low back pain there is low quality evidence that NSAIDs are 
slightly better in reducing pain and disability than placebo, although when only low 
risk of bias studies are taken into account no significant difference between NSAIDs and 
placebo is found. It is questionable if NSAIDs are effective in the treatment of chronic low 
back pain and if so whether the effects are clinically relevant. It is still unclear if NSAIDs 
are more effective than other drugs and there is no evidence that one type of NSAID is 
more effective than other types. When considering NSAIDs it is important to take both 
these possible small effects as the costs and possible adverse events into account.
implications for research
Quality of evidence for NSAIDs compared to placebo in patients with chronic low back 
pain is at best moderate. When studies have higher quality, effects of NSAIDs become 
smaller or disappear. It is questionable if additional research will change these findings 
and the estimate of effect. Especially since the observed differences between NSAIDs 
and placebo are small and possibly not clinically relevant. Since it is seen in studies with 
flare designs that some patients do respond to NSAIDs, it might be worthwhile looking 
into subgroups finding patients who are likely to respond well to NSAIDs.
diffeRences Between PROtOcOl And ReView 
NSAIDs which were no longer available on the market, like rofecoxib, were excluded 
from the review. This was not previously stated in the protocol.
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The aim of this thesis was to describe: 1) the characteristics of older adults with back 
pain; 2) the various ways of identifying different types of patient subgroups, and their 
course and prognosis of back pain; and 3) healthcare use due to back pain in a popula-
tion of older adults. 
This chapter discusses the findings of the presented studies, including recommenda-
tions on how to interpret the results and implications for clinical practice. The strengths 
and limitations of the studies are also addressed, and some ideas for future research are 
presented. 
mAin findings
Older adults with back pain
It is known that older patients with back pain differ from younger patients regarding 
the severity of their back complaints;1 furthermore, older patients more often have co-
morbidities.2 Although there seem to be differences between older and younger adults 
with back pain, older adults with back pain are often excluded from randomized con-
trolled trials.3 Due to the exclusion of these older patients, less is known about back pain 
in this specific subgroup of patients and the efficacy of the therapy that they receive. 
This thesis focuses on older adults with back pain, because we hypothesized that 
there are important differences in back pain and patients’ characteristics as compared to 
younger patients with back pain. 
Within our study population of patients aged over 55 years, several baseline charac-
teristics were shown to differ between the relatively ‘younger’ and ‘older’ patients in this 
group (Chapter 2). For example, disability was significantly higher and quality of life was 
significantly lower in the older patients. Furthermore, the older patients experienced 
more kinesiophobia and depressive symptoms, and scored lower on the back beliefs 
questionnaire. However, the differences between the two groups were relatively small. 
For disability measured with the Roland Morris Disability Questionnaire (RDQ),4 the 
difference was 2.7 points on a scale ranging from 0 to 24; a difference of at least 2 to 5 
points is considered to be clinically relevant.5 6 Furthermore, the difference in disability 
probably increases when the difference in mean age between the two groups becomes 
larger. Moreover, when compared to even younger patients (i.e. aged less than 55 years) 
this difference in disability might be even greater. Other studies report similar results, 
with more disabling back pain in older patients than in younger patients.7 8 In an earlier 
study that also used the RDQ, the authors found small differences between patients 
aged 65-69 years compared to the oldest age group of patients aged over 85 years.7 
Another study defined disability in a different way, but it is unclear whether the reported 
differences in disability between the age groups are clinically relevant.8 Overall, these 
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earlier studies, and our study presented in Chapter 2, show that in back pain patients 
older age is associated with more disability. When patients experience more disability 
they may become less physically active, especially with increasing age.9 Physical inac-
tivity is also associated with more severe back pain and more disability;10 this might 
lead to a negative spiral in which patients become less physically active and experience 
more back pain and disability. Ultimately this could lead to a sedentary lifestyle in which 
especially the oldest patients might need extra care or are no longer able to lead an 
independent life. Therefore, it is important to be aware that back pain is probably even 
more disabling among the oldest adults. 
In the two age groups studied (> 55-74 years vs ≥ 75 years) the differences between the 
other baseline variables were relatively small. For example, quality of life was measured 
on a 0-100 scale and, on the physical component summary scale, the difference was 
only 3.8 points. Co-morbidity was also more frequently present in the older patients. 
As co-morbidity is known to increase with age, it is not surprising that differences were 
found between the two age groups for this variable. Furthermore, co-morbidities and 
back pain are known to be associated with each other.11 It is questionable whether co-
morbidities can be prevented or should receive extra attention in the treatment of back 
pain. Co-morbidities can complicate treatment, since analgesic usage in patients with 
co-morbidities such as renal problems, cardiovascular disorders and gastro-intestinal 
complaints, is associated with a higher risk of adverse drug reactions.12 13 
subgroups
Identifying subgroups in the heterogeneous population of back pain patients might 
add to our understanding of the course and prognosis, and may also help to specify 
treatment for different subgroups. In our population of older adults with back pain we 
identified subgroups in different ways and at different time points: 1) patients who were 
at risk for experiencing neuropathic pain were identified at baseline, 2) patients who 
might experience back pain due to an underlying serious pathology were also identi-
fied, 3) patients reporting non-recovery were compared to those who reported recovery 
after three months, and 4) different trajectories of back pain were identified based on 
the course of back pain over a 3-year follow-up period. 
Neuropathic pain
In back pain, although the mechanism of neuropathic pain is not fully understood, 
different mechanisms probably play a role in the development of neuropathic pain. 
Back pain might be a ‘mixed’ type of pain, consisting of nociceptive and neuropathic 
components. Neuropathic pain may be caused by lesions of nociceptive sprouts in the 
degenerated intervertebral discs, by mechanical compression of the nerve root, or by 
action of inflammatory mediators from degenerated intervertebral discs.14 It is impor-
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tant to identify this subgroup of patients because they might derive more benefit from a 
different type of analgesic treatment. Whereas nociceptive pain is generally treated with 
analgesics such as paracetamol and NSAIDs, neuropathic pain is preferably treated with 
anti-depressants and anti-epileptic medication.15 16 
In our study population of older adults, neuropathic pain as measured with the DN4 
was barely present. Only 2% of the patients experienced neuropathic components in 
their back pain (Chapter 3). Different mechanisms may have played a role and may partly 
explain the differences compared with earlier studies, where the proportion of patients 
experiencing neuropathic pain was substantially higher.17-23 Also, the use of different 
tools to measure neuropathic pain might cause differences in the found prevalence 
of neuropathic pain, although this may not explain all variation. Furthermore, a study 
comparing S-LANSS and DN4 as tools to identify neuropathic pain showed that DN4 
identified more patients than the S-LANSS.22 It is unlikely that the pathologic pathway 
of neuropathic pain differs between younger and older adults and it is unclear whether 
neuropathic pain is less of a problem in this older population, or whether the tools used 
are not sensitive enough for this particular group. Since few data are available on neu-
ropathic pain in older adults, it remains unclear how we should interpret these findings. 
It might be useful to assess whether existing tools for neuropathic pain have the same 
diagnostic value in both older and younger patients. 
Specific underlying pathology
It is likely that the course of back complaints is different when the back pain is caused 
by an underlying pathology. Furthermore, in most cases of a serious underlying pathol-
ogy, diagnosis of the underlying pathology is important because a different type of 
treatment is required. Because serious underlying pathology increases with age, it was 
surprising that only 6% of our older patients with back pain were diagnosed with a seri-
ous underlying pathology during 1-year follow-up (Chapter 4), while in previous studies 
with an all-age population in primary care 1-5% was found.24 25 The distribution of the 
underlying causes in our patients was similar to that reported in a previous study.24 Of 
all serious underlying pathology, in our older patients vertebral fractures were the most 
common. 
To help physicians diagnose vertebral fractures, most clinical guidelines recommend 
the use of red flags.26 27 In our study, several red flags were positively associated with 
the diagnosis of vertebral fracture; some of these red flags were associated, but their 
diagnostic value was relatively low. Other studies on red flags for vertebral fractures in 
primary care also found a few associated red flags.28 In our study, age ≥75 years, trauma, 
osteoporosis and a back pain intensity score ≥7 were all positively associated with un-
derlying pathology. Age and trauma are also mentioned in other studies as being associ-
ated with vertebral fractures, whereas osteoporosis and back pain intensity score were 
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not. In the earlier studies, only prolonged corticosteroid use had good diagnostic value, 
whereas the other variables showed low diagnostic accuracy for the identification of 
vertebral fractures in back pain patients.28 In our study population, use of corticosteroids 
was not an associated red flag whereas osteoporosis was. Osteoporosis is thought to 
be a mediator in the relation between prolonged use of corticosteroids and fractures.29 
It is possible that corticosteroids cause osteoporosis; however, in our population of 
older adults, osteoporosis may well have been present without the prolonged use of 
corticosteroids.
Other red flags for vertebral fractures have a (very) low diagnostic value and it is ques-
tionable whether they should be addressed in the guidelines as red flags. For instance, 
percussion tenderness of the spine, female gender and a sudden decrease in height, 
were red flags that were not associated with the diagnosis vertebral fracture. Due to the 
contradictory results in various studies, it is difficult to decide which red flags should 
in fact be recommended in the guidelines. In clinical practice, red flags are often used 
when a patient with back pain consults a physician. However, since the diagnostic value 
of red flags is low, it is questionable whether they really are valuable for diagnosing the 
underlying pathology. For example, in clinical practice the situation may arise where a 
red flag is present but there is no underlying pathology or, vice versa, a pathology may 
be present but there is no red flag. In this way, an underlying pathology can be missed 
and the patient may miss out on appropriate treatment. On the other hand, if a red flag 
cannot rule out or prove an underlying pathology, patients might more frequently be 
referred for additional tests, e.g. imaging for a suspected underlying pathology. How-
ever, both frequent imaging and missing out on treatment are undesirable situations, 
whereas the use of red flags is supposed to provide support for these decisions. In the 
presence of back pain, we need to find or develop tests which can make a clearer and 
more accurate distinction between patients with and without underlying pathology. 
It appears to be difficult to develop tests which can adequately discriminate between 
patients with and without these different pathologies. Vertebral fracture as an underly-
ing pathology is the most frequently studied, because it occurs most often. Red flags for 
other underlying pathologies, such as malignancies or infections, are difficult to assess 
because they require a very large study population of back pain patients. One possible 
solution is for institutions to collaborate and share their data; the pooling of different 
cohorts might add to the knowledge on red flags for rare pathologies. Another possible 
solution is to use a different type of study design. Also, since our outcome of interest 
is relatively rare, it might be feasible to perform case-control studies to investigate red 
flags. 
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Non-recovery and back pain trajectories
In our study, non-recovery of back pain was determined after the first 3 months 
of follow-up (Chapter 5). This revealed that the mean pain score of the patients had 
improved (baseline 5.2 (SD 2.7); 3 months 3.6 (SD 2.8)), despite that after 3 months non-
recovery was still reported by 380 patients (61%). Subsequently, the course of back pain 
in these older patients was assessed over a 3-year period and different trajectories were 
identified (Chapter 6). These trajectories were based on the pain scores that patients 
reported at eight time points during the 3-year follow-up period. Three trajectories were 
identified: ‘high pain scores’, ‘intermediate pain scores’ and ‘low pain scores’. Because the 
course of back pain is more informative than back pain status at a single moment in 
time, the study of trajectories in back pain patients has recently received more atten-
tion.30-36 Trajectories are identifiable courses of back pain in subsets of patients within 
a larger heterogeneous pool of back pain patients. It is thought that identifying these 
trajectories might help to identify prognostic factors. Although some studies have al-
ready identified trajectories30-36 most of their analyses did not take growth over time into 
account. Also, it is important to include the probability of membership in a trajectory 
when analysing and identifying prognostic factors. 
It is probably more meaningful to follow patients over a longer period of time and to 
employ more time points. In our study, with six time points in the first year and only two 
time points in both the second and third year, it is questionable whether we identified 
the potentially recurrent pattern of back pain in these last two years. Had more time 
points been included during the 3-year follow-up, the recurrent character of back pain 
(if present) might have been more apparent. In some studies this already takes place 
using the short messaging service (SMS);37 38 this will probably add a substantial amount 
of information about the course of back pain. The use of techniques such as the SMS has 
the potential to reveal a more precise pattern of back pain per patient. 
In Chapter 5 the baseline characteristics of patients reporting non-recovery and 
recovery at 3 months were compared; in Chapter 6 differences found in baseline 
characteristics between patients led to the establishment of three trajectories at the 
3-year follow-up. Variables associated with both non-recovery after 3 months, and a 
less favourable outcome in the trajectory study over 3 years, were negative expecta-
tions of recovery at baseline and a longer duration of back pain. Another study in older 
adults also assessed the prognosis of back complaints and found that patients with a 
longer duration of symptoms had higher pain scores during one year;39 also, patients 
with negative expectations for recovery at baseline had more disability at baseline and 
showed less improvement over one year. Expectations of patients with back pain in pri-
mary care are reported to be stable over time.40 Also, this study could not show that an 
early change in expectations was associated with a more favourable course of back pain. 
However, importantly, no specific intervention was performed and it remains unclear 
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whether influencing a patient’s expectations is beneficial in adjusting the course of back 
pain. A longer duration of pain (at baseline) is also associated with a less favourable 
outcome. To prevent patients from developing long-lasting back pain, patients at high 
risk can be identified using the Start Back tool.41 This promising tool is already used in 
some clinical settings and the value of this tool is being evaluated in various languages 
and populations.42-46 It would also be worthwhile to evaluate this tool in a population 
of older adults. Although other prognostic factors have also been studied in back pain 
research, the question as to which factors are true predictive factors for poor recovery 
still remains unanswered.47 Reported associations are weak and validation in indepen-
dent samples is often not performed.47 48 The importance of identifying patients at high 
risk for chronic back pain is clear and might lead to specific interventions to prevent 
chronicity of back pain. However, it might be better to focus more on the validation 
of earlier prognostic factors and tools, rather than developing new tools. Even in our 
own study population, two different (statistical) methods and different follow-up times 
produced different prognostic factors associated with non-recovery. This implies that 
the prognostic factors found should preferably be validated in independent samples 
and that the clinical use of these prognostic factors should also be evaluated. Eventually 
this might help identify patients who are at risk for a less favourable outcome. Patients 
at high risk for a less favourable outcome may need extra attention or a different type 
of treatment. However, because this has not yet been studied, it is unknown whether an 
additional or other type of therapy can prevent this unfavourable course of back pain. 
healthcare utilization
Guidelines for back pain recommend that patients stay active and, if necessary, are also 
supported by the prescription of analgesics.49 However, because of the high rate of co-
morbidity in older adults, we need to consider the possible adverse reactions of these 
analgesics. According to the WHO pain ladder paracetamol is the first choice, mainly 
because it has fewer side-effects. Although paracetamol is widely used for different 
types of pain (including musculoskeletal pain), evidence for its effectiveness is scarce. 
A recent study on paracetamol even reported that paracetamol in patients with acute 
low back pain is not more effective than placebo.50 However, this result has not been 
replicated in another population of back pain patients and has not yet been compared 
with patient reassurance and the advice to stay active. A second step in the pain ladder 
is the use of NSAIDs, which are known to have (possible) serious adverse reactions such 
as renal failure, cardiovascular risks and gastro-intestinal problems.12 13 Therefore, the 
use of NSAIDs in older patient requires special consideration, since the risk of gastro-
intestinal events is higher in these patients. The choice for an NSAID in older patients 
should preferably be for a short period only and, if necessary, together with the prescrip-
tion of a gastro-protective drug. Nevertheless, despite this importance, it is reported 
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that only 41% of patients at high risk of a gastro-intestinal event using NSAIDs were also 
prescribed a gastro-protective drug.51 
Furthermore, it remains questionable how effective these NSAIDs are in patients with 
back pain. In all-age populations, for chronic low back pain the effect of NSAIDs was 
found to be significant, but very small (Chapter 8). For example, when NSAIDS were 
compared with placebo, there was a significant difference in the pain score of only -3.30 
(95% CI -5.33 to -1.27) on a pain scale ranging from 0 to 100. Although this might imply 
some effect of NSAIDs, since the differences between patients using NSAIDs compared 
to placebo are very small, it remains questionable whether this is a relevant difference 
for clinical practice. Similar very small differences were also found in patients with acute 
back pain.52 Although these latter studies were not specifically performed in older adults, 
they show that the magnitude of the effect of NSAIDs is generally not large. 
Despite that analgesics do not seem particularly effective compared to placebo, 
a considerable proportion of patients with back pain use these medications, either 
prescribed or over-the-counter (Chapter 7). We hypothesized that, since paracetamol 
in the Netherlands is mostly obtained over-the-counter, that more use of paracetamol 
would be apparent. However, although paracetamol was indeed mostly obtained 
over-the-counter, overall the NSAIDs were more frequently used. Especially in an older 
population it is important that patients are aware of the risks of analgesic medications. 
In many cases paracetamol and NSAIDs obtained over-the-counter are not used accord-
ing to the established guidelines, often exceeding the recommended daily maximum 
dose or used by patients with contra-indications for such treatment.53 54 Our study also 
revealed that some patients used different types of NSAIDs, both over-the-counter and 
via prescription; however, we could not evaluate whether these medications were taken 
simultaneously. 
Because the efficacy of analgesics (e.g. paracetamol and NSAIDs) are rarely studied 
in older adults, it is difficult to assess the benefit/harm ratio. Since the harms might be 
greater in these older patients than in a younger population, knowledge on the efficacy 
of these analgesics becomes even more important. Furthermore, it would be interesting 
to examine other forms of treatment without these potential adverse events, such as 
exercise therapy. Although staying active is advised in guidelines on back pain,49 it is 
useful to establish whether exercise therapy or walking therapy is indeed effective for 
low back pain in older adults. 
methOdOlOgicAl issues 
BACE is a cohort study which allows to evaluate the course of back pain after visiting 
their GP, without interfering with usual care. However, this method may have some dis-
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advantages. For example, we can identify associations between baseline characteristics 
and, for instance, different courses of back pain over time, but are unable to determine 
causality.
We aimed to include all consecutive patients aged over 55 years with back pain who 
were presenting with a new episode to their GP. However, when compared to incidence 
per age category in primary care, it appeared that relatively more younger patients were 
included.55 This can cause some issues regarding generalizability, and some findings 
might be altered due to the underrepresentation of the oldest patients in our study. 
However, because the differences found between our relatively younger and older 
patients were small and probably not clinically relevant, the selected population prob-
ably had only a minor impact on the results. On the other hand, it is possible that, for 
example, the proportion of patients with an identified specific underlying pathology as 
a cause of back pain in our population could have been an underestimation. 
clinicAl imPlicAtiOns
The presented findings suggest that back pain in older adults is an important problem. 
A considerable proportion of the included patients had back pain over a prolonged 
period of time and, particularly for the older adults, disability is an important problem. 
Disability can lead to inactivity and, in turn, inactivity can lead to more back pain and 
disability. This negative spiral should be prevented in older adults, since both mobility 
and independence are susceptible to negative influences. 
Some variables were associated with a less favourable course of back pain in this 
population of older adults. Although variables such as a longer duration of back pain (at 
baseline) are known to be associated with a higher risk for a less favourable course, other 
variables (like patients’ expectations of recovery) have not been well studied. These lat-
ter variables should be further investigated and tested to establish whether intervention 
on these variables can alter the course of back pain. 
Red flags are also discussed in relation to the diagnosis of vertebral fracture in these 
older adults. In most studies the red flags seem to have no or only limited diagnostic 
value. In addition, contradictory results from various studies make it difficult to decide 
which red flags should be recommended in the guidelines and which should not. One 
important red flag with the relatively highest diagnostic value is ‘trauma’, which should 
be taken into account when older patients with back pain present to their GP. 
In our study population the use of analgesics was widespread. Since older adults are 
prone for adverse events and, especially since the efficacy of analgesics seems low, it 
is important to establish whether these analgesics are in fact effective in these older 
adults. Therefore, healthcare professionals should consider both the benefits and harms 
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of these analgesics. Also, patients should be informed about the potential benefits 
and harms of the analgesics that they buy over-the-counter themselves, or have been 
prescribed. It is not yet known whether reassurance and the advice to stay active might 
be as effective as prescribing analgesics; this is worth investigating, especially because 
related adverse events are generally minor. 
RecOmmendAtiOns fOR futuRe ReseARch
The aim of the BACE cohort study is to gain knowledge on older patients with back pain. 
Although this thesis offers additional valid information about different subgroups and 
the healthcare use of these patients, it also raises some questions. 
Identifying patients with underlying pathology, or ruling out underlying pathology 
as a cause of back pain, remains a challenge and the use of red flags should be further 
investigated. Because of the low prevalence of underlying pathologies as a cause of 
back pain, it might advantageous to address questions about the associations of red 
flags via case-control studies. At the same time, some red flags have been analyzed in 
other cohorts and it might be worthwhile to combine these cohorts to further analyze 
the usefulness of red flags for different underlying pathologies. 
The course of back pain has recently been studied in several populations of back pain 
patients. Although this provides additional information, the statistical analyses and 
the study designs differ considerably; this can lead to differences in findings and also 
makes it difficult to compare these studies. For future studies on back pain, it would 
be beneficial to reach consensus on the use of similar statistical methods and study 
designs. Furthermore, it would be interesting to not only create subgroups based on 
pain scores but also on disability, since functioning in daily life is an important factor of 
independence. Another important item to be evaluated is the use of physical activity 
and its relationship with the course of back pain. 
Regarding analgesics, since the effects of various analgesic options in older adults are 
unknown and levels of harm might be higher in this specific population, the efficacy 
of these analgesics needs further evaluation. Also, we need to assess whether physical 
activity and/or exercise therapy is beneficial in this group of patients. Although guide-
lines already advise to stay active, it remains unclear exactly how one should stay active 
and whether certain exercises are more beneficial than others. In younger chronic back 
pain patients (mean age 41 years) there is some evidence that exercise is slightly more 
effective in decreasing pain and improving disability than no exercise at all. However, in 
acute back pain patients such physical activity was not more effective than no exercise.56 
Also, we need to further investigate whether older patients benefit from physical activ-
ity, especially since physical activity has shown beneficial effects in older adults with 
158 Chapter 9
other musculoskeletal complaints.57-59 If this proves positive for back pain this would not 
only benefit their condition, but may also be beneficial for other co-morbidities such as 
obesity, osteoporosis and osteoarthritis.60 
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Summary
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summARy
The aim of this thesis was to describe: 1) the characteristics of older adults with back 
pain; 2) the various ways of identifying different types of patient subgroups and their 
course and prognosis of back pain; and 3) healthcare use due to back pain in a popula-
tion of older adults. 
Most of the results described in this thesis are based on the BACE study population. 
The characteristics of these older adults with back pain are described in chapter 2. A 
total of 675 back pain patients were included in the BACE study, with a median age 
of 65 years (interquartile range 60–71 years). Patients aged >55–74 years had a mean 
disability score of 9.4 (SD 5.8) on the 0-24 Roland Morris Disability Scale. Compared with 
patients aged ≥75 years who had a mean score of 12.1 (SD 5.5) (p ≤ 0.01). Although this 
difference was statistically significant, the absolute difference between the groups was 
2.7 points; a difference of at least 2 to 5 points is considered to be clinically relevant. The 
older patients also reported more additional musculoskeletal disorders and more often 
had low bone quality than patients aged >55–74 years. 
Different ways of identifying subgroups of patients were used in this thesis. Results on 
prevalence of neuropathic pain and associations of neuropathic pain with baseline char-
acteristics in this cohort of older adults is presented and discussed in chapter 3. Of the 
261 included patients available for this analysis were 250 patients (96%) with the DN4 
interview plus physical examination, and 259 patients (99%) with the DN4 interview. 
In the DN4 interview plus physical examination 5 patients (2%) scored positive for the 
presence of neuropathic pain. A higher score was associated with pain radiating below 
the knee (p<0.001) and use of paracetamol (p=0.02). For the DN4 interview alone 29 pa-
tients (11%) scored positive and this was associated with a higher body mass index (BMI) 
(p=0.01), pain radiating below the knee (p=0.001) and use of paracetamol (p=0.002). The 
found prevalence of neuropathic pain in this study was remarkably lower than reported 
in other studies including back pain patients. 
chapter 4 presents the assessment of underlying pathology as a cause for the back 
pain in this population of older adults. Of all included patients 6% were diagnosed during 
1 year follow-up with a serious underlying pathology. Most of these patients (n=33; 5%) 
were diagnosed with a vertebral fracture. Multivariable regression analysis showed that 
age ≥75 years (OR 3.5; 95% CI 1.5 to 6.8), trauma (OR 7.8; 95% CI 2.7 to 22.5), osteoporosis 
(OR 2.5; 95% CI 1.0 to 6.2), a back pain intensity score ≥7 at baseline (OR 3.1; 95% CI 1.4 
to 7.2), and presence of thoracic pain (OR 2.1; 95% CI 0.9 to 4.9) were associated with 
a higher chance of getting the diagnosis vertebral fracture. Of these variables, trauma 
showed the highest positive predictive value for vertebral fracture of 0.25 (95%CI 0.09 
to 0.41) and a positive likelihood ratio of 6.2 (95% CI 2.8 to 13.5). A diagnostic prediction 
model including all five red flags did not increase these values. In clinical practice red 
166 Chapter 10 
flags are often used when a patients consults the physician with back pain. Since the 
diagnostic value of the red flags was low, it is questionable if these red flags do really add 
to the diagnosis of vertebral fractures.
The course and prognosis of their back pain until three months after baseline, was 
assessed and reported in chapter 5. The course of back pain was described in terms of 
self-perceived recovery, back pain severity, disability, pain medication, and GP visits dur-
ing 6 weeks and 3 months follow-up. At 6 weeks follow-up 64% of the patients reported 
no recovery from their back pain. At 3 months follow-up 61% still reported no recovery, 
but only 26% of these patients had revisited their GP. Longer duration of the back pain 
(OR 4.4; 95% CI 2.5 to 7.7), severity of back pain at baseline (OR 1.2 95% CI 1.1 to 1.3), 
history of back pain (OR 1.7; 95% CI 1.0 to 3.0), absence of radiating pain in the leg below 
the knee (OR 0.7; 95% CI 0.4 to 1.0), number of comorbidities (OR 1.2; 95% CI 1.1 to 1.3), 
patients’ expectation of non-recovery (OR 0.4; 95% CI 0.3 to 0.6), and a longer duration of 
the timed ‘Up and Go’ test (OR 1.1; 95% CI 1.0 to 1.2) were associated with non-recovery 
in a multivariable regression model (AUC 0.79).
Also, after a follow up of 3 years different trajectories of back pain severity were defined 
in this population. Characteristics of patients in these trajectories were identified and 
described in chapter 6. Using the different indices of fit and the usefulness of the classes 
in clinical practice, a 3-class cubic model was determined as the best model. The three 
trajectories were defined as ‘low pain trajectory’, ‘high pain trajectory’ and ‘intermediate 
pain trajectory’. Compared to the low pain trajectory, patients in the intermediate trajec-
tory were more likely to be female (OR 2.04; 95% CI 1.23 to 3.37), had a higher BMI (OR 
1.07; 95% CI 1.01 to 1.14), more often had a back pain duration > 3 months at baseline 
(OR 4.87; 95% CI 2.29 to 10.37), had lower scores on the SF-36 physical summary scale 
(OR 0.94; 95% CI 0.90 to 0.98) and more negative expectations of recovery (OR 2.02; 
95% CI 1.40 to 2.91). Some of these variables were also associated with membership of 
the trajectory with high pain scores. These associations were even stronger (with higher 
ORs) in the high pain trajectory: duration of back pain > 3 months at baseline (OR 7.70; 
95% CI 3.34 to 17.74), disability (OR 1.15; 95% CI 1.06 to 1.25), SF-36 physical summary 
scale (OR 0.92; 95% CI 0.86 to 0.97) and negative expectations of back pain (OR 3.48; 
95% CI 2.08 to 5.80). These characteristics might help to identify patients at risk for a less 
favourable outcome.
Pain medication is often prescribed for patients with back pain. The use of these 
analgesics, both prescribed and over-the-counter was described in chapter 7. Of 
all 675 patients, 484 (72%) reported pain medication use at baseline. Non-steroidal 
anti-inflammatory drugs (NSAIDs) (57%) were more often used than paracetamol (49%). 
Paracetamol was mostly obtained over-the-counter (69%) and NSAIDs were mostly 
obtained by prescription (85%). At baseline, patients with severe pain (NRS ≥7) used 
more paracetamol (p=0.04), opioids (p<0.01) and muscle relaxants (p=0.02). Patients 
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reporting chronic pain (back pain >3 months) at baseline reported more often the use 
of paracetamol (p=0.03), while patients with a shorter duration of pain more often 
reported NSAID use (p<0.01). During follow-up there was an overall decline in pain 
medication use; however, at 3 and 6-months follow-up 36% and 30% of the patients, 
respectively, still used analgesics.
To determine the efficacy of NSAIDs for patients with chronic low back pain, a Co-
chrane systematic review was performed and the results are reported in chapter 8. 
NSAIDs reduced pain and disability in patients with chronic low back pain compared 
to placebo. However the differences were small: 3.3 points on a 100 point scale for pain 
intensity. Regarding disability, patients receiving NSAIDs scored 0.9 points better on a 
0-24 disability scale also indicating a significant, but small difference between NSAIDs 
and placebo. The number of adverse events was not significantly different between the 
patients receiving NSAIDs and patients receiving placebo, but large cohort studies with 
long duration would be needed to identify rare or delayed adverse events, or important 
drug interactions. Different types of NSAIDs seem not to show significantly different 
efficacy. NSAIDs were also compared to other drug types: paracetamol, tramadol and 
pregabalin. There were no differences found between NSAIDs and paracetamol and 
pregabalin in either effectiveness or adverse events. A single study comparing celecoxib 
with tramadol showed a better global improvement than in patients using only celecox-
ib. One study compared NSAIDs with ‘home-based exercise’. Exercise patients improved 
more than patients receiving NSAIDs with regard to disability, but pain scores were not 
statistically different. The efficacy of analgesics like paracetamol and NSAIDs are rarely 
studied in older adults, and therefore it is difficult to assess the benefit/harm ratio. Since 
the harms might be greater in these older population than in younger populations, 
knowing the efficacy of these analgesics in this population is even more important.
chapter 9 summarizes the main findings of the studies presented in this thesis, 
discusses the results and the clinical implications. Finally, ideas for further research are 
described. 
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Het doel van dit proefschrift was om 1) kenmerken te beschrijven van ouderen met 
rugklachten; 2) verschillende manieren te beschrijven voor het identificeren van sub-
groepen van patiënten; en 3) het gebruik van zorg in het kader van rugklachten in een 
populatie ouderen in kaart te brengen. 
De meeste resultaten beschreven in dit proefschrift zijn gebaseerd op de BACE studie 
populatie. De kenmerken van deze ouderen met rugklachten zijn beschreven in hoofd-
stuk 2. In totaal zijn 675 patiënten geïncludeerd in de BACE studie, met een mediane 
leeftijd van 65 jaar (interkwartielbereik 60-71 jaar). Patiënten met een leeftijd >55-74 
jaar hadden een gemiddelde fysieke beperking score van 9.4 (SD 5.8) op de 0-24 Roland 
Morris Disability schaal. Zij werden vergeleken met patiënten met een leeftijd ≥75 jaar, 
die een gemiddelde score hadden van 12.1 (SD 5.5) (p ≤ 0.01). Dit verschil was statistisch 
significant, echter het absolute verschil tussen de groepen was 2.7 punten; een verschil 
van minimaal 2 tot 5 punten wordt beschouwd als klinisch relevant. De oudere groep 
patiënten rapporteerden ook vaker andere klachten van het bewegingsapparaat en zij 
hadden vaker een lagere botdichtheid dan patiënten in de leeftijd >55–74 jaar.
Verschillende manieren om subgroepen te identificeren zijn gebruikt in dit proefschrift. 
De prevalentie van neuropathische pijn en associaties tussen neuropathische pijn en 
baseline karakteristieken in dit cohort van ouderen met rugklachten is beschreven in 
hoofdstuk 3. Van de 261 geïncludeerde patiënten in deze analyse, waren 250 patiënten 
(96%) beschikbaar voor de DN4 interview met lichamelijk onderzoek en 259 patiënten 
(99%) voor de DN4 interview alleen. In de DN4 interview met lichamelijk onderzoek 
scoorden 5 patiënten (2%) positief op de aanwezigheid van neuropathische pijn. Een 
hogere score was geassocieerd met uitstralende pijn onder de knie (p<0.001) en het 
gebruik van paracetamol (p=0.02). Voor de DN4 interview alleen scoorden 29 patiënten 
(11%) positief en dit was geassocieerd met een hogere body mass index (BMI) (p=0.01), 
uitstralende pijn onder de knie (p=0.001) en het gebruik van paracetamol (p=0.002). 
De prevalentie van neuropathische pijn in deze studie was beduidend lager dan gerap-
porteerd in andere studies met rugpijn patiënten. 
hoofdstuk 4 laat de onderliggende pathologie zien als oorzaak voor rugklachten in 
deze populatie van ouderen met rugklachten. Van alle geïncludeerde patiënten werd 
6% gediagnosticeerd met een ernstige onderliggende pathologie gedurende 1 jaar 
follow-up. De meeste patiënten (n=33; 5%) werden gediagnosticeerd met een wervel-
fractuur. Mutivariabele regressie analyse liet zien dat leeftijd ≥75 jaar (OR 3.5; 95% CI 1.5 
tot 6.8), trauma (OR 7.8; 95% CI 2.7 tot 22.5), osteoporose (OR 2.5; 95% CI 1.0 tot 6.2), een 
rugpijnscore ≥7 op baseline (OR 3.1; 95% CI 1.4 tot 7.2), en aanwezigheid van thoracale 
pijn (OR 2.1; 95% CI 0.9 tot 4.9) waren geassocieerd met een hogere kans op het krijgen 
van de diagnose wervelfractuur. Van deze variabelen had trauma de hoogste positief 
voorspellende waarde voor het krijgen van de diagnose wervelfractuur van 0.25 (95%CI 
0.09 tot 0.41) en een positieve likelihood ratio test van 6.2 (95% CI 2.8 tot 13.5). Een 
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diagnostisch model met alle vijf de rode vlaggen gecombineerd kon deze waarden niet 
verder verhogen. In de klinische praktijk worden rode vlaggen vaak gebruikt wanneer 
een patiënt de arts bezoekt met rugklachten. Omdat de diagnostische waarde van de 
rode vlaggen laag is, is het de vraag of deze rode vlaggen bijdragend zijn voor het stel-
len van de diagnose wervelfracturen. 
Het beloop en de prognose van rugklachten  tot drie maanden na baseline, is onder-
zocht en beschreven in hoofdstuk 5. Het beloop van de rugklachten is beschreven op 
basis van het ervaren herstel, ernst van de rugklachten, fysieke beperking, pijn medica-
tie en bezoek aan de huisarts gedurende 6 weken en 3 maanden. Na 6 weken follow-
up rapporteerde 64% van de patiënten geen herstel te ervaren van hun rugklachten. 
Na 3 maanden follow-up rapporteerde 61% geen herstel, maar slechts 26% van deze 
patiënten heeft hun huisarts opnieuw bezocht. Langere duur van de rugklachten (OR 
4.4; 95% CI 2.5 tot 7.7), ernst van de rugklachten op baseline (OR 1.2 95% CI 1.1 tot 
1.3), rugklachten in de voorgeschiedenis (OR 1.7; 95% CI 1.0 tot 3.0), afwezigheid van 
uitstralende pijn onder de knie (OR 0.7; 95% CI 0.4 tot 1.0), aantal comorbiditeiten (OR 
1.2; 95% CI 1.1 tot 1.3), negatieve patiënt verwachtingen van het herstel (OR 0.4; 95% CI 
0.3 tot 0.6), en een langere duur van de 'Up en Go' test (OR 1.1; 95% CI 1.0 tot 1.2) waren 
geassocieerd met geen herstel in een multivariabel regressie model (AUC 0.79).
Na 3 jaar follow-up werden er verschillende rugpijntrajecten vastgesteld op basis 
van de ernst van de rugklachten. Patiëntkenmerken in deze verschillende trajecten 
zijn beschreven in hoofdstuk 6. Met verschillende indicatoren om de juistheid en de 
bruikbaarheid in de klinische praktijk te beoordelen, werd een 3 klassen kubisch model 
vastgesteld als beste model. De drie trajecten waren gedefinieerd als 'lage pijn traject', 
'hoge pijn traject' en 'middel pijn traject'. Vergeleken met het lage pijn traject, waren pa-
tiënten in het middel pijn traject vaker vrouw (OR 2.04; 95% CI 1.23 tot 3.37), hadden een 
hogere BMI (OR 1.07; 95% CI 1.01 tot 1.14), hadden vaker rugklachten met een duur > 3 
maanden op baseline (OR 4.87; 95% CI 2.29 tot 10.37), hadden lagere scores op de SF-36 
fysieke schaal (OR 0.94; 95% CI 0.90 tot 0.98) en hebben meer negatieve verwachtingen 
van herstel (OR 2.02; 95% CI 1.40 tot 2.91). Sommige van deze variabelen waren ook 
geassocieerd met het hoge pijn traject. Deze associaties waren nog sterker (met hogere 
ORs): duur van de rugklachten > 3 maanden op baseline (OR 7.70; 95% CI 3.34 tot 17.74), 
fysieke beperking (OR 1.15; 95% CI 1.06 tot 1.25), SF-36 fysieke schaal (OR 0.92; 95% CI 
0.86 tot 0.97) en negatieve verwachtingen van het herstel (OR 3.48; 95% CI 2.08 tot 5.80). 
Deze karakteristieken zouden kunnen helpen in het identificeren van patiënten met een 
risico op een minder gunstig beloop van de rugklachten.
Pijnmedicatie wordt veel voorgeschreven voor patiënten met rugklachten. Het ge-
bruik van deze medicatie, zowel voorgeschreven door een arts als vrij verkrijgbaar door 
de patient zelf is beschreven in hoofdstuk 7. Van alle 675 patiënten, 484 (72%) rap-
porteerde het gebruik van pijnmedicatie op baseline. Non-steroidal anti-inflammatory 
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drugs (NSAIDs) (57%) werden meer gebruikt dan paracetamol (49%). Paracetamol was 
meest zelf verkregen (69%) en NSAIDs werden het meeste voorgeschreven (85%). Op 
baseline gebruikte patiënten met erge pijn (NRS ≥7) meer paracetamol (p=0.04), opioï-
den (p<0.01) en spierontspanners (p=0.02). Patiënten die chronische pijn rapporteerden 
(rugpijn >3 maanden) op baseline rapporteerden vaker paracetamol gebruik (p=0.03), 
terwijl patiënten met een kortere duur van de klachten vaker NSAID gebruik rappor-
teerden (p<0.01). Gedurende follow-up was er een algehele daling in het gebruik van 
pijnmedicatie; maar op 3 en 6 maanden follow-up gebruikte respectievelijk 36% en 30% 
van de patiënten nog pijnmedicatie. 
Om de effectiviteit van NSAIds te bepalen voor patiënten met chronisch lage rug-
klachten, is een Cochrane systematische review uitgevoerd en de resultaten hiervan 
staan in hoofdstuk 8. NSAIDs reduceerden pijn en fysieke beperkingen  in patiënten 
met chronisch lage rugklachten in vergelijking met placebo. Echter de verschillen waren 
klein: 3.3 punten op een 100 punt schaal voor pijnintensiteit. Met betrekking tot fysieke 
beperkingen scoorde patiënten die NSAIDs kregen 0.9 punten beter op een 0-24 schaal, 
wat een significant, maar klein verschil betekent tussen NSAIDs en placebo. Het aantal 
bijwerkingen was niet significant verschillend tussen patiënten die NSAIDs kregen en 
patiënten die placebo kregen, maar grote cohort studies met langere duur zijn nodig om 
zeldzame of uitgestelde bijwerkingen of medicatie-interacties te identificeren. Verschil-
lende typen NSAIDs lijken geen significant verschillend effect te laten zien. NSAIDs zijn 
ook vergleken met andere medicatie: paracetamol, tramadol en pregabaline. Er werden 
geen verschillen gevonden tussen NSAIDs en paracetamol en pregabaline in effectivi-
teit of bijwerkingen. Een studie vergeleek celecoxib met tramadol en liet een betere 
algehele verbetering zien in patiënten die celecoxib gebruikten. Een studie vergeleek 
NSAIDs met het doen van oefeningen thuis. Patiënten die thuis oefenden verbeterden 
meer dan patiënten die NSAIDs kregen in fysieke functie, maar de pijnscores waren niet 
significant verschillend. De effectiviteit van pijnmedicatie als paracetamol en NSAIDs 
zijn zelden bestudeerd in ouderen en daarom is het moeilijk om de verhouding tussen 
de baten en de schadelijkheid te beoordelen. Het is mogelijk dat de schadelijkheid in 
een populatie ouderen groter is dan in een jongere populatie en daarom is het extra 
belangrijk om de effectiviteit van deze pijnmedicatie te weten in deze populatie.
hoofdstuk 9 vat de belangrijkste bevindingen samen van de studies beschreven in 
dit proefschrift, bediscussieert de resultaten en de klinische implicaties. Tenslotte zijn 
ideeën voor  verder onderzoek  beschreven. 
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Dit proefschrift had niet tot stand kunnen komen zonder de hulp van velen. Ik wil ieder-
een daarvoor bedanken en een aantal van hen hier specifiek noemen. 
Allereerst wil ik alle patiënten in het BACE onderzoek bedanken. Zonder hen zouden 
we deze mooie set data niet hebben kunnen verzamelen en was het onderzoek niet 
mogelijk geweest. 
Pim, ik wil je bedanken voor al je hulp in de afgelopen jaren als mijn co-promotor. Je 
bent een zeer toegankelijke en prettige begeleider die me de ruimte heeft gegeven ti-
jdens het gehele onderzoek. Ondanks je drukke schema wist je al mijn stukken zeer snel 
te voorzien van opbouwende kritiek. Mede daardoor is mijn onderzoek zo voorspoedig 
gelopen. Dank hiervoor!
Bart, ook jij bedankt voor jouw positieve en scherpe manier van begeleiden. Jouw 
netwerk in het rugpijnonderzoek is enorm en heeft me erg geholpen tijdens het onder-
zoek. Dit heeft me ook de gelegenheid gegeven een deel van mijn onderzoek te doen 
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Graag wil ik ook de leden van de leescommissie, prof.dr. H.E. van der Horst, prof.dr. 
F.J.P.M. Huygen en prof.dr. J.A.N. Verhaar bedanken voor het lezen en beoordelen van 
mijn proefschrift. 
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Richard Deyo, Judith Geuze, Wilco Peul, Pepijn Roelofs, Jantine Scheele, Maurits van Tul-
der; bedankt voor het lezen van mijn artikelen. Jullie opmerkingen hebben me kritisch 
naar mijn eigen artikelen doen kijken. 
Iris, bedankt voor je hulp bij de Mplus analyse. Annet, bedankt voor het lezen van alle 
Nederlandse teksten. 
Lieve collega's, Aafke, Adinda, Alex, Alyt, Annemieke, Arianne, Arthur, Bart, Carolien, Da-
vid, Desiree, Diana, Dieuwke, Ellen, Evelien, Erwin, Fiona, Gijs, Jacoline, Janneke, Jantine, 
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Metthilde, Nadine, Nienke, Nynke, Patrick, Pauline, Pim, René, Rianne, Rianne, Roxanne, 
Saskia, Sita, Theun, Toke, Wendelien, Winifred, jullie zijn de reden dat ik altijd met veel 
plezier naar mijn werk ben gegaan en me vol enthousiasme op mijn onderzoek kon 
storten. Zowel op de Westzeedijk als in het Na gebouw heb ik mij altijd erg thuis gevoeld 
en was er ruimte voor lief, leed en vooral heel veel lol. Ik denk met veel plezier terug 
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aan de lunch en thee op het zonnige balkon aan de Westzeedijk, traplopen, work-outs, 
etentjes, gezellige congressen en het 'lenen' van de giraffe van de 27e!
Nienke, wij startten tegelijkertijd ons AIOTHO traject en zaten daarna ook samen in ons 
eerste jaar van de huisartsopleiding. Ik vond het een erg gezellige tijd en NIHES volgen 
met jou en Symen was een feestje. Ik ben blij dat je naast me wil staan als paranimf.
Er zijn verschillende vriendinnen op wie ik kan bouwen. Voor wijntjes, etentjes, week-
endjes weg, shoppen en een goed gesprek kan ik bij jullie terecht, lieve meiden dank dat 
jullie er zijn! Annet, Carey, Heide en Madelon, ik geniet enorm van onze gezamenlijke 
etentjes, sinterklaasfeestjes en reisjes door Europa. Anna, Jorie, Lalini, Margaux, Mar-
greeth, Michelle, Sanne en Wendelien jullie weten als geen ander hoe hectisch het leven 
kan zijn als je je onderzoek combineert met de huisartsopleiding. Ik ben blij met onze 
fijne weekendjes weg en etentjes samen! Eva, ik hoop dat we samen nog vele gezellige 
avonden kunnen vullen.
Daarnaast heb ik het geluk gehad om het eerste huisartsjaar in een enorm fijne groep 
terecht te zijn gekomen. Ik wil Eveline, Marieke, Marieke, Marjan, Nienke en Petra bedan-
ken voor onze gezellige dinsdagmiddagborrels en de fijne sfeer tijdens de terugkomda-
gen. Dat we onze traditie van borrelen in Rotterdam en stappen in Breda nog maar lang 
mogen voortzetten. 
Lieve pap en mam, jullie hebben me alle mogelijkheden en vrijheid gegeven me te 
ontwikkelen in welke richting ik wilde. Het betekent veel voor me dat jullie altijd 100% 
achter me staan. Bedankt voor jullie steun, maar vooral ook alle gezelligheid tijdens de 
fijne etentjes en avonden met elkaar! 
Mick, bedankt dat je mijn paranimf wil zijn en achter me staat tijdens deze belangrijke 
dag. Ik ben een trotse ‘grote’ zus!
Kees ik wil je bedanken voor je onvoorwaardelijke steun, liefde en vertrouwen in mij. Ik 
geniet van elk moment samen. 
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